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Gerrit S. Zijlstra Chapter 1 
 




In the eighties of the previous century, a strong desire to administer 
biopharmaceuticals systemically through the pulmonary route (1-3) 
fuelled formulation and device development for pulmonary drug 
administration. After approximately 15 years of development, in 2006, 
the launch of Exubera
® (4), the first dry powder inhalation device with a 
biopharmaceutical (insulin) marked a milestone. The next milestone was 
reached a year later when Pfizer, the company marketing Exubera
®, 
withdrew the product from the market because according to Pfizer “it did 
not meet customers’ needs or financial expectations”, leaving Pfizer with 
a pre-tax loss of 2.8 billion dollar. Other commentaries were that safety 
issues (decrease in lung function, alleged increase of lung cancer) made 
physicians reluctant in prescribing Exubera
®. Furthermore, the patients’ 
conception of the relatively large inhaler and the limited dosing 
possibilities (only 3 an 8 IU) were mentioned as factors. Despite the bitter 
taste for Pfizer, the major lesson learned for the inhalation community is 
that any new marketed product for inhalation should hold a true 
(therapeutic) advantage over existing treatment and should certainly not 
be related to any additional safety questions compared to existing modes 
of administration. Next to that, the device should be convenient and 
robust for routine use, which now is the aim for many companies working 
on the development of new drug therapies for inhalation ( In general, the 
withdrawal of Exubera
® forced most companies involved in the 
development of biopharmaceutical products for inhalation or those 
working on advanced inhalation systems to re-evaluate the strategy of 
their development projects. 
 
The bright side of the Exubera
® c a s e  i s  t h a t  b o t h  P f i z e r  a n d  N e k t a r  
Therapeutics, the product originator, have demonstrated that it is 
possible to develop an inhalable and stable dry powder product of a 
biopharmaceutical drug and obtain a marketing authorization; through 
demonstrating good formulation quality, efficient drug administration via 
a completely new route, clinical safety and efficacy. If the lessons 
described above are addressed appropriately, any new biopharmaceutical 
for inhalation may obtain a market authorization and be successfully 
marketed. Therefore, the withdrawal of Exubera
® is expected to reduce 
research efforts to formulate biopharmaceuticals as products for 
inhalation only to a limited extend. Furthermore, it may shift the Chapter 1 
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activities to other drug compounds for which now an increased 
investment potential will become available.  The interesting aspect of 
this shift is that the number of potential drug candidates suitable for 
inhalation is large and will continue to increase in the future. Next to the 
many biopharmaceuticals (of which several are already in development as 
products for inhalation), also compounds like vaccines, antibiotics, or 
analgesics are widely considered to be interesting drugs for pulmonary 
administration.  
 
BIOPHARMACEUTICALS, FORMULATIONS AND PROCESSES 
Biopharmaceuticals include amongst others nucleic acids, peptides and 
proteins, which are produced by extraction from non-engineered 
biological sources, or by other means such as extraction from engineered 
biological sources. The difference between nucleic acids and 
peptides/proteins is that nucleic acids are macromolecules build of 
nucleotides (nitrogenous base, a sugar, and a phosphate group) and 
peptides/proteins of amino acids. The distinction between peptides and 
proteins is arbitrary, but generally peptides rely on their primary 
structure (amino acid sequence) for their activity, in contrast to proteins 
which rely on their tertiary structure (combination of α-helices and β-
sheets) for their activity. Consequently, peptides have relatively low 
molecular weights, whereas proteins are of relatively higher molecular 
weights. Next to the above mentioned three groups the class of 
biopharmaceuticals includes more complex systems in which proteins or 
nucleic acids are contained in a specifically structured way. Examples of 
such systems are, whole inactivated virus vaccines, liposomes, lipoplexes 
or virosomes. 
 
In practice, peptides tend to be more stable than proteins, because the 
tertiary structure of proteins is sensitive to changes. Pathways for 
deactivation are of physical and/or chemical nature. Examples of physical 
pathways include aggregation, precipitation, adsorption to surfaces and 
defolding. Examples of chemical inactivation include hydrolysis, 
deamidation, racemization and oxidation (6). Most deactivation pathways 
are related to temperature and physical and chemical stress, such as 
shear stress or pH. Any change in tertiary structure may affect activity, 
immunogenicity and/or toxicity of the protein. Therefore, General Introduction 
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biopharmaceuticals require special attention in terms of formulation and 
process development and stability. 
 
In liquid formulations, most of the mentioned degradation pathways have 
relatively fast kinetics as a consequence of which refrigeration is 
required. Furthermore, handling of the biopharmaceutical products 
before their use (storage, shaking) and during administration (shear 
forces) may further induce physical and/or chemical degradation. In 
contrast, many degradation kinetics are significantly slower in the dry 
state compared to the liquid state. This fact could even open the 
possibility to store the product at room temperature. However, this 
requires appropriate formulation and processing (drying) in order to 
prevent degradation of the biopharmaceutical during the production 
process and subsequent storage. 
 
BIOPHARMACEUTICALS FOR INHALATION 
Next to stability, formulations of biopharmaceuticals for inhalation 
require special attention regarding size, shape and density of the powder 
since the efficacy of the inhaled biopharmaceutical is related to the 
aerodynamic particle size. For instance, a biopharmaceutical for local 
pulmonary action may need a different aerodynamic particle size than 
biopharmaceuticals intended for systemic action administered via the 
pulmonary route. The appropriate aerodynamic particle size distribution 
depends on the desired target region within the lung and on the 
inhalation manoeuvre exerted by the patient, which is related to the 
inhalation device used. With various techniques based on   
pharmacokinetics, pharmacodynamics or scintigraphic techniques, 
attempts have been made to establish the preferable particle size 
distribution for various drugs for pulmonary administration. For example, 
in vivo deposition studies have confirmed that particles in the 
aerodynamic size range between 3 and 6 µm are optimal for deposition in 
the central airways (7, 8), whereas peripheral (or alveolar) deposition, 
typically needed for maximum systemic absorption of larger molecules 
(1.4 – 22 kDa), can be maximised by using particles of 1.5-3 µm (7, 9-12). 
 
Biopharmaceuticals are designed to treat a large variety of diseases, 
which are of systemic or local nature. In inhalation, the lung can be used 
to reach four different treatment targets: Chapter 1 
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1)  to treat local lung diseases (e.g. asthma, COPD or cystic fibrosis),  
2)  to treat systemic diseases by achieving systemic absorption (e.g. 
protein deficiency),  
3)  to obtain a systemic effect without systemic absorption (e.g. 
vaccination) and 
4)  to obtain both a local as well as a systemic effect (e.g. antibiotics in 
cystic fibrosis or tuberculosis)  
 
Examples of biopharmaceuticals used to treat local lung diseases are 
recombinant human deoxyribonuclease I (13-17) and α1-antitrypsin (18, 
19). Recombinant human deoxyribonuclease I (rhDNase; Pulmozyme
®) is 
used in cystic fibrosis as a liquid for nebulization. RhDNase is an enzyme 
with a molecular weight of 32 kDa that cleaves extracellular DNA present 
from recurrent infections. By cleaving extracellular DNA, the viscosity of 
sputum decreases and thereby enables better sputum clearance and 
hence lowers the risk of recurrent infections. α1-Antitrypsin (AAT) is used 
as chronic replacement therapy in individuals who lack AAT and have an 
inherited form of panacinar emphysema. Lack of AAT leads to 
emphysema, which is marked by damage of alveolar epithelium resulting 
in inefficient breathing and shortness of breath. To reduce or limit the 
progress of emphysema, the AAT level can be restored by inhalation. 
The lung can also be used as a portal to reach sufficient systemic plasma 
levels to treat a variety of systemic diseases. This option is often referred 
to as “needle-free administration”, since this administration is often 
considered as an interesting option to replace parenteral administration. 
Examples of biopharmaceuticals used to treat systemic diseases include 
cetrorelix (20, 21), insulin (22, 23) and human growth hormone (24). 
Absorption from the lung of these substances depends largely on their 
molecular weight. If the molecular weight is between 1.4-22 kDa, 
absorption can only occur via the alveolar membrane. Therefore these 
substances require deposition in the peripheral part of the lung. The 
recognition of the lung as a non-invasive port of entry to obtain systemic 
absorption (3, 25-27) is due to the large alveolar surface area, its 
extensive vascular system, thin alveolar epithelia and large intercellular 
pores, which not only enable effective gas exchange but also effective 
diffusion/transport. Beneficial over oral administration are the shorter 
route before absorption (resulting in a much faster onset of effect) and 





Figure 1. Schematic presentation which shows the major differences between 
pulmonary and oral administration (the circular arrow between gut and liver 
represents the enterohepatic cycle). 
 
A further treatment objective of pulmonary administration may be to 
obtain a systemic effect that is reached without absorption of the 
biopharmaceutical product. Examples include vaccines (e.g. influenza, 
measles). These vaccines will not be absorbed from the lungs, but instead 
they will promote a systemic immune response after deposition in the 
lungs (28-31). 
Finally, there are a number of drugs that are used via the pulmonary 
route to obtain both an increased local effect as well as a systemic drug 
level, which elicits a systemic effect of the drug. The most widely used 
example of this kind of use is the inhaled antibiotics in cystic fibrosis 
related Pseudomonas infections or in tuberculosis. In both diseases the 
primary infection in the lung can be effectively treated by the high drug 
levels in the lung resulting from the inhalation, whereas infections in 
other parts of the body or lung sites not directly reached by the inhaled 
drug are treated by the antibiotic absorbed from the lung (32-36). Also 
the inhalation of amphotericin B encapsulated in liposomes (AmBisome
®) 
used to treat aspergillosis is an example of this type of pulmonary drug 
use (37-39). Another therapeutic area in which local and systemic levels 
may be beneficial is in the field of lung transplantation. 
Immunosuppressants, such as calcineurine inhibitors (Cyclosporine A), are 
given systemically to obtain a therapeutically effective level to suppress 
rejection. Unfortunately, calcineurine inhibitors are nephro- and 
neurotoxic. This toxicity leads to dose adjustments, which leads to higher 
chance of rejection. Ultimately, the balance between dose-related Chapter 1 
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efficacy and toxicity may lead to chronic rejection. When chronic 
rejection occurred, no treatment options are available next to re-
transplantation. It is in the stage of chronic lung rejection where inhaled 
cyclosporine A as additional on-top-off therapy has demonstrated to be 
effective (40, 41).  
 
For any biopharmaceutical drug product that is intended for inhalation, a 
variety of parameters determines its stability and efficacy. The stability 
of the product depends both on its qualitative and quantitative 
formulation as well as on the production process. However, the 
formulation and production process may also affect the properties of the 
aerosol, which in turn is a major parameter determining efficacy. Efficacy 
may depend on factors as particle size distribution of the aerosol, 
efficiency of the aerosol production, the inhaler device used and its ease 
of operation which in turn may be related to patient compliance. Finally, 
when a certain formulation and device have been developed, how do we 
bridge the gap between technological development and in vivo efficacy? 
Thus, for any biopharmaceutical for which a beneficiary therapeutic 
effect is expected upon pulmonary administration, at least three relevant 
questions should be addressed:  
1)  Which administration method available for pulmonary administration 
needs to be used and what type of formulation would be best? 
2)  Which manufacturing process should be chosen? 
3)  How do we test the device and formulation for safety and efficacy? 
 
ADMINISTRATION METHODS 
Various inhalation methods rely on producing an aerosol from a liquid; the 
liquid can either be a solution or a suspension. The aerosol can be 
created by disruption of a liquid jet or surface (nebulization) (42-44), 
pushing liquid through fine nozzles, perforated membranes or vibrating 
meshes (soft mist inhalers) (45, 46) or release from a pressurized canister 
(metered dose inhalers) (47, 48). Liquid aerosol systems generally require 
energy in the form of electricity or pressure to produce the aerosol.  
Other methods relies on inhalation of a powder aerosol (dry powder 
inhalers) (49, 50) in which particles that contain the active ingredient are 
in the appropriate size range for inhalation. In contrast to the liquid 
aerosol systems, the inhalation airflow generated by the patient delivers General Introduction 
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the energy for particle agglomerate disruption necessary to produce the 
aerosol. 
The various currently available systems differ significantly in many 
aspects. Aerosol characteristics, inhalation manoeuvre  efficiency of 
aerosol generation, lung deposition, ease of operation,  maximal dose 
weight, dose release mode (as a bolus or gradually during a longer period) 
and lung deposition are just a few examples. The pros and cons of the 
different aerosol systems have been reviewed extensively (42-51). 
Pharmaco-economics may also play a role in the decision for a liquid or a 
dry powder formulation (52). In general, dry powder inhalation systems 
are considered most patient friendly because of the operability, patient 
mobility and device/formulation robustness. In general dry powder 
inhalers offer one other important advantage over the liquid aerosol 
systems and that is storage stability. As mentioned, powder formulations 
of biopharmaceuticals can be stable for long times at room temperature. 
Dry powder inhalers are therefore considered the preferred system for 
the administration of biopharmaceuticals by inhalation.  
 
FORMULATIONS 
Most biopharmaceuticals are produced in an aqueous environment. When 
the biopharmaceutical is going to be formulated as a dry powder for 
inhalation, a subsequent drying step is needed. Some biopharmaceuticals 
can be dried without loss of activity, such as e.g. peptides, but most will 
need special formulation techniques, such as sugar glass technology. To 
minimize loss of activity (and related increase in unwanted 
immunogenicity) during production and to improve storage stability. 
Sugar glass technology implies the stabilization of biopharmaceuticals 
during drying and storage by low molecular mass sugars such as trehalose, 
mannitol, sucrose, or a mix of a low molecular sugars with a polymeric 
excipients such as dextran (53, 54). This technology is the most used 
technique for stabilization of biopharmaceuticals. Higher molecular mass 
sugars, such as inulin have also been reported as good stabilizers during 
drying and storage (28, 29, 55). The addition of carbohydrates during 
drying serves two purposes: 
-  Introduce a physical barrier to prevent aggregation and degradation 
(56). 
-  Reduce the molecular mobility to minimize physical and/or chemical 
degradation reactions (57).  Chapter 1 
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Two mechanisms have been proposed by which the excipients stabilize 
the biopharmaceutical: a thermodynamic and kinetic mechanism. The 
thermodynamic mechanism, also referred to as the water substitution 
hypothesis, states that stabilization of the native protein structure results 
from replacing hydrogen bonds from water by hydrogen bonds from the 
excipient during the drying process, thereby thermodynamically 
stabilizing the protein. Such an effect is unlikely to depend strongly on 
drying processes conditions. The kinetic mechanism proposes that 
stability relies on suppressing global motions, known as α-relaxations, via 
the formation of a rigid glassy matrix which is highly viscous. α-
Relaxations mainly occur due to translational or rotational changes of the 
complete molecule; these motions are strongly dependent on the 
diffusivity. In turn, in amorphous, glassy matrices, diffusivity depends on 
temperature, especially around the Tg. Since global relaxation is 
impacted by thermal history, different drying processes and process 
conditions may result in different stabilities (58, 59). A typical 
characteristic of sugar glass stabilization is that the formulations are in 
the amorphous state. 
 
In addition, formulations for inhalation require special attention since the 
deposition efficiency of the inhaled biopharmaceutical is related to the 
aerodynamic particle size of the powder. Depending on the target site in 
the lungs, particles in the aerodynamic size range between 3-6 µm or 1.5-
3 µm are needed for central or peripheral deposition, respectively (7-12). 
The aerodynamic diameter can be expressed as the diameter of a unit-






e ae d d =          ( 1 )  
where dae is the aerodynamic diameter, de the geometric particle size 
(often the equivalent laser diffraction diameter is used for this 
parameter), ρp the density of the particles (g/cm
3), ρ0 the unit density 
(1 g/cm
3) and χ the dynamic shape factor (1 for spherical particles). The 
particle density, ρp, in this equation is not equal to the true density of 
the dried material, instead the particle density is the mass of the particle 
divided by the volume of a sphere of diameter de and thus can be General Introduction 
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significantly lower than the true density, because both internal and 
external voids are included. 
When the biopharmaceutical is formulated as a stable powder in the size 
range for inhalation, the powder may need further formulation to 
improve flow and dispersion properties. To improve the flowability, 
formulations used in dry powder inhalation are either soft (spherical) 
agglomerates of the active ingredient with or without excipients, or 
(adhesive) mixtures with (carrier) excipient. Upon inhalation, dispersion 
of the powder to an aerosol is necessary for inhalation, which means that 
the soft agglomerates and adhesive mixtures need to be deagglomerated. 
One of the major challenges in dpi-technology is therefore to find the 
proper balance between the interparticulate forces in the powder 
mixture originating from the production process and de-agglomeration 
during inhalation. The forces acting between the drug-drug or drug-
excipient particles have been described before (60, 61) and new 
approaches aim to increase the fine particle output by:  
-  Weakening the interparticulate forces  
o  due to smoothened carrier surface, removal of adhering fines and 
minimize strong bonding sites 
  Surface treatment of carrier excipient particles by re-
crystallisation (62), 
  Submersion in ethanol or ethanol-water mixtures (63, 64) and 
  Corrasion (65, 66).  
o  Selecting the most appropriate size fraction of carrier excipient 
(67, 68), 
o  by adding ternary excipients  
  Adding lactose fines (69, 70),  
  Adding PEG 6000, leucin or magnesium stearate (e.g. (71)) 
-  Particle engineering techniques to reduce cohesion and increase 
respirability  
o  Preparation of highly porous particles using different methods (72-
74)  
o  Supercritical fluid crystallization 
All approaches have in common that they aim on increasing the fine 
particle output (the percentage of deagglomerated particles). In addition Chapter 1 
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several techniques aim to improve respirability of the spray dried 
powders by designing particles that have a low density (ρp) and relatively 
large geometric diameter (de). These particles are termed “large porous 
particles” and can be produced by two techniques: the so-called folded 
shells and solid foam particles (75). The term “large porous particles” was 
first introduced for polymer particles produced by a double- and single 
emulsification solvent evaporation process followed by a freeze-drying 
step (76). Later, large porous particles were associated with spray dried 
particles from a sub-azeotropic ethanol-water co-solvent system. The 
solid phase contained dipalmitoylphosphatidylcholine (dppc), a lung 
surfactant, albumin and saccharides (77-79). Due to the low aqueous 
solubility of DPPC and high Peclet number, DPPC acts as an early shell 
former. The low density arises from the low feed concentration, typically 
around 0.1% w/v, and the fact that the solid particle is produced at the 
first instance of spray drying, thus in a relatively large droplet. As a 
result, densities of less than 0.1 g/cm
3 are found in such particles (79). 
Such large porous particles showed good aerosolization performance in 
comparison to conventional dry powders. For instance, high emitted doses 
of 90-100% were reported (24, 80-82). Total lung deposition and 
variability were superior to conventional systems (81). However, the 
efficiency of deposition of large porous particles has been doubted in a 
different study (83) due to lower diffusion efficiency and gravitational 
sedimentation of large porous particles compared to submicron particles. 
 
Folded shells are particles that contain internal and external void space 
caused by a soft surface layer which folds to form a wrinkled morphology. 
A soft surface layer can be achieved by a high initial saturation, low 
diffusion constant, a relatively low inlet air temperature or a combination 
of the three. During drying, a shell is formed which remains rubbery 
throughout the drying process. The internal pressure builds up due to 
evaporation of the solvent. When the internal pressure exceeds the 
tensile strength of the rubbery shell, the shell disrupts which leads to 
shrinking of the particle. Further drying leads to a wrinkled (raisin-like) 
morphology. 
 
Solid foam particles are produced by spray drying an emulsion in which 
the dispersed phase consists of submicron droplets and a solvent that 
evaporates slower than the continuous phase. The dispersed phase is General Introduction 
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stabilized by phospholipids, which decrease coalescence that would have 
occurred upon evaporation, and thus shrinking. Shrinking continues until 
the dispersed phase is tightly packed, and then forms a foam-like 
structure. This predominant method is marketed under the trade name 
Pulmospheres
TM (84, 85). To date, a consensus on the mechanism of drying 
of emulsions is not reached. The dispersed phase in Pulmospheres
TM 
usually consists of perfluorooctylbromide (86, 87), stabilized with 
distearylphosphatidylcholine (72, 86, 88). The phospholipid properties can 
be altered with calcium chloride. The active ingredient is usually 
dissolved in the continuous phase, but poorly soluble drugs have been 
suspended in the continuous phase as small crystals (88). The 
performance of Pulmospheres
TM in combination with a passive capsule 
inhaler was reported to be more efficient than conventional dosage forms 
for dry powder inhalation (72, 87) or mdi’s (86). Furthermore, 
Pulmospheres
TM with tobramycin were reported to be nine times more 
efficient than nebulized tobramycin (87). 
 
MANUFACTURING PROCESS 
Several manufacturing processes are available to produce formulations of 
biopharmaceuticals in the appropriate size range for inhalation. These 
include milling, spray drying, freeze-drying, spray freeze-drying and 
supercritical fluid drying. The best known process to achieve particles in 
the appropriate size range for inhalation is milling. Freeze-drying is most 
widely used for drying of biopharmaceuticals, but lack of control over the 
particle size distribution makes a second processing step, such as milling, 
necessary. Unfortunately, many biopharmaceuticals are not able to 
withstand the forces induced during the milling process (20, 89-91). 
Therefore, milling has limited applicability, which reduces its 
applicability in inhalation of biopharmaceuticals. Spray drying, spray 
freeze-drying and supercritical fluid drying appear to be more suitable 
methods to produce biopharmaceutical powders for inhalation. These 
methods incorporate the drying process and provide control over the 
particle size distribution. These drying techniques are also used for 
particle engineering. Particle engineering is a discipline that uses the 
understanding of particle formation during drying to design particles with 
special properties such as low density (ρp) or specific shapes (χ) to 
improve specific (inhalation) properties and/or stability. Recently, a Chapter 1 
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number of reviews were published, which give an adequate description of 
particle engineering techniques (75, 92-94). 
 
Spray drying is a single step production process which is relatively simple 
and fast. In the past, spray drying was regarded primarily as a technique 
to produce particles in a certain size range and to remove solvent without 
increasing the product temperature to an extreme. Today, spray drying is 
getting more advanced through the use of special liquid compositions and 
excipients resulting in advanced particles, such as large porous particles 
(73, 76). Major advantages of spray drying are that the process can easily 
be scaled-up and many critical parameters are well known. Disadvantages 
of spray drying include shear stresses due to the atomization, heat stress 
caused during drying and the risk of crystallization due to use of elevated 
temperatures.   
 
The spray drying process can be divided into 4 stages:  
1)  atomization of a feed solution into a wet aerosol,  
2)  aerosol mixing with air,  
3)  drying of the droplets at elevated temperature and  
4)  separation of the dried product from air.  
 
For each step a large number of process and/or formulation variables can 
be applied, such as solid concentration, type of atomizer, liquid feed 
rate, inlet air temperature and flow rate. Stage 1 and 2 determine the 
droplet size distribution, which has a strong relationship to the particle 
size distribution of the end product. Stage 3, the drying of the wet 
aerosol, is the most critical step in the process because on one hand the 
temperature margin between drying and inducing physical and/or 
chemical degradation is small while, on the other hand, properties (e.g. 
protein concentration on the surface, morphology, specific surface area) 
that influence the product quality may be strongly affected by 
temperature and drying rate. In general, drying of the droplets is 
achieved by evaporation, followed by decrease in droplet size and shell 
formation. At a certain moment, a shell of solid material may be formed 
whereas the inside of the particle still contains a solution. This solvent 
diffuses through the particle shell and evaporates at the particle surface 
during further drying, leaving a solid (often wrinkled) or (smooth) hollow 
particle at the end of the drying process (figure 2). In a properly designed General Introduction 
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spray drying process all parameters, such as inlet air temperature, inlet 
air flow rate, liquid feed rate and atomizing air flow are balanced with 
formulation parameters (e.g. composition or desired moisture content) 
and desired product properties like particle size distribution, particle 
morphology, yield and solid state.  
 
 
Figure 2. Scanning electron micrograph of spray dried inulin showing hollow 
spheres at a magnification of 2000x. Remarkably, particles with smooth surface 
display holes in the surface due to internal pressure build-up. The smaller, 
wrinkled particles apparently had a softer shell at the time of internal pressure 
release. 
 
Spray freeze-drying is a process in which a fine mist is sprayed into a 
vessel with a cryogenic liquid, such as nitrogen, oxygen or argon. Due to 
the low temperature, the droplets are immediately frozen, a process that 
already starts in the cold vapor (95-98). The frozen droplets then settle to 
the bottom of the vessel as a result of their higher relative density. After 
lyophilization, a porous particle in the approximate size of the original Chapter 1 
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droplet remains  (Figure 3) (99, 100). Advantages of spray freeze-drying 
include the low crystallization risk and capability to produce engineered 
particles. Disadvantages include exposure to shear and freezing stress, 
relative high costs, length of the process (which may be 1 to 3 days) and 
probably most important current absence of large scale pharmaceutical 
production facilities. However, knowledge on the spray freeze-drying 
process is evolving, and with the recent availability of atmospheric spray 
freeze-drying, which has been reported to be finished within a couple of 




Figure 3. Scanning electron micrograph of spray freeze-dried inulin from an 
aqueous solution at an atomizing pressure of 400 Ln/h. Magnification was 500x. In 
this micrograph, the porous structure can perfectly be seen. Moreover, in the 
surface of the middle particle, the ice crystal structure can clearly be seen. 
 
With spray freeze-drying, mass transfer processes during drying are 
completely different from those during spray drying. The most important General Introduction 
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reason for this is the time to reach immobilization of the molecules; for 
spray freeze-drying this time is much shorter than for spray drying. While 
with spray drying the viscosity of the shell and of the droplet increases in 
time gradually up to a maximum upon reaching the final moisture 
content, high viscosities are reached almost instantaneously upon 
freezing of the droplet with spray freeze-drying. The whole system will be 
below the Tg within tenths of a second. This difference makes spray 
freeze-drying especially suitable for substances that show extensive phase 
separation, such as poorly soluble drugs (e.g. Cyclosporine A or ∆9-
tetrahydrocannabinol) or very labile drugs (e.g. rhDNase, influenza 
subunit vaccine) (29, 99, 100). 
 
Recently, supercritical fluid technology as a powder preparation 
technique for high molecular weight drugs was reviewed (104). 
Supercritical fluid technology is claimed to be a process with great 
control over particle size, shape and polymorphic purity (74, 105). 
Supercritical fluids (SF) are gases and liquids at temperatures and 
pressures above their critical points, Tc and Pc, respectively. In 
pharmaceutical applications, CO2 is generally being used as supercritical 
fluid (SFCO2) due to the low Tc (31.2 °C) and Pc (7.4 MPa). Of particular 
interest are the conditions at which the supercritical fluid is present as a 
single phase but with advantageous properties of both liquids and gases. 
These conditions are met within the range of 1<T/Tc<1.1 and 1<P/Pc<2 
(93). In these ranges, the density is such that solvation is enabled, while 
the viscosity in supercritical fluids is lower than in solution. As a 
consequence, the diffusivity is higher, which facilitates effective mass 
transfer. Of great practical use is the high compressibility of supercritical 
fluids, with which the density and thus solvation power can be controlled. 
Advantages include process speed and the possibility to produce 
engineered particles. A major disadvantage is that supercritical fluid 
technology is still in development, and thus has a limited knowledge base 
and relative high costs. Another disadvantage is atomization-induced 
shear stress. Despite its infancy, supercritical fluid technology receives a 
great deal of research interest. For example, process conditions such as 
type of nozzle (106), flow rate (107), type of modifier (108) and modifier 
(ethanol) faction (109, 110) have been investigated on functional 
outcomes as polymorphism (107, 111) and particle size/morphology (110). 
The fraction of the modifier ethanol plays role in polymorphism (111) and Chapter 1 
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storage stability as residual ethanol lowers the Tg (109). Different 
modifiers as methanol, 2-propanol or acetone may also be used (108). For 
protein stabilization, regular carbohydrates such as e.g. dextran, 
chitosan, maltose, sucrose and trehalose (109, 112-116) have been used 
for stabilizing proteins. As any other drying technique used for 
stabilization of biopharmaceuticals, supercritical fluid technology is likely 
to result in tailor-made process/formulation approaches, as illustrated by 
Jovanovic, who needed to tailor the process that was successful for 
processing lysozyme to a process suitable to produce a stable dry powder 
formulation of IgG with the right quality attributes as structure, 
aggregation and solubility (116, 117). In animals, chitosan proved to be a 
functional excipient, not only in stabilization of for example insulin (114), 
but also to improve the bioavailability in rats when using a chitosan type, 
with a degree of quaternization of 60% (DQ60) , to a level almost similar 
as a subcutaneous injection. Chitosan DQ60 functions both as a 
mucoadhesive and a permeation enhancer (112). A combination of 
chitosan and Diphteria toxoid also demonstrated to be at least equivalent 
to subcutaneous injection in immunological response and neutralizing 
antibody titers (115). All these examples together demonstrate a proof of 
concept, showing that although this manufacturing method is still in its 
infancy, there may be a successful future for supercritical fluid 
technology. 
 
Each method thus has its own typical advantages and disadvantages. The 
relevance of the different disadvantages may be determined by the 
characteristics of the biopharmaceutical, the formulation and process 
parameters. Because of the huge knowledge base, long-term industrial 
experience and ease of the process, spray drying seems to be the best 
choice to produce a powder for inhalation of biopharmaceuticals. This 
may explain why spray drying received most attention in literature as 
drying method for proteins in inhalation (figure 4).  
 
In summary, many biopharmaceuticals may be produced to a powder for 
inhalation by using spray drying. In a limited number of cases, other 
manufacturing methods may be needed, for example when the stability of 
the biopharmaceutical is such that it cannot withstand the stresses 
caused by spray drying. Alternative methods are then spray freeze-drying 





























Figure 4. Number of publications (A: absolute; B: relative ratio) per year on 
milling (black bars), spray drying (dark grey bars), spray freeze-drying (light grey 
bars) and supercritical fluid technology (white bars). Search terms were 
“inhalation” and “milling”, or “spray drying”, or “spray freeze-drying”, or 
“supercritical” in the title in the Pubmed database. 
 
BRIDGING THE GAP BETWEEN FORMULATION TECHNOLOGY AND 
IN VIVO EFFICACY AND SAFETY 
In the development of innovative medicinal products animal models are 
essential to provide indispensable knowledge on absorption, distribution, 
metabolism, excretion and the related toxicology, safety and efficacy. An 
animal model is an intact animal preparation that has a defined scientific Chapter 1 
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utility (118). In addition, animal models may be used to determine 
biopharmaceutical aspects such as the deposition characteristics of 
inhalation medicines and serve as a comparative in vivo screening method 
for different formulations. A common problem in all animal models used 
in inhalation research is the question how the drug should be 
administered to have the best extrapolation to humans and which animal 
could best be used. 
 
Understanding the differences in airway anatomy between animals and 
humans is important for adequate extrapolation between species. Most 
obvious are the differences in nasal anatomy (119, 120), but the tracheo-
bronchial tree and the deep lung region differ also (119-123). Humans 
have a relatively simple nasal anatomy, while other mammals have a 
complex internal structure with a large olfactory apparatus (119, 120). In 
addition, rats and possibly other rodents are obligatory nose breathers, 
incapable of mouth breathing (124). This property enables their use in 
nose-only exposure models as will be detailed below. The complex 
olfactory apparatus limits the probability of inhaling particles larger than 
a few micrometers (118). 
 
In humans and some animals (dogs, cats, monkeys and ferrets), the 
transition from cilated tracheobronchial airways to fully alveolated 
alveolar ducts is gradual and several orders of respiratory bronchioles are 
present (122, 123). In contrast, in mice and rats the respiratory 
bronchioles are absent while in other animals such as hamsters, guinea 
pigs, oxen, sheep and pigs respiratory bronchioles are very abbreviated 
(122, 123). An implication of having respiratory bronchioles is a slower 
alveolar clearance (125). In addition, with increasing body size, the 
alveolar size, number alveoli, and total lung surface area increases (126). 
 
Information about comparative deposition studies is scarce even though 
particle deposition in laboratory animals has been reviewed (126, 127). In 
general, humans have a larger peak particle size for pulmonary deposition 
than dogs, guinea pigs, monkeys and rats. The highest deposition rate in 
the tracheo-bronchial tree and alveolar region is obtained with particles 
smaller than 1 µm in rodents, in dogs with particles between 1 and 2 µm 
and in humans between 3 and 5 µm. The total deposition efficiency of 
particles having an aerodynamic particle size between 1 and 5 µm for General Introduction 
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humans, dogs, guinea pigs and monkeys is roughly similar, but lower for 
rats (124, 127-130).  
 
Generally, the following administration methods are available to 
administer aerosols to animals. These methods can be divided into passive 
and active administration methods, referring to the principle by which 
the aerosol is brought into the lung. 
 
-  Passive methods (animal inhales aerosol by breathing)  
o  Whole body chambers 
o  Nose-only exposure 
-  Active methods (animal gets aerosol administered) 
o  Intratracheal instillation 
o  Intratracheal insufflation 
 
The passive methods are divided into whole body chambers and nose-only 
exposure. A benefit of using passive methods is that the aerosol is inhaled 
in a physiologic manner, enabling research on the lung penetration and 
deposition of the aerosol (e.g. the effect of particle engineering). In 
addition, the complete respiratory tract is covered and the animal does 
not have to be anaesthetized. A disadvantage of passive methods is that 
the inhaled dose cannot be adequately controlled. Since the animals need 
a number of breathing cycles to inhale a substantial dose and the dose is 
to be given over a longer period of time (131). 
 
With whole body chambers, the animal generally is unanaesthetized and 
unrestrained. An aerosol is externally created and transferred to the 
aerosol chamber, where the animals may inhale the aerosol. This method 
is generally used for small laboratory animals, such as mice, rats and 
guinea pigs. Sophisticated method development of the whole body 
chamber concept has led to amongst others a model that allows 
investigation of chronic asthma and airway remodeling (132). A specific 
disadvantage of whole body exposure is that the aerosol will also deposit 
on the fur. After licking the fur, the drug may be absorbed via the oral 
route, making possible effects less attributable to inhalation. To reduce 
possible absorption through the oral route, nose-only exposure models 
have been developed. With nose-only exposure, the animals are fixated in 
restrainers to allow adequate positioning in an orifice that is connected to Chapter 1 
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a chamber containing the aerosol. In this way, only the nose is exposed to 
the aerosol, thereby reducing fur deposition. Such nose-only methods 
were mainly developed for liquid aerosols or smoke exposure (131, 133), 
but can also be used for dry powder aerosols (134). 
 
The active methods have as benefit that they allow precise dose metering 
and that the dose can be given in a bolus, this enables for example dose-
response measurements. Furthermore, the method is relatively simple, 
even though transoral intubation is needed. Fur deposition is not an issue 
with the invasive methods. Disadvantages include that the method is non-
physiologic and that the upper respiratory tract is avoided. Furthermore, 
anesthesia is required for the intubation procedure. Anesthesia 
potentially may alter clearance rates and influence the effects (135). Two 
methods different active administration methods have been developed: 
intratracheal instillation and intratracheal insufflation.  The difference 
between the two is that instillation is performed with a liquid(21) and 
insufflation with a liquid or powder aerosol (29). Important factors to 
consider with intratracheal administration are the intubation method, the 
administered dose and the method of anesthesia. For instillation, 
additional factors are the vehicle to suspend or dissolve the drug in and 
the total volume used. Intratracheal administration is widely used due its 
relative simplicity, low cost and the accurate dose metering. The 
intubation procedure requires skilled personnel. 
 
How do passive and active methods relate in terms of deposition 
patterns, absorption and clearance? First of all, the dose administration 
rate is different for the two methods: with active methods the dose is 
given as bolus, while with passive methods dosing takes a certain period 
of time encompassing a number of inhalation cycles. In addition, with 
passive methods, the upper respiratory tract is also exposed to the 
aerosol in contrast to the active methods. Therefore, with passive 
methods the deposition pattern relies more on the aerodynamic particle 
size than with active methods. The deposition pattern obtained with 
passive methods is more homogeneous than obtained with active 
methods. There are indications that by using active methods, more 
“patchy” deposition patterns are observed, which may have a 
consequence for clearance, the site and degree of systemic absorption 
and local toxicity (131, 135-138). For example, clearance by macrophages General Introduction 
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has been described to be dependent on the administration method (138). 
With active methods, a large variation could be observed in foreign 
material load of macrophages, with some containing no foreign material 
while other macrophages were overloaded. In contrast, by using passive 
methods, the macrophages contained a relatively similar amount of 
foreign material. Therefore, the different methods have their own 
distinct pros and cons. In practice, the choice for any administration 
method will often rely on the type of study (dose needed, length of 
study, type of drug, desired lung-deposition profile) and the available 
expertise in aerosol administration to laboratory animals. 
 
Through experimental handling, a specific disease can be developed in 
animals. Such animal models do not only enable improved understanding 
of certain diseases but also the conduct of efficacy studies in animals. For 
example, animal models have been developed for tuberculosis infection 
(139, 140), chronic obstructive pulmonary disease (133, 141), asthma 
(142, 143), cystic fibrosis (144) and lung transplantation (145). Some 
animal models only require inhalation of toxic or infectious substances 
(COPD and tuberculosis model) while other models require gene 
manipulation (cystic fibrosis) or surgery (lung transplantation). By 
combining such animal models with a certain administration method, 
early proof of principle or proof of concept can be generated. Such 
studies are needed to bridge the gap between formulation development 
and first trials in humans and are for ethical reasons essential.   
 
CRITICAL NOTES 
In the field of inhalation (of biopharmaceuticals) several aspects are still 
the subject of intense discussions and conflicting opinions. A major point 
of discussion focuses on what the best device and/or formulation for a 
specific patient would be. Irrespective of the device used the patients 
characteristics (age, lung function, disease status, compliance) determine 
to a large extend the choice for an inhalation system and essential 
characteristics of the inhalation such as the extend of lung deposition as 
well as location of the deposition (predominantly central or peripheral). 
On the other hand, the type of formulation (liquid or dry, powder 
production technique which affects size and density) and the combination 
with a certain device (nebulizers, pressured metered dose inhalers, 
passive or active dry powder inhalers) determine also the aerodynamic Chapter 1 
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particle size distribution and thereby deposition characteristics. 
Ultimately, only an in-depth evaluation of the complex of relevant 
parameters in the context of their mutual interrelationships may lead to 
an optimal choice for the therapy, formulation and device. Some major 
parameters playing a role in this complex are: 
-  Patient characteristics (lung function, age, disease state, compliance, 
etc.) 
-  Desired lung deposition 
-  Deposition target in the lung, 
-  Physico-chemical characteristics of the drug and the formulation 
-  Type of device 
However, the set of parameters given above is far from complete, and it 
should be realized that the simple optimization of just one parameter, 
may too often not lead to an optimal therapeutic result. The best 
available therapy is not always that device-formulation combination that 
would result in the highest fine particle fraction, but it is the combination 
of patient (age, lung function, disease status, compliance) with a certain 
device-formulation combination that is effective. For instance, a dry 
powder inhaler is not effective in children younger than 5 years old. 
Instead, often a combination of a MDI with valved holding chamber is 
used. Therefore, the primary determinant to choose a certain formulation 
and/or device depends on the patient, whose characteristics cannot be 
controlled. It should therefore be appreciated that general improvements 
on formulations and devices will bring highly differentiated improvements 
in therapy for different patient groups. 
 
The strategies thought of that improve the formulation and device are the 
following. First, the formulation needs to be such that the powder is 
easily dispersible into the primary particles. In addition, the batch-to-
batch variation of the primary particle size needs to be very small to 
ensure that the physical properties of the powder are constant. 
Monodisperse aerosols are also under investigation for claimed targeted 
deposition. Most of the improvements are found in the devices and relate 
to improvement of the fine particle fraction, reduction of coordination 
problems and improvement of the deep lung deposition. To improve the 
fine particle fraction, the device should reproducibly produce the fine 
particle fraction, which preferably is dependent on the patients’ 
inhalation characteristics. Some devices are under development that use General Introduction 
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auxiliary energy to improve the fine particle fraction, and some of them 
adapt the aerosol generation to the breathing pattern of the patient to 
reduce coordination problems. To further reduce coordination problems, 
the dose should be given after breath actuation. The time in which the 
dose is released should be within 0.5 second to improve deep lung 
deposition. The particle velocity from the inhaler should be reduced to 
minimize oropharyngeal deposition (loss) in favor of deep lung deposition 
(51). Devices that improve patient compliance and reduce healthcare 
costs are easy and robust to use (light, easy to carry and not require 
electricity or pressurized air), give feedback on the success of the 
inhalation maneuver and contain a multidose compartment with dose 
counter (51). 
 
Most new inhalers have been described to exercise insufficient control 
over the flow manoeuvres (12), which could lead to a variation in 
deposition patterns. To decrease the influence of variability in inspiratory 
air flows, the inhaler resistance can be increased (146). However, the 
acceptance of high resistance dry powder inhalers is still low as it is 
believed that patients with strongly reduced lung function may find it 
difficult operate such devices successfully (147), which is a widespread 
misconception. High resistant inhalers are generally efficient delivery 
(and dispersion) devices (12) due to higher turbulence compared to low 
resistant inhalers at a certain air flow and the fact that different dry 
powder inhalers tend to be operated at the same respiratory effort (148). 
As a result, they are capable of producing high fine particle doses already 
at relatively low pressure drops (149-151). Even when being operated at 
the same pressure difference, the amount of work (product of pressure 
drop, volumetric flow rate and inspiration time) delivered by a patient to 
inhale the same volume remains similar when the resistances differ as 
much as between the Aerolizer (R = 0.019 kPa
0.5.min.l
-1) and the Inhalator 
Ingelheim (R = 0.044 kPa
0.5.min.l
-1) when operated at comfortable 
inspiratory effort (148). Besides that, patients tend to generate the 
highest pressure drops through the highest air flow resistances (146).  
 
The performance of so-called passive dry powder inhalers (dpi’s) has been 
criticised in respect of undesired dependence on the patient’s inspiratory 
flow (12, 72, 152, 153). Whether this is really a disadvantage or not, may 
depend on the desired site of deposition and the extent to which the fine Chapter 1 
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particle dose is affected by the inhalation flow rate. Considering that the 
deposition of particles shifts to higher airways when the flow rate is 
increased (e.g. (154)), it may be expected that a more constant therapy 
is obtained when the fine particle dose is balanced with the inhalation 
manoeuvre, which means that more particles have to be delivered at 
higher flow rates to compensate for higher losses in the upper respiratory 
tract. There is not much evidence in literature for this expectation, as 
most marketed devices up to now produce a more or less constant fine 
particle dose at all flow rates (155). As a result of that, the 
manufacturers have no interest in showing the clinical effect as function 
of the inspiratory flow rate. Yet, there are some indications which seem 
to prove the importance of balancing. Nelson et al. (156) showed for the 
Spiros dry powder inhaler with battery powered dispersion system, 
delivering a flow rate independent fine particle dose, that lung deposition 
of beclomethasone propionate decreased from 41 to 30% (and 
oropharyngeal deposition increased from 37 to 54%) when the flow rate 
was increased from 15 to 60 l/min. Also Usmani et al. (7) reported for 
monosized salbutamol particles of different sizes a strongly decreasing 
aerosol penetration into the lung when the flow rate was doubled from 31 
to 67 l/min. As to be expected, the difference was greatest for the 
largest particles. In line with these findings, Newman et al. (157) found 
for the Novolizer, which produces a very fine aerosol and exhibits an 
increasing fine particle dose with increasing flow rate (150), that 
peripheral lung deposition may almost be the same at all flow rates 
(between 45 and 90 l/min). The flow-independent deposition behaviour is 
explained by the higher fine particle dose generated at higher inspiratory 
flows, which compensate the increased inertial impaction in the upper 
respiratory airways caused by the higher inspiratory airflow (51). 
 
Monodisperse aerosols are claimed to consist of particles of the same 
size. The geometric standard deviation (GSD) ideally has unity, but 
practically a value below 1.22 is considered to describe a monodisperse 
size distribution (158). Monodisperse aerosols are thought to have greater 
specificity of airway targeting than polydisperse aerosols (159). However, 
deposition modelling studies show that particles of uniform size are 
deposited in all airway generations, with peaks in fractional deposition 
that vary with the inspiratory flow manoeuvre (e.g. (154)). The effect of 
flow rate and inhaled volume is even different for particles of different General Introduction 
 
27 
size (160), particularly when oropharyngeal deposition is taken into 
account. This makes comparing the deposition efficacies of monosized 
particles with different aerodynamic diameters rather arguable when the 
inspiration manoeuvre is not precisely controlled with respect to flow 
rate, duration and inhaled volume. Besides, deposition is also influenced 
by lung morphology (airway dimensions) and local obstructions (161), 
factors that are uncontrolled and highly variable from patient to patient. 
It is thus easy to understand that it will be impossible to define just one 
optimal aerodynamic diameter that can be applied for targeting to a 
specific site of action for the whole population, even when the inspiratory 
flow conditions are fully controlled and precisely the same. From this 
point of view it may be questioned whether polydisperse aerosols in spite 
of their lower specificity, are not better to use since they at least will 
always result in some deposition at the site of action.  
 
Finally, several dry powder inhaler systems are in development to replace 
wet nebulization, for instance in antibiotic therapy for cystic fibrosis 
patients (87, 151, 162). Although the advantages of dry powder 
administration seem to be clear and a significant improvement of CF 
therapy is expected from this replacement in administration systems 
(163), many aspects still remain uncertain. There is for instance a 
difference between single inhalation (as from a dpi) and drug delivery 
during several breathing cycles at tidal breathing level (as during 
nebulization). From the total lung volume of (adult male) humans 
(approx. 6 L) and the residual volume (1.2 to 2.5 L), it can easily be 
calculated that the maximal refreshment of air is 3.5 to 4.8 L (60 to 80% 
of total lung volume). Practically, inhaled volumes through dpi’s are often 
considerably lower, as patients often exhale insufficiently before taking a 
dose. Particularly for COPD patients and older asthmatics inhaled volumes 
may be confined to only 1.5-2.5 L. This has consequences for the 
penetration depth of airborne particles, particularly when the entire 
aerosol is not released as a bolus at the beginning of the inhalation 
manoeuvre. Taking into account that a laminar air flow exists at all flow 
rates beyond generation 5, it may be expected that mixing of residual air 
and newly inhaled air (containing the aerosol) during a single inhalation is 
rather incomplete. Therefore, inhaled volumes of 1.5 to 2.5 L 
(corresponding with 25 to 40% refreshment) may reach no further than 
generation 19 and 21 respectively. When the entire aerosol is Chapter 1 
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homogeneously distributed in the first litre of inhaled air, 50% of the dose 
may travel not further than generation 17 to 19. This has the 
consequence that a major portion of the airborne particles which possess 
the potential to enter the alveoli on the basis of their aerodynamic 
properties, will not get there. This, in contrast with wet nebulization over 
several inhalation cycles during which mixing by convection and diffusion 
will be more complete. High doses of dry powders inhaled in one single 
manoeuvre may also cause a different response in the patient (e.g. cough 
and chest tightness) than wet aerosols administered at much lower 
concentrations over a longer time; this may also depend on the (physico-
)chemical properties of the drug. It may therefore be questioned whether 
spreading a high powder dose over a small number (2-3) of subsequent 
inhalations burdens the patient less and will be more effective than 
inhaling the entire dose in only one manoeuvre.  
 
For biopharmaceuticals, much effort has been devoted to advanced 
particle engineering. One of the developments is the use of so-called 
large porous particles that have densities of less than 0.1 g/cm
3 (79). The 
relevance and benefit of using large porous particles is claimed to be 
improved dispersion characteristics and improved aerosol behaviour and 
deposition characteristics (76, 79, 81). However, improved dispersion 
characteristics can also be achieved by effective inhalation devices, such 
as those with high resistance (149-151). In addition, despite total lung 
deposition and variability of large porous particles were superior to 
conventional systems (81), the efficiency of deposition of large porous 
particles has been doubted in a different study (83) due to lower diffusion 
efficiency and gravitational sedimentation of large porous particles 
compared to submicron particles. Finally, surface characteristics such as 
specific surface area and surface concentration of the drug may affect 
stability of the particles. Especially different drying methods may result 
in different surface characteristics. For instance, the specific surface 
area of particles prepared by spray drying or spray freeze-drying differ 
largely (20, 99). Some studies have demonstrated that particles with 
higher specific surface areas demonstrated inferior storage stability 
compared to similar formulations with lower specific surface areas even 
though secondary structures of the molecules were similar for the 
different drying methods (98, 164). In addition, the surface concentration 
was also reported be of influence on storage stability. For instance, a General Introduction 
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formulation of recombinant human interferon-γ (rhIFN-γ ) that was spray 
freeze-dried had a higher protein concentration on the surface and lower 
stability compared to the freeze-dried formulation (98). 
 
CONCLUSION 
To produce inhalation formulations of active substances many particle 
engineering techniques may be used, next to a variety of formulations 
and devices. Recent trends in inhalation product development can be 
summarized by maximization of lung deposition by increasing the fine 
particle dose, improvement of particle characteristics with regard to both 
the aerosolization behavior as well as the stability of the powder and the 
development of inhalation devices that enable more effective inhalation 
as well as a more comfortable inhalation. The increasing number of 
biopharmaceuticals has fuelled research both in formulation technology 
and device technology. However, many of the research is still performed 
on small scale and little has been picked up by the industry. Moreover, 
much of the research focuses only on one or two relevant parameters and 
tends to neglect the interacting other parameters determining the 
success of an inhalation therapy. So far, the first inhalable insulin 
product, Exubera
®, made it to the market but the product was withdrawn 
by the company within one year after market introduction. Despite the 
bitter taste for Pfizer, the lesson learned for the inhalation community is 
that any new marketed product for inhalation should hold a true 
therapeutic advantage over the existing treatment and be free from any 
doubts regarding safety compared to the conventional therapy. Moreover, 
the device should be convenient and robust for routine use. Finally, in 
many European countries a large emphasis is placed on the costs for 
medicines. In short, the cost for a medicine to save one life year should in 
general not exceed the benefit of that life year. Therefore, for a 
successful launch of a product for inhalation, formulation research and 
device development should go hand-in-hand with regular cost evaluations.  
Finally, although the current investments in the development of new 
inhalation therapies is high and it is easy to imagine a multitude of 
potential improvements and advantages of these therapies. It should be 
realized that due to the high attrition rate in the pharmaceutical industry 
only a small number of the developments discussed in this chapter will 
reach the market. 
 Chapter 1 
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AIM AND OUTLINE OF THIS THESIS 
Next to Exubera
®, there are very few biopharmaceuticals products for 
inhalation (only Pulmozyme
®) that have reached the market. There are 
various therapeutic possibilities, not only for new substances, but also for 
improvement of current therapy with existing substances. The research 
described in this thesis focuses on contributing to knowledge on 
pharmaceutical aspects of inhalation of biopharmaceuticals. Emphasis 
was placed on dosage form development (especially dry powder 
inhalation systems) and on preclinical efficacy and safety investigations. 
The research was based on a number of model compounds that each had 
their own characteristics and problems.  
In the first phase of the research, systemically acting peptides were 
investigated for which only formulation aspects were relevant, since their 
absorption after pulmonary administration was already proven. The first 
peptide investigated was cetrorelix. For this peptide, only the 
formulation research had to be carried out, since aspects related to 
efficacy of the pulmonary administration were already investigated. A 
range of different formulation techniques was evaluated to find the best 
formulation for use of the product in the Novolizer
® inhaler. The second 
peptide investigated was cyclosporine A. Because the pulmonary use of 
this drug with nebulizers had failed in clinical studies, probably because 
of formulation related side-effects, it was decided to develop an 
innovative dry powder formulation of this drug. However, this approach 
not only required formulation development but also the development of 
an adequate lung transplantation model in animals to test efficacy and 
safety.  
Subsequently, a larger locally acting protein (rhDNase) was chosen as 
subject for formulation research. Next to that, also pharmacoeconomic 
aspects of the newly developed product were investigated.  
Finally, a highly innovative approach was chosen in which the therapeutic 
protein was not administered by inhalation, but its endogenous synthesis 
was induced by a small organic substrate that was inhaled. A major 
advantage of this approach is that the formulation of organic compounds 
is much easier than formulating proteins as powder for inhalation. 
 
In chapter 2, the role of particle engineering techniques with respect to 
in vitro aerosol behavior of the decapeptide cetrorelix, a GnRH-
antagonist used for ovarian super stimulation and intended for systemic General Introduction 
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administration, was investigated. Cetrorelix was milled, spray dried, 
spray freeze-dried and subsequently formulated as an adhesive mixture. 
The effect of inhaler design (deagglomeration principle) on aerosol 
properties in relation to the differently produced particles was also 
investigated.  
 
In chapter 3, the lipophilic cyclic undecapeptide cyclosporine A was spray 
freeze-dried to obtain an inulin-based glassy solid dispersion for 
inhalation. Several pharmaceutical aspects of this product were 
investigated. In vitro aerosol characteristics were determined, but also 
the inclusion and molecular arrangement of Cyclosporine A in the inulin 
glass was studied with Fourier Transformation Infrared spectroscopy. 
 
In chapter 4A, the inulin-based solid dispersion of cyclosporine A was 
tested in an in vivo left lung transplantation rat model and compared to 
orally administered Neoral
®. In this study, the cyclosporine A solid 
dispersion was administered with the PennCentury insufflator to obtain 
intrapulmonary administration. First, the pharmacokinetics of a single 10 
mg/kg dose of cyclosporine solid dispersion and Neoral were determined. 
Next, the efficacy and safety of the cyclosporine A solid dispersion and 
Neoral were investigated. 
 
In chapter 4B, the safety of the cyclosporine A solid dispersion, the 
excipients and the administration technique were further investigated 
and compared to healthy control animals. 
 
In chapter 5, the choice of excipients (sucrose, trehalose or inulin as 
stabilizer) and powder preparation technique (spray drying or spray 
freeze-drying) to produce a stable and inhalable amorphous glass 
formulation of (recombinant human) deoxyribonuclease I was 
investigated. The best performing formulation in terms of stability and in 
vitro inhalation behavior was subsequently tested for its efficacy of 
reducing the viscoelasticity of sputum from 5 cystic fibrosis patients. 
 
In chapter 6, pharmacoeconomic aspects of different modes of pulmonary 
administration of recombinant human deoxyribonuclease I, a 33 kDa 
protein were investigated. Factors such as the costs of the medicine, the 




® was compared to the dry powder inhalation 
product. 
 
In chapter 7, the organic molecule ferriprotoporphyrrin (hemin) was 
formulated as a powder for inhalation to induce heme oxygenase 
synthesis in the lung. The heme oxygenase in turn is  able to attenuate 
inflammation by virtue of its end-products ferritin, bilirubin and 
carbonmonoxide. First, spray drying as a powder preparation method was 
evaluated. Furthermore, a non-invasive, nose-only exposure chamber was 
developed to administer powders for inhalation to small rodents such as 
mice and/or rats. Finally, the efficacy of the pulmonary administration of 
hemin was evaluated in mice. 
 
In chapter 8, the findings of the studies described in this thesis form the 
basis for some concluding remarks and a discussion on the perspectives 
for future research in the field of the pulmonary administration of 
biopharmaceuticals. 
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We formulated cetrorelix acetate, as an adhesive mixture for use in 
dry powder inhalation. To achieve the highest possible deposition 
efficiency we investigated both the influence of different 
micronization techniques and different inhalers. The Novolizer with an 
air classifier as the powder de-agglomeration principle and the ISF 
inhaler were used for in vitro deposition experiments (cascade 
impaction). Micronization by milling as the classical approach and 
micronization by spray drying and spray freeze drying as advanced 
particle engineering techniques were investigated to determine 
whether advanced techniques are necessary to obtain high fine 
particle fractions (FPF) for this specific drug. It was found that the 
effects obtained with a certain micronization technique depended on 
the complex interaction of the physical characteristics of the drug 
substance with the type of formulation chosen, as well as with the de-
agglomeration principle used. The combination of particle engineering 
by spray drying and the use of the air classifier technology resulted in 
a fine particle fraction of 66%, while spray freeze drying yielded 
extremely fragile particles resulting in a FPF of only 25%. The 
behaviour of the milled material showed similar trends as the spray 
dried material but FPF values were lower. It was concluded that when 
a drug is to be formulated as a powder for inhalation with high fine 
particle fractions, it is profitable to use advanced particle engineering 
techniques, however the applied technique should be tuned with the 
characteristics of the formulation type and process as well as with 




Cetrorelix acetate, for convenience referred to as cetrorelix, is used for 
the controlled ovarian super stimulation for assisted reproductive 
technique in a 0.25 mg dose (multiple dose regimen). However, there are 
more therapeutic opportunities for this decapeptide, which are captured 
under the term “sex-hormone dependent pathologies” (1, 2).  
Cetrorelix, a decapeptide, is currently used in a subcutaneous dosage 
form. For systemic administration, the pulmonary route offers 
opportunities as well as great advantages compared to other non-invasive 
routes of administration (3-8). The large surface area of the lung 
(approximately 40 – 100 m
2), thin alveolar epithelia, the extensive 
vascular system, and avoidance of the first-pass effect contribute to the 
expectation that the pulmonary route is the most promising non-invasive 
route by which (deca-) peptides can be administered to obtain systemic 
absorption (9-11). 
Lizio et al. showed that after pulmonary administration of a liquid 
cetrorelix formulation systemic absorption occurred, demonstrating the 
suitability of this route of administration (1, 2, 12). However, for 
widespread use dry powder formulations may be advantageous (13, 14).  
The aerosol of a drug for dry powder inhalation should preferably have a 
high fraction of particles in the aerodynamic size range of 1 – 5 µm (fine 
particle fraction) for effective delivery to the lung (14, 15). To obtain a 
powder in the required size distribution, several techniques can be 
applied (14, 16). These techniques include standard techniques such as 
milling (14, 17), and more advanced techniques such as spray drying (18-
20), spray freeze drying (21, 22), super critical fluid extraction (23, 24) 
and crystallization (25). Optimization of the fine particle fraction has 
often been sought in either advanced particle engineering to generate 
particles with improved aerosolization behaviour (e.g. large porous 
particles, PulmoSphere) or solutions to overcome the increase of surface 
free energy which is inherent to milling (26-28).  
The aim of this study is to formulate cetrorelix with a high fine particle 
fraction as a powder for inhalation using three different methods for 
micronization, namely milling, as an example of a standard technique, 
and spray drying and spray freeze drying as examples of more advanced 
techniques applied in particle engineering. We investigated the effects of 
the three methods on shape, size and density in relation to the 
aerosolization behaviour, in order to decide which micronization method Chapter 2 
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delivers the particles that are most suitable for inhalation using the 
adhesive mixture type of formulation. For dispersion of the formulations 
we used the Novolizer dry powder inhaler (29, 30), and the ISF inhaler 
(31). De-agglomeration in the Novolizer is mainly based on inertial forces 
occurring in the air classifier which results in high de-agglomeration 
forces. In the ISF inhaler de-agglomeration is based on lift and drag as 
well as inertial forces. These two inhalers were used to test the 
hypothesis that both the types of particle engineering technology applied 
in the formulation as well as the efficiency of the de-agglomeration 
principle are relevant to the performance of the dry powder inhalation 
system (generation of the fine particle fraction).  
 
MATERIALS AND METHODS 
Materials 
Cetrorelix acetate was obtained from Sofotec (Frankfurt, Germany) in the 
form of a lyophilisate. The lyophilisate was used as raw material for the 
comminution studies. 
Small batches (50 gram) of lactose, size fraction 63-90 µm, were derived 
from Pharmatose 100M (DMV International, Veghel, The Netherlands) by 
20 min. vibratory sieving (in a Fritsch Analysette 3, Idar Oberstein, 
Germany) followed by 10 min. air jet sieving (in an Alpine A200 LS, 
Augsburg, Germany).  
 
Methods 
Preparation techniques for cetrorelix 
Milling 
The milling of cetrorelix was performed with a pearl-mill equipped with a 
cryostat. The system was cooled to -60°C and 5 gram of cetrorelix 
lyophilisate in 243 ml HFA 227 was milled with 100 ml ZrO2-Ir stabilized 
pearls (diameter = 0.6 mm) for 15 min. Using this process, only minute 
amounts of degradation products (<1.17%) were found, which is indicative 
of the stability of cetrorelix (17). Furthermore only minimal metal 
contaminants (Zr = max. 0.6 ppm; Fe, Cr, Ni, Ba < 0.14 ppm; Al = 1.1 
ppm) were found,. 
 
Spray drying 
For the spray drying experiments, 2.5 gram of lyophilized cetrorelix was 
dissolved in a mixture of 40 ml tert-butanol (TBA) and 60 ml of distilled Cetrorelix: Particle engineering, formulation and de-agglomeration principle 
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water. Tert-butanol was added because it was described (32) that this 
solvent creates improved dispersion characteristics. The resulting solution 
was then spray dried with a Büchi 190 Mini Spray Dryer (Büchi, Flawil, 
Switzerland) equipped with a two-fluid nozzle (0.5 mm). The setting of 
the pump was 3 (corresponding to 2.37 ml/min), aspirator 18 (-75 mbar), 
heating 8.5 and the atomizing airflow was 800 ln/h. These settings 
resulted in an in- and outlet temperature of 117 and 75 °C, respectively. 
The obtained powder was subsequently stored at 20 °C and 50% RH. 
 
Spray freeze drying 
For spray freeze drying, the same solution of 2.5 gram cetrorelix in a 
40/60 TBA/water (v/v) mixture was used. The solution was sprayed into a 
bowl of liquid nitrogen with the two-fluid nozzle (diameter 0.5 mm) of 
the Büchi Mini Spray Dryer. The nozzle was placed approximately 10 cm 
above the surface of the liquid nitrogen and the cetrorelix-solution was 
atomized with an air flow of 800 ln/h. After the spraying was completed, 
the bowl with liquid nitrogen and cetrorelix was transferred to a Christ 
model Alpha 2-4 freeze dryer (Salm & Kipp, Breukelen, The Netherlands) 
and subsequently freeze dried at a shelf temperature of -35 °C and a 
pressure of 0.220 mbar. Secondary drying was started after 21 h. by 
gradually increasing the shelf temperature to 20 °C and decreasing the 
pressure to 0.060 mbar over a time period of 3 h. Secondary drying lasted 
another 24 hours. The obtained powder was subsequently stored at 20 °C 
and 50% RH. 
 
Preparation of adhesive mixtures 
The dose for Cetrorelix when administered subcutaneously is 0.25 mg. 
Based on this parenteral dose, the required fine particle dose for 
pulmonary administration was estimated to be around 0.30 mg. To deliver 
0.30 mg as fine particle mass it was calculated that for a fine particle 
fraction of 40% a dose of 0.75 mg would be sufficient. When adhesive 
mixtures with a 5% w/w drug load are used, this would mean that the 
dose weight would be 15 mg of powder. 
Adhesive mixtures were prepared by mixing Cetrorelix with Pharmatose 
110 M (63-90 µm) in a tumbling mixer (Turbula T2C, W.A. Bachofen, 
Basel, Switzerland) at 90 r.p.m. for 30 min. in a stainless steel container 
of 40 ml. To obtain adequate coefficients of variation for milled 
cetrorelix it was necessary to use two stainless steel balls with a diameter Chapter 2 
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of 7 mm, as grinders for the drug, since the milled cetrorelix contained 
many agglomerates. The mixtures were stored for at least 7 days at 20 °C 
and 50% RH before use to reduce the effects of electrostatic charging. 
 
Physical characterization of the starting materials and mixtures 
Characterization of materials 
The specific surface areas (m
2/g) of all materials (i.e. milled, spray dried 
and spray freeze dried cetrorelix and Pharmatose) were obtained by BET 
(nitrogen adsorption) measurement with a Tristar 3000 model 
(Micromeritics, Norcross, U.S.A.) using a 5 point analysis at -195.65 °C. 
The samples were inserted into test tubes and rinsed with helium prior to 
the measurement.  
The apparent particle densities of the micronized materials were 
measured at a temperature of 20 °C with helium pycnometry 
(Quantachrome, Syosset, NY, USA).  
Moisture isotherms of micronized cetrorelix were determined with a 
dynamic vapour sorption apparatus (DVS 1000, Surface Measurement 
Systems Ltd., London, UK) at 25°C. About 10 mg of material was weighed 
in the sample cup and exposed to 0% RH until the rate in change of mass 
per minute (dm/dt) was less than 0.0005%/min. The relative humidity was 
subsequently increased with incremental steps of 10% from 0 to 90% RH. 
Each step was triggered on a dm/dt of 0.0005%/min. 
Particle size distributions of the micronized materials were measured in 
duplicate (differences for all samples were <1%) with a HELOS Compact 
model KA laser diffraction apparatus (Sympatec GmbH, Clausthal-
Zellerfeld, Germany: 100 mm lens and the Fraunhofer theory) equipped 
with a RODOS disperser. The powders were dispersed at a pressure of 5 
bar.  
Scanning electron micrographs (SEM) were recorded with a JEOL JSM 
6301-F Microscope (JEOL, Japan). The powder was dispersed on top of 
double-sided sticky carbon tape on metal disks and coated with 150 nm of 
gold/palladium in a Balzers 120B sputtering device (Balzers UNION, 
Liechtenstein). 
The purity of the starting materials, as well as that of the raw material of 
cetrorelix was determined with HPLC (33). The elution condition for the 
peptide from the column (Lichrospher 60 RP-Select B 5 microns, 250x4 
mm I.D.) was isocratic with a 49:51 mixture of an ammonium acetate 
buffer (0.05 mol/l, pH 4) and methanol-acetonitrile (1:1 v/v), Cetrorelix: Particle engineering, formulation and de-agglomeration principle 
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respectively. The detection of the peptide was done with fluorescence 
detection with an excitation wavelength of 227 nm and emission 
wavelength of 340 nm.  
 
Characterization and dosing of mixtures 
The adhesive mixtures were filled out in the dosing system of the 
inhalers. For the Novolizer cartridges were filled and dosing was 
performed with the built-in metering system, while for the ISF device, 
capsules were filled to the same degree as the commercial product which 
corresponded to approximately 25 mg. The consistency of the delivered 
dose from the Novolizer (Sofotec, Frankfurt, Germany) was determined 
by dosing 20 samples which were individually weighed. Each dose was 
dissolved in 25 ml de-ionized water and analyzed spectrophotometrically 
at 226 nm with a Philips PU 8720 UV-VIS spectrophotometer (Philips, The 
Netherlands). Results of dose consistency were also used for the mixtures 
used in the ISF inhaler. 
 
Aerosol characterization 
Particle size distributions of aerosols generated by formulations of milled, 
spray dried and spray freeze dried cetrorelix, respectively, were 
measured with a HELOS Compact model KA laser diffraction apparatus 
(100 mm lens and the Fraunhofer theory) equipped with the INHALER 
adapter (Sympatec GmbH, Clausthal-Zellerfeld) (34, 35). The powders 
were dispersed with the Novolizer at a pressure-difference of 4 kPa (71 
l/min) across the inhaler for 3 s. The obtained data often show a bimodal 
size distribution in which the first peak is that of the micronized drug and 
the distinct, second peak is from the carrier. To obtain an estimate of the 
drug size distribution, the second distinct peak of the coarser carrier 
material was eliminated from the curve. This procedure has been 
validated by checking whether the second peak (coarse carrier) in the 
original bimodal size distribution really was originating from the carrier 
material. This was done by removing the particle size distribution of the 
drug (the first peak) and subsequent comparison of the of the obtained 
carrier particle size distribution with the original carrier particle size 
distribution. If discrepancies in the carrier size distributions were found, 
then the measurement was considered as wrong and a new measurement 
was performed. Chapter 2 
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Cascade impactor analysis was carried out with a glass constructed four 
stage liquid impactor of the Fisons type (Elgebe, Leek, The Netherlands). 
The ISF inhaler or the Novolizer was attached to a dry bent induction 
port. The airflow, created with a pressure-difference of 2.8 kPa (90 
l/min, theoretical cut-off diameters 13.32, 6.77 and 3.35 µm for the first, 
second and third stage, respectively) for the ISF inhaler or 4 kPa (71 
l/min, theoretical cut-off diameters 14.80, 7.58 and 3.74 µm for the first, 
second and third stage, respectively) for the Novolizer through the 
inhaler and cascade impactor was controlled with a solenoid valve in 
combination with a time controller to start and stop the flow. The 
pressure-difference of 4 kPa for the ISF inhaler could not be reached due 
to the low resistance of this inhaler and disruption of the capsule. The 
European Pharmacopoeia (2002) describes that for capsule inhalers a flow 
rate of 100 l/min should be used. However, due to the relative high 
resistance of the Fisons cascade impactor only 90 l/min was achievable 
which corresponds to 2.8 kPa. For each cascade impactor analysis a total 
dose of 125 mg had to be delivered. For the Novolizer the total mass was 
delivered in 10 doses, while for the ISF inhaler this was achieved in 5 
doses. The difference in the number of doses was due to the fact that the 
capsules of the ISF inhaler had to be filled to the same degree as the 
marketed product in order to utilize the ISF inhaler to the best 
performance. Cascade impactor measurements were performed in 
duplicate. The amount of drug deposited on the different stages was 
determined by dissolving in water followed by ultra-violet spectroscopy 
(226 nm). Depositions on the stages are expressed as a percentage of the 
metered dose. The fine particle fraction is the sum of the deposition on 
the third and fourth stage. 
 
RESULTS 
Effect of preparation technique on cetrorelix properties 
Table 1 shows that all three micronization techniques could be applied 
without degradation of cetrorelix. This shows that a dry powder 
formulation of cetrorelix can be obtained without complex formulation 
methods and that we can use dry powder formulation techniques based 
on the pure micronized drug. With respect to crystallinity it should be 
mentioned that all three different cetrorelix materials were amorphous, 
as was confirmed by differential scanning calorimetry (data not shown). 
 Cetrorelix: Particle engineering, formulation and de-agglomeration principle 
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Table 1. Physical characteristics of the starting materials 
Material Type  Purity
1  Surface Area  Density 
      (%)  (m
2/g) (g/cm
3) 
Pharmatose 110M  Size fraction 63-90 µm  -  0.171  - 
        
Cetrorelix Milled  103.8  20.09  1.276 
 Spray  dried  100.6  9.15  1.187 
   Spray freeze dried  98.3  49.23  0.675 
1 The purity is defined as the ratio between the amount of active before and after the 
micronization step multiplied by 100% 
 
Table 2. Details of micronized cetrorelix as starting materials and in the aerosol 
from the Novolizer 
  x 10 x 50 x 90 
      (μm) (μm) (μm) 
Milled Cetrorelix  Starting material  0.55  1.34  48.50 
 Aerosol  cloud  0.56  1.38  3.11 
        
Spray dried Cetrorelix  Starting material  1.02  2.30  4.62 
 Aerosol  cloud  1.42  2.58  4.52 
        
Spray freeze dried   Starting material  0.90  2.32  5.22 
Cetrorelix   Aerosol cloud  0.78  2.13  6.73 
 
In Fig. 1 the particle size distributions of the pure micronized materials 
from RODOS dispersion are shown, and in Table 2 the accompanying 10%, 
50% and 90% values from the cumulative undersize curves are presented. 
As can be seen from the bimodal shape of the cumulative curve, milled 
cetrorelix contains several agglomerates larger than 10 µm in the starting 
material. Fig. 1 also shows that spray dried and spray freeze dried 
cetrorelix have almost similar median particle size diameters. Clearly all 
three micronization techniques result in particles that are within the 



















Figure 1. Particle size distributions of micronized cetrorelix. Open symbols 
represent the particle size distributions of the starting materials obtained from 
RODOS dispersion ({ = milled cetrorelix, V = spray dried and  = spray freeze 
dried). 
 
The densities of milled and spray dried cetrorelix (Table 1) are similar. 
The spray freeze dried powder has a significantly lower density than the 
two other products; indicating a higher porosity of this material.  
The specific surface area of the micronized materials differ considerably 
(Table 1). Spray dried cetrorelix has the lowest specific surface area, 
whereas milled and especially spray freeze dried cetrorelix have larger 
surface areas. Scanning electron micrographs (SEM’s, Fig. 2) reveal that 
milled cetrorelix (Fig. 2a) consists of agglomerates of very small primary 
particles which are mostly smaller than 1 µm. Spray dried cetrorelix has a 
different – flake like - shape (Fig. 2b) and a larger particle size compared 
to milled cetrorelix. Spray freeze dried cetrorelix (Fig. 2c) seems to be 
much more porous than spray dried cetrorelix although the particle size is 
similar.  
 






Figure 2. Scanning electron micrographs of micronized cetrorelix by milling (a,), 
spray drying (b) and spray freeze drying (c). The photographic magnification in 
all three micrographs is 10,000 times. 





































Figure 3. Dynamic vapour sorption studies of micronized cetrorelix (a), spray 
dried cetrorelix (b) and spray freeze dried cetrorelix (c). Open symbols represent 
vapour sorption, closed symbols vapour desorption. Squares represent the first 
measurement, triangles the second measurement. Cetrorelix: Particle engineering, formulation and de-agglomeration principle 
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Results of the dynamic vapour sorption studies are given in Fig. 3. Fig. 3a 
shows the results of two consecutive DVS measurements of milled 
cetrorelix. It can be seen that the difference in mass after the first 
sorption and desorption cycle is about 3%. After the second cycle, no 
significant change in mass can be observed. Spray dried cetrorelix, which 
is shown in Fig. 3b, shows the same trend as the first cycle of milled 
cetrorelix. Finally, spray freeze dried cetrorelix (Fig. 3c) shows no change 
in mass at all between the start and end of the sorption cycle. This is 
similar to the second sorption and desorption cycle of the milled 
cetrorelix. Obviously, the exposure to very low pressure (freeze drying) 
changes the behaviour during DVS measurements. This change also 
occurred after a full sorption-desorption cycle. This shows that although a 
minor volatile impurity is removed from the milled and spray dried 
material during the first cycle, no significant differences occur between 
the surface properties of the three different materials.  
 
Physical properties of the adhesive mixtures 
Mixing experiments with pure carrier material with and without stainless 
steel balls indicated that the presence of these balls has no significant 
effect on the particle size and morphology of the carrier (results not 
shown).  
Table 3 shows the characteristics of all produced adhesive mixtures. We 
produced three adhesive mixtures with 5% (w/w) carrier payload 
(Pharmatose as carrier). The mixture with spray dried cetrorelix had the 
highest coefficient of variance (CV= 4.28%), the lowest dosing weight and 
the highest spread in the dosing weight. However, all formulations met 
the requirement of a coefficient of variance below 5%. 
 
Table 3. Overview of the used adhesive mixtures and dose metering from the 
Novolizer 
Carrier Drug  Drugload  CV  Dosing  weight 
                            (w/w drug/carrier)    (mg ± SD) 
Pharmatose Milled  cetrorelix  4.73% 1.95%  13.19  ±  0.33 
Pharmatose 
Spray dried 
cetrorelix 4.49%  4.28%  12.56  ±  1.07 
Pharmatose 
Spray freeze 
dried cetrorelix  4.72%  1.65%  13.02 ± 0.26 






Figure 4. Scanning electron micrographs of the adhesive mixtures at a 
magnification of 500x of milled cetrorelix/pharmatose (a), spray dried cetrorelix 
(b) and spray freeze dried cetrorelix (c). Cetrorelix: Particle engineering, formulation and de-agglomeration principle 
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Scanning electron micrographs of the micronized materials formulated as 
an adhesive mixture with Pharmatose (5% w/w) are shown in Fig. 4. 
Milled cetrorelix (Fig. 4a) and spray dried cetrorelix (Fig. 4b) appear to 
spread over the surface of the carrier with a tendency to be stowed away 
in irregularities. The micrographs also reveal that the spray freeze dried 
material (Fig. 4c) has a smaller particle size after formulation into an 
















Figure 5. Particle size distributions of cetrorelix. Open symbols represent the 
particle size distributions of the starting materials obtained from RODOS 
dispersion, closed symbols represent the particle size distributions of the emitted 
aerosol-cloud from the Novolizer for the 5% w/w adhesive mixtures (■ & solid 
line = milled cetrorelix, ♦ & dashed line = spray dried and ● & dotted line = spray 
freeze dried). 
 
Effect of the preparation technique and device on aerosol properties 
of cetrorelix 
Fig. 5 shows the effect of formulation on the particle size distribution in 
the aerosol cloud from the Novolizer compared to the particle size 
distribution of the starting materials obtained from RODOS dispersion. 
The cumulative undersize values of the data presented in Fig. 5 are 
depicted in Table 2. The size distributions the starting material and 
formulated drug are very similar for milled cetrorelix. Only the x90-value 
for the starting material is higher; this is explained by the presence of Chapter 2 
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agglomerates as described above. These agglomerates are not present in 
the formulation, showing that the stainless steel balls in the mixing 
process were effective in breaking up agglomerates. For the other two 
materials the size distributions of starting material and formulated drug 
were similar. However, the fine particle fraction obtained by cascade 
impactor analysis with the Novolizer with this spray freeze dried material 
was only 25 %. This was considered insufficient and no further 

















Figure 6. Results from cascade impactor analysis of 5% w/w adhesive mixtures of 
micronized cetrorelix by milling and spray drying at 2.8 kPa with the ISF inhaler 
and 4 kPa with the Novolizer. The white and grey bar represent dispersions of 
milled cetrorelix dispersed with the ISF inhaler (white bars) and Novolizer (grey 
bars), whereas the patterned and black bars represent dispersions of spray dried 
cetrorelix with the ISF inhaler (patterned bars) and Novolizer (black bars). Error 
bars represent the highest and lowest value. 
 
Fig. 6 shows the results from cascade impactor analysis for the 5% 
mixtures with milled and spray dried cetrorelix, respectively as 
performed with the ISF inhaler and the Novolizer. With the ISF inhaler, 
device accumulation is higher than for the Novolizer, but loss in the 
induction port is higher for the Novolizer. This is due to centrifugal exit of 
the aerosol cloud from the mouthpiece. Furthermore, for milled Cetrorelix: Particle engineering, formulation and de-agglomeration principle 
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cetrorelix the first stage deposition is relatively high with either the ISF 
inhaler or Novolizer. First stage deposition is much smaller for spray dried 
cetrorelix, also resulting in higher fine particle fractions (Stages 3 + 4). 
The differences between both the type of micronization and the type of 
inhaler is remarkable. 
We performed univariate analysis of variance on the obtained fine 
particles fractions. We observed large differences between both the type 
of inhaler (p= 0.001, 95% confidence interval: 7.97 – 14.24) and method of 
micronization (p<0.001, 95% confidence interval: 23.26 – 29.53).  
 
DISCUSSION 
Advanced formulation techniques, like the use of Force Control Agents or 
large porous particles may be necessary to obtain the required quality 
attributes for an inhaler product. Typical examples are stabilization of 
unstable proteins (36, 37), improvement of de-agglomeration (into an 
inhalable aerosol) and improvement of flow properties (necessary for 
processing of the bulk powder). However, whether all these technologies 
always need to be applied depends on the complex interaction between 
parameters such as the requirements stemming from the nature of the 
drug product, the type of formulation used and the de-agglomeration 
efficiency of the inhaler. For cetrorelix we showed that the different 
micronization techniques could be applied without further degradation of 
the material. The different micronization techniques resulted in particles 
with different physical characteristics which determined their 
performance when formulated in an adhesive mixture. 
The milling process used in this study resulted in agglomerates consisting 
of primary particles which were generally smaller than 1 µm, but larger 
agglomerates of more than 10 µm were also found. This necessitated the 
use of grinders, such as stainless steel balls, during mixing. However, as a 
result of this mixing process the (small) drug particles were firmly pressed 
on the carrier which increased the adhesive forces; this had a negative 
effect on the FPF obtained with this formulation. 
The observation that spray dried Cetrorelix had a higher fine particle 
fraction than milled Cetrorelix is explained both by the particle size of 
the drug powder and the (flake like) shape of this powder. As a result of 
the irregular surface of spray dried cetrorelix, the de-agglomeration into 
an aerosol is improved, as shown by the low first stage deposition (Fig. 6). Chapter 2 
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Finally the improved aerosol characteristics (aerodynamic diameter) of 





e ae d d =
,         
which is only valid in the Stokes regime, a larger aerodynamic shape 
factor (χ) of spray dried cetrorelix (flakes) results in a lower aerodynamic 
diameter (dae) compared to milled cetrorelix (spheres) which has a 
profound effect on the deposition of the particles as measured by cascade 
impactor analysis. This is explained by the fact that particles with a high 
aerodynamic shape factor (higher resistance) can accelerate very quickly 
in a changing air flow (change of particle trajectory). In fact, Shekunov et 
al. (23) found comparable results upon comparison of milled and 
supercritically-processed salmeterol xinafoate, the higher aerodynamic 
shape factor of the later material, improved dispersion characteristics 
and yielded a higher FPF.  
The physical characteristics we found for the spray freeze dried product 
are comparable to those found by other authors, e.g. large surface area, 
high porosity (21, 39). However, the performance of the spray freeze 
dried powder in the adhesive mixture was poorest. This is ascribed to the 
fact that this advanced particle engineering technique results in very 
fragile particles which cannot withstand the production process of an 
adhesive mixture. During the mixing process, the fragile particles of spray 
freeze dried cetrorelix are exposed to impact forces from colliding 
lactose particles. These forces crush the fragile spray freeze dried 
cetrorelix particles into smaller fragments. Once attached to the carrier, 
these very small fragments are more difficult to separate again from the 
carrier during inhalation because of their small diameter and low density 
(small amount of mass per particle). This results in relatively low 
separation (impaction) forces, since the force resulting from an impaction 
is depending on mass (F= m·a). The low separation force explains the low 
FPF during cascade impactor analysis. This shows that the type of 
formulation largely influences the performance of particles processed 
with different techniques. Obviously, spray freeze drying produces large 
porous particles that are not suitable to be processed into an adhesive 
mixture. On the other hand, large porous particles were successfully 
applied in other types of formulations (27, 40, 41). Therefore, 
formulation types and processes that could be survived by large porous Cetrorelix: Particle engineering, formulation and de-agglomeration principle 
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particles would still be of interest since they would potentially allow the 
advantages in de-agglomeration and aerodynamic behaviour of this 
particle type.  
Next to the physical characteristics of the drug particles in the adhesive 
mixtures the fine particle fraction generated by a dry powder inhalation 
system is also determined by the efficiency of the de-agglomeration 
principle applied in the inhaler. The higher de-agglomeration efficiency 
of the Novolizer is reflected in the lower first stage deposition compared 
to the ISF inhaler. On the first stage, mainly drug particles that are still 
attached to the carrier are deposited. For both formulations the first 
stage drug deposition is higher for the ISF inhaler.  
It is clear that the higher de-agglomeration efficiency of the air classifier 
in the Novolizer results in higher fine particle fractions than the fractions 
obtained with the ISF inhaler. Fig. 6 furthermore shows that the 
magnitude of the difference between the de-agglomeration principles was 
independent from the different drug particle types (milled vs. spray 
dried) used in the formulations. For both types of formulations an 
increase of about 11% in FPF was found. The difference in FPF caused by 
the change in particle type was for both inhalers about 26% whereas the 
more efficient de-agglomeration principle yielded an increase of only 11% 
for both formulations. Shekunov et al. (23) stated that powders with low 
dispersion forces (e.g. spray dried cetrorelix) would exhibit device 
independent performance. However, our results show that the 
performance in terms of fine particle fraction is actually dependent on 
the device, although the role of particle physics is more important in the 
systems tested in this study.   
Finally, it should be mentioned that the lower first stage deposition of 
the Novolizer would not only reduce the waste of valuable drug but could 
also potentially reduce side effects. 
 
CONCLUSIONS 
The effects of different techniques for micronization used in the 
development of a peptide-containing dry powder formulation for 
inhalation were investigated. High fine particle fractions in the aerosol 
are required and losses during inhalation should be minimized to obtain 
the highest possible effect and lowest waste of drug. We showed that it is 
possible for a stable peptide to be micronized with milling, spray drying 
and spray freeze drying without degradation of the drug. Whether a Chapter 2 
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micronization technique produces particles that are suitable for use in an 
inhalation formulation was found to depend on the type of formulation 
and formulation process used. Furthermore, the performance of the 
different formulations (aerosolization behaviour expressed as fine particle 
fraction) was found to depend on the efficiency of the de-agglomeration 
principle applied. 
By combining the best particle engineering technique for this type of 
formulations with the most efficient de-agglomeration principle very high 
3
rd and 4
th stage depositions could be obtained. Such an inhalation system 
could be further developed to be a non-invasive alternative for routine 
administration of cetrorelix.  
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For lung transplant patients, a respirable, inulin-based solid dispersion 
containing cyclosporine A (CsA) has been developed. The solid 
dispersions were prepared by spray-freeze drying. The solid dispersion 
was characterized by water vapor uptake, specific surface area 
analysis and particle size analysis. Furthermore, the mode of inclusion 
of CsA in the dispersion was investigated with Fourier transform 
infrared spectroscopy. Finally, the dissolution behavior was 
determined and the aerosol, that was formed by the powder, was 
characterized. The powder had large specific surface areas (~ 160 m
2). 
The water vapor uptake was dependant linearly on the drug load. The 
type of solid dispersion was a combination of a solid solution and solid 
suspension. At a 10% drug load, 55% of the CsA in the powder was in 
the form of a solid solution and 45% as solid suspension. At 50% drug 
load, the powder contained 90% of CsA as solid suspension. The 
powder showed excellent dispersion characteristics as shown by the 
high emitted fraction (95%), respirable fraction (75%) and fine particle 
fraction (50%). The solid dispersions consisted of relatively large (x50 ≈ 
7 μm), but low density particles (ρ ≈ 0.2 g/cm
3). The solid dispersions 
dissolved faster than the physical mixture, and inulin dissolved faster 
than CsA. The spray freeze drying with inulin increased the specific 
surface area and wettability of CsA. In conclusion, the developed 
powder seems suitable for inhalation in the local treatment of lung 




To improve the immunosuppressive therapy in lung transplant patients, 
studies with inhalation of cyclosporine A (CsA, Figure 1) have been 
conducted (1, 2). The overall survival of lung transplant patients 
increased dramatically when aerosolized CsA was administered on top of 
base therapy (3). The formulation for inhalation used in the published 
study was a solution of CsA in propylene glycol. A disadvantage of this 
approach was that nebulization of propylene glycol caused extreme 
irritation in the airways, which was reduced by the use of aerosolized 
local anesthetics. Despite the use of local anesthesia, a substantial 
number of patients (± 10%) could not complete the study due to extreme 
irritation (4). Apparently, there is a need for a less irritating formulation 
for inhalation. A second disadvantage of nebulization of CsA dissolved in 
propylene glycol is the low deposition efficiency, which has been reported 
to be 5.4 - 11.2% of the metered dose (4), which is consistent with other 
studies on nebulization (5-7). To obtain a significant improvement in 
pulmonary function in lung transplant patients with chronic rejection 
requires a deposition of at least 5 mg CsA in the lower airways (peripheral 
part of the lung) (1), which can only be achieved by high metered doses. 
This further underlines the need for more effective formulations for 
inhalation. A third problem is the lipophilicity of CsA (aqueous solubility 
of 3.69 mg/L at 37 ºC, log P = 3.0) (8, 9), which limits the choice of 




Figure 1. Molecular structure of Cyclosporine A. Chapter 3 
 
76 
We proposed that a dry powder formulation consisting of a solid 
dispersion could overcome these problems. Firstly, with dry powder 
inhalation the use of local anesthesia and irritating solvents can be 
avoided. Secondly, the higher deposition efficiency of dry powder 
inhalation compared to nebulization reduces the need for high metered 
doses (10). Finally, solid dispersions are known for their dissolution rate 
enhancing properties of poorly soluble drugs, such as CsA (11-13).  The 
dissolution rate of poorly soluble drugs from inulin-based solid dispersions 
has been shown to increase when compared to the pure hydrophobic drug 
(14). 
A powder for local administration in lung transplant patients should meet 
two requirements. Firstly, the drug substance should dissolve within a 
reasonable time span, since removal of particles by mucociliary clearance 
occurs within a couple of hours (15, 16). Secondly, the powder should 
have an aerodynamic size range which is suitable for inhalation (1 – 5 µm) 
(17, 18). Regarding the first requirement, benefit may be gained with a 
rapidly dissolving dry powder formulation. The second requirement can 
be met by using spray freeze drying as production method (19-21). 
The purpose of this study was to develop a powder for inhalation as an 
alternative for nebulized CsA. We investigated the feasibility of an inulin-
based solid dispersion with CsA. CsA in the solid dispersion can be 
distributed as separate molecules, defined as a solid solution, or as 
multimolecular clusters of CsA, defined as a solid suspension or as 
combination of both (22). The type of solid dispersion of CsA in inulin, 
e.g. solid solution, solid suspension or a combination of both was 
investigated with Fourier transform infrared spectroscopy. Furthermore, 
other physical characteristics relevant for the performance as powder for 
inhalation were investigated. 
 
MATERIALS AND METHODS 
Materials 
CsA was obtained from LC Labs (Woburn, MA, USA). Inulin, with an 
average degree op polymerization of 23 was a generous gift from Sensus 
(Roosendaal, The Netherlands). Tert-butyl alcohol (TBA), methanol, 
acetonitrile, sodium dodecyl sulphate (SDS), KBr and anthrone reagent 
were of the highest available grade of purity (KBr was spectroscopy 
grade) and purchased from commercial suppliers. The water used in the 





The CsA solid dispersions were produced as described previously (20). 
Briefly, CsA was dissolved in TBA and inulin in water. Next, the solutions 
were mixed at a TBA/water ratio of 40/60 v/v. The concentrations of CsA 
in TBA and inulin in water were chosen such that the combined mass of 
CsA and inulin in the solution was constant (5% w/v) while the drug load 
varied. Immediately after mixing, the resulting TBA/water solution was 
sprayed onto liquid nitrogen with a heated two-fluid nozzle (orifice 0.5 
mm, atomizing airflow 500 L/h, liquid flow 6 mL/min). The solutions did 
not show any phase separation as indicated by clearness of the solution 
during processing. Upon completion of spraying the liquid nitrogen was 
evaporated and the frozen droplets were freeze dried in a Christ model 
Alpha 2-4 lyophilizer (Salm and Kipp, Breukelen, The Netherlands). The 
shelf temperature of the lyophilizer was maintained at -35 ºC with a 
pressure of 0.220 mbar for 24 hours. The temperature was then gradually 
increased to 20 ºC, while the pressure was decreased to 0.050 mbar. 
These conditions were maintained for another 24 hours. During the whole 
freeze drying process the condenser temperature remained -55 ºC. After 
freeze drying the samples were stored over silica gel in a vacuum 
desiccator until analysis. 
 
Chemical analysis 
The drug content and concentration during dissolution was determined by 
an HPLC method(23) which was slightly modified for our purpose. In 
short, undiluted samples (100 µL) were injected using a Gilson 234 auto 
injector (Gilson, Middleton, WI, USA) on a reversed phase C8 column (5 
µm Hypersil BDS 250 x 4.6 mm, Thermo Hypersil Ltd., Runcorn, UK) 
equipped with a thermostat (Jones Chromatography model 7990) at 70 ºC. 
A flow rate of 0.9 mL/min of the mobile phase (85/15 acetonitrile/water) 
was maintained with a Waters model 510 pump (Waters, Milford, MA, 
USA). Detection of CsA was performed with a Waters 490 programmable 
wavelength detector (Waters, Milford, MA, USA) at 212 nm. These settings 
resulted in an elution time for CsA of approximately 6 minutes. The 
obtained data was analyzed with KromaSystem 2000 software version 1.83 
(Winooski, VT, USA). All measurements were performed in triplicate. Drug 
content was within ±2.5% of the theoretical drug content and dissolution 
of CsA was 100±2.5% of the metered dose for dissolution. Chapter 3 
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The concentration of inulin during dissolution was determined by the 
anthrone assay (24). Samples of 0.25 mL were diluted with water to 1.00 
mL. Subsequently, 2.00 mL of a freshly prepared 0.1% w/v anthrone 
reagent in concentrated sulfuric acid was added and immediately 
vortexed. Due to the exothermic character of the reaction enthalpy of 
mixing, the mixture heated up. After cooling to room temperature 
samples (200 µL) were pipetted in a 96-wells plate and analyzed 
spectrophotometrically at 630 nm in a plate reader (Benchmark plate 
reader, BioRad, Hercules, USA). A freshly prepared calibration curve of 
inulin (0 – 0.100 mg/mL, 11 points) was measured for each determination. 
All measurements were performed in triplicate. 
 
Physical characterization of samples 
Specific surface areas of the formulations were measured using the 
Brunauer, Emmett and Teller (BET) method with a Tristar 3000 model 
(Micromeritics, Norcross, USA). Prior to the measurement samples were 
placed into test tubes and purged for at least 3 hours with helium at 30 ºC 
to evaporate residual moisture. Subsequently, a nine point isotherm was 
recorded at a sample temperature of -196 ºC (liquid nitrogen). 
The vapor sorption behavior of the solid dispersions at 25 °C was 
determined by dynamic vapor sorption (DVS 1000, Surface Measurement 
Systems Ltd., London, UK). About 10 mg of material was weighed in the 
sample cup and exposed to 0% relative humidity (RH) until equilibrium 
(dm/dt<0.0005%/min) was reached. The RH was subsequently increased 
to 30%. An RH of 30% was chosen because inulin remains in the glassy 
state upon exposure to 30% RH at 25 °C (9, 25). 
Changes in the secondary structure of CsA caused by spray freeze drying 
and incorporation in inulin were studied with Fourier transform infrared 
(FTIR) spectroscopy. Powder samples were prepared by mixing ~ 2-3 mg 
of the different CsA formulations with ~ 300 mg KBr. These mixtures were 
compacted into a 13 mm disc at 37 MPa pressure with a hydraulic press. 
The liquid sample was prepared by dissolving CsA in a mixture of 
methanol and acetonitrile. Water was gently added to obtain a 
concentration of 100 mg/mL and volume percentages of 32% MeOH, 32% 
ACN and 36% H2O. Spectra of dry powders were recorded on a Bio-Rad 
FTS6000 FTIR spectrometer with Win-IR Pro software (Cambridge, MA, 
USA). 256 Scans were co-added at a resolution of 2 cm
-1 and scan speed of 
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solution were collected by averaging 1024 scans. All absorbance spectra 
were corrected for water vapor and if necessary for the co-solvent 
solution (26). The measured spectra were smoothed with a 13-point 
Savitzky-Golay function (27) and second derivative spectra were 
calculated. The derivative spectra were also smoothed with a 13-point 
Savitzky-Golay function and inverted. 
To establish similarity of the unresolved amide I bands, the specific area 
overlap was determined (28, 29). The spectra were truncated to contain 
only the amide I band. Next, the amide I band was baseline-corrected, 
area-normalized to unity, and exported to a spreadsheet-program. The 
area overlap of two spectra, with the amide I band of CsA in the co-
solvent solution as reference, was calculated by creation of a new 
spectrum consisting of the lowest absorption value of the two spectra at 
each data point. The area under this new spectrum corresponds to the 
percentage area overlap. 
 
Aerosol characterization 
Particle size distributions of the spray freeze dried samples were 
measured with a Helos Compact model KA laser diffraction apparatus (100 
mm lens, Fraunhofer theory) equipped with a RODOS dispersing system 
(Sympatec GmbH, Clausthal-Zellerfeld, Germany) at a pressure difference 
of 0.5 bar. All measurements were performed in triplicate. 
Since the particle size distributions were found to be log-normal, the 
geometric standard deviation (GSD) was calculated from laser diffraction 
data as follows (30):  
 
          ( 1 )  
 
in which x84 and x16 represent the 84% and 16% cumulative undersize 
diameter, respectively. The aerodynamic diameter, as measured with 
cascade impactor analysis, depends on the equivalent particle diameter, 
shape factor and density (30): 
 
          ( 2 )  
 
in which dae is the aerodynamic diameter, de the equivalent laser 
diffraction diameter, ρp the density of the particles (g/cm




3) and χ the dynamic shape factor (1 for spherical 
particles). 
For cascade impactor analysis a multi-stage liquid impinger (MSLI, 
Erweka, Heusenstamm, Germany) was used with a test inhaler(31) 
attached to the induction port. A solenoid valve was used in combination 
with a timer to control the flow (60 L/min) through the inhaler and the 
cascade impactor for the duration of 3 seconds. The stages of the cascade 
impactor were filled with 20 mL of 85/15 v/v acetonitrile/water for 
extraction of CsA from the deposited powder. A total amount of 50 mg 
was delivered in 10 separate doses. The deposition of the drug on the 
different stages was measured by HPLC as described above. The 
deposition was subsequently calculated as the percentage of the metered 
dose. The emitted fraction was defined as the metered dose minus 




th and filter stage and the fine particle fraction 
(FPF) was calculated by the sum of deposition on the 3
rd, 4
th and filter 
stage. The emitted fraction, respirable fraction and FPF are expressed as 
a percentage of the metered dose. Cascade impactor analysis was 
performed on only the solid dispersions with 30% and 50% w/w drug loads. 
All experiments were carried out in triplicate. 
 
Dissolution rate 
Dissolution experiments were carried out using an USP dissolution 
apparatus I (Rowa Techniek B.V., Leiderdorp, The Netherlands) at 37 ºC 
in 1000 mL water containing 0.25% w/v SDS with constant stirring of 100 
rpm. Prior to the dissolution study a series of solubility tests were 
conducted with SDS concentrations up to 1% w/v to investigate at which 
SDS concentration sink conditions (maximal concentration= 0.20×Csaturated) 
were met. At the maximal CsA concentration (30 mg/L) it was found that 
sink conditions were met at 0.25% SDS (data not shown). The formulations 
were weighed into the baskets of the dissolution apparatus. For the 
formulations containing 10, 20, 30 and 50% w/w CsA, amounts of 
respectively 300, 150, 100 and 60 mg powder were weighed in order to 
keep the total amount of CsA in the dissolution vessel constant at 30 mg. 
A physical mixture of 30 mg spray freeze dried CsA and 70 mg spray 
freeze dried inulin was used as a reference. Samples were analyzed with 
HPLC and anthrone assay for determination of the CsA and inulin Cyclosporine A formulation 
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concentration, respectively. All experiments were performed in 
triplicate.  
 
RESULTS AND DISCUSSION 
Physical characterization 
In Table 1 the specific surface areas and moisture uptake of the produced 
solid dispersions are shown. Spray freeze drying generally results in 
powders with large specific surface areas and the powders in this study 
are no exception (20, 32, 33). The large specific surface area is related to 
the spray freeze drying process because with spray freeze drying the 
aerosol is rapidly frozen which causes the formation of a large number of 
small solvent crystals. Around these small solvent crystals the freeze 
concentrated fraction is distributed. Solvent removal by freeze drying 
thus results in a large specific surface area. The produced batches did not 
differ substantially in specific surface area, with pure spray-freeze dried 
CsA as an exception (Table 1). The lower specific surface area of pure 
spray freeze dried CsA may be caused by the absence of sugar which 
might influence the freezing behavior. 
 
Table 1. Specific surface areas and water vapor uptake (at 30% RH and 25 °C) of 
the spray freeze dried powders. 
Batch  Specific surface area  Moisture uptake 
 (m
2/g) (%  w/w) 
10% w/w CsA  152  6.08 
20% w/w CsA  185  5.44 
30% w/w CsA  185  4.84 
50% w/w CsA  145  3.97 
Pure spray-freeze dried CsA  40  1.03 
 
Possible degradation of CsA during spray freeze drying has not been 
investigated. However, we have no reason to assume that degradation of 
CsA did occur during spray freeze drying for various reasons. First of all, 
results from drug content analysis and dissolution were all within ±2.5% of 
the theoretical drug content and metered dose, respectively, which 
suggests a complete mass balance for CsA. Second, FTIR did not reveal 
possible degradation by fingerprint inspection. Furthermore, CsA appears 
to be a stable compound since it has been processed in several ways 
without noting degradation in various studies (34-36). Finally, a Chapter 3 
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chemically less stable compound than CsA, ∆
9-tetrahydrocannabinol, has 
successfully been spray freeze dried from a TBA/water solution without 
noticeable degradation (20), thus showing that spray freeze drying is a 
reliable production technique, which minimally distorts the formulated 
compounds. 
The produced powders were susceptible to water vapor uptake (Table 1), 
which was linearly dependent on the drug ratio ([moisture content] = -
0.057·[drug ratio] + 0.067;  R
2= 0.995). Drug ratio was defined as [drug 
mass]/[drug mass + mass of excipient] without the addition of water 
vapor. This shows that the solid dispersion behaves like a physical 
mixture, which indicates that the two components remain in the same 
physical state, irrespective of the drug load. Furthermore, it shows that 
CsA does not influence the hydrophilicity of inulin and vice-versa, i.e. CsA 
and inulin each absorb a fixed amount of water vapor, irrespective of the 
drug load.  
The linear dependency of moisture uptake versus drug load for inulin-
based solid dispersions has been shown before (22). In that study, van 
Drooge et al (22) showed that the water vapor sorption of inulin-based 
solid dispersions was independent of the type of solid dispersion, defined 
as a fully amorphous solid solution, fully amorphous solid suspension or a 
combination of both (22). The type of solid dispersion is therefore not 
discernable with only water vapor sorption measurements.  
In general, the physical state of solid dispersions can be determined by 
differential scanning calorimetry (DSC). However, DSC measurements of 
CsA and inulin result in substantial overlap of thermal events of both 
components, which makes it difficult to draw unambiguous conclusions 
about the physical state of the solid dispersion. Fortunately, the 
secondary structure of CsA, which can be measured with FTIR, has been 
reported to depend on the physical state (37, 38). Furthermore, FTIR 
might give information about the type of solid dispersion, based on the 
secondary structure of CsA.  
CsA has four amide groups, which, according to Stevenson et al (37), in a 
hydrophilic environment result in intermolecularly oriented hydrogen 
bonds. In contrast, a lipophilic environment results in intramolecularly 
oriented hydrogen bonds. In the case of a solid solution, the amide groups 
are hypothesized to be intermolecularly oriented due to hydrogen bond 
interaction with inulin. Conversely, in a solid suspension, the amide 
groups are predominantly intramolecularly oriented due to the lipophilic Cyclosporine A formulation 
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CsA clusters. A combination of a solid solution and suspension should thus 
result in both inter- and intramolecularly orientated amide groups, in a 
ratio that would be dependent on the drug load. 
 
Secondary structure of CsA 
First, two control samples, CsA in the crystalline state and dissolved in a 
co-solution of methanol/acetonitrile/water, were measured to show the 
effect of full intra- and intermolecular orientation of the amide groups, 
respectively. Bands were assigned according to previously published data 
(37).  
 
In the crystalline state (Figure 2A), the four amide groups in the CsA 
molecule (Figure 1) are assumed to be intramolecularly oriented to allow 
intramolecular hydrogen bonds (37). In contrast, when CsA was dissolved 
in the co-solvent solution (Figure 2B), the amide groups are assumed to 
be directed outwards to allow hydrogen bonding with the solvent (37). 
Specifically, dissolution of CsA in the co-solvent solution compared to CsA 
in the crystalline state results in a β-sheet band at higher wave numbers, 
which is indicative of a looser β-sheet structure (Table 2). Furthermore, 
the  γ-loop changed into a γ-turn upon dissolution in the co-solvent 
solution, which is associated with a change in orientation of the bond 
between MeLeu
9 and MeLeu
10 from cis to trans (37). This change in 
orientation is caused by the hydrogen bond between D-Ala
8NH and 
MeLeu
6C=O, which bifurcates to include the D-Ala
8C=O and solvent. The 
sharing of the amide proton between two carbonyls and solvent twists the 
backbone conformation at D-Ala
8, by which the orientation of the MeLeu
10 
side chain changes. Finally, if the MeBMT
1 side chain (see Figure. 1) is in 
proximity of the backbone, as is the case in the crystalline state, then the 
β-OH is able to bond with MeBMT
1C=O, resulting in a MeBMT-turn (37). 
Clearly, the MeBMT-turn is not present upon dissolution of CsA in the co-
solvent solution, which indicates that the MeBMT
1 side chain is directed 






































Figure 2. Second derivative FTIR spectra of the CsA crystalline control (A) and a 
solution of 10% (w/v) of CsA in 32% MeOH/32% ACN/36% (w/v) H2O (B). Peak 
wavenumbers in the crystalline control (A): 1624 (antiparallel  β-sheet), 1636 
(loose β-sheet), 1653 (γ-loop), 1674 (type-II β-turn), 1688 (MeBMT-turn) and 1695 
cm
-1 (aggregate β-sheet); peak wavenumbers in the co-solvent solution (B): 1630 
(β-sheet), 1663 (γ-turn) and 1678 cm
-1 (type-II β-turn). See also Table 2. 
 Cyclosporine A formulation 
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If the type of solid dispersion of CsA and inulin would be a solid solution, 
then the amide groups of CsA would be intermolecularly oriented. 
Therefore in a solid solution, the FTIR spectrum of CsA should have the β-
sheet band at high wavenumbers (~1630 cm
-1), contain a γ-turn band 
(~1663 cm
-1), and the MeBMT-turn band (~1685 cm
-1) should be absent. In 
contrast, if the type of solid dispersion would be a solid suspension, then 
the amide groups would be intramolecularly oriented, resulting in an FTIR 
spectrum with a β-sheet band at low wavenumbers (~1624 cm
-1), a γ-loop 
band (~1653 cm
-1) and the MeBMT-turn band at ~1685 cm
-1. A combination 
of a solid solution and a solid suspension should contain variable amounts 
of each structural feature, depending on the drug load.  
CsA in the inulin solid dispersions (Figures 3A to 3D) apparently has few 
outward oriented amide groups as all solid dispersions, as well as pure 
spray-freeze dried CsA (Figure 3E), contain a β-sheet, γ-loop, and MeBMT-
turn. The peak position of the β-sheet band of the solid dispersions and 
pure spray-freeze dried CsA is in between of the peak positions seen in 
the crystalline state and in the co-solvent solution (Table 2). 
Furthermore, the presence of the γ-loop and the absence of the γ-turn in 
the secondary structure indicates that CsA adopts a cis orientation 
between MeLeu
9 and MeLeu
10. Finally, the presence of the MeBMT-turn 
indicates that the MeBMT
1 side chain is in the proximity of the backbone. 
At higher drug loads, the relative intensity of the MeBMT-turn seems to 
increase.  
 
Based on the data obtained by measurement of the secondary structure of 
CsA in the solid dispersion, the type of solid dispersion can best be 
described as a combination of a solid solution and suspension. Firstly, the 
peak position of the β-sheet band of the solid dispersions and pure spray-
freeze dried CsA indicates that the type of solid dispersion is a 
combination of a solid solution and suspension, i.e. CsA is present in a 
molecular distribution and as clusters. Secondly, the presence of the γ-
loop and corresponding cis orientation between MeLeu
9 and MeLeu
10 
suggests an intramolecular orientation of D-Ala
8NH, which suggests a 
lipophilic environment. Thirdly, proximity of the MeBMT
1 side chain to the 
backbone suggests the presence of CsA clusters. Finally, the increasing 
intensity of the MeBMT-turn suggests that powders with higher drug loads 
contain more CsA clusters. Therefore, the amount of CsA in the form of 







































































Figure 3. Second derivative FTIR spectra of the 10% (A), 20% (B), 30% (C), 50% (D) 
w/w solid dispersions and pure spray freeze dried CsA (E). Peak wavenumbers: 
1626 - 1628 (β-sheet), 1653 (γ-loop), 1672 - 1676 (type-II β-turn) and 1684 - 1688 
cm
-1 (MeBMT-turn). See also Table 2. 
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Table 2. Peak positions of structural elements in the secondary structure of 
Cyclosporine A. 
Data from Stevenson et al. (34) 
Sample  β-sheets 








-  -  -  1661  1679  -  - 
Spray-dried 
from ethanol 
1624  1638  1653  -  1673  1686  - 
Crystalline  1624  -  1645  -  1672  1683  - 
 
 
             
Data from this study 
Sample  β-sheets 








1630  -  -  1663  1678  -  - 
10% w/w  1628  -  1653  -  1672  1684  - 
20% w/w  1628  -  1653  -  1674  1684  - 
30% w/w  1628  -  1653  -  1674  1684  - 




1626  1636  1653  -  1674  1688  - 
Crystalline  1624  1636  1653  -  1674  1688  1695 
*1 In CsA two β-sheets occur: an antiparallel β-sheet (1624 cm
-1) and a looser β-sheet (1636 
cm
-1) (37). In some samples both β-sheets overlap, resulting in a single β-sheet band at a 
wavenumber between 1624 and 1636 cm
-1. 
 
The percentage of solid solution and solid suspension can be quantified by 
examination of the unresolved amide I bands. The amide I band depends 
on the orientation of the amide groups as shown in the secondary 
structure. The amide I band in the crystalline state clearly differs from 
the amide I in the co-solvent solution (Figure 4A). Furthermore, the 
amide I band of CsA in the inulin solid dispersion depends on the drug 
load (Figure 4B). As can be seen, the amide I band becomes more similar 
to the amide I band of the crystalline state with increasing drug loads. 






























Figure 4. Base-line corrected and normalized amide I peak from FTIR spectra of 
CsA. (A) controls of crystalline CsA (───) and in MeOH/ACN/H2O (─  ─). (B) solid 
dispersions containing 10% w/w (───), 20% w/w (········), 30% w/w (─  ─) and 
50% w/w (─ ·· ─ ·· ─) CsA, and pure spray freeze dried CsA (──    ──). 
 
By calculating the percentage of area-overlap of the different amide I 
bands relative to the amide I band of CsA in the co-solvent solution, it is 
possible to quantify the differences caused by an inter- to intramolecular 
change in rotation of the amide groups (Figure 5). CsA dissolved in the co-
solvent solution mainly has an intermolecular orientation of the amide 
groups as shown by analysis of the secondary derivative. In contrast, CsA Chapter 3 
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in the crystalline state mainly has intramolecular orientation of the amide 
groups. Similar to the secondary structure, the percentage area overlap 
of the amide I band of both CsA in the solid dispersion and pure spray 
freeze dried is in between those of CsA in the co-solvent solution and 
crystalline CsA. 
 
The 10% w/w solid dispersion already has 3.8% difference in percentage 
area overlap in comparison with CsA in the co-solvent solution, indicating 
that at a drug load of 10% relatively much of the amide groups are 
oriented intramolecularly. The difference in percentage area overlap 
increases up to the 50% w/w solid dispersion. The 50% w/w solid 
dispersion has a difference in percentage area overlap which is nearly the 
same as for pure spray-freeze dried CsA, indicating that the majority of 
the amide groups are intramolecularly orientated. Pure spray freeze dried 
CsA has a difference in percentage area overlap of 8% with CsA in the co-





















Figure 5. Difference in percentage area overlap of the amide I bands compared 
to the amide I band of CsA in the co-solvent solution. Cyclosporine A formulation 
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If on the one hand pure spray freeze dried CsA is assumed to represent a 
complete solid suspension and on the other hand CsA dissolved in the co-
solvent solution to represent a complete solid solution, then it is possible 
the calculate the percentage of each type of solid dispersion. However, 
the polarity of the co-solvent solution and amorphous inulin presumably 
differs. As a result, the ability to establish orientation of the amide 
groups of CsA by the co-solvent solution in comparison with inulin may 
therefore be different. The calculation thus only gives an indication about 
the percentage of type of solid dispersion. The 10% w/w solid dispersion 
has a 3.7% difference in percentage area overlap. When compared to the 
8.1% difference in area overlap of pure spray freeze dried CsA, which was 
assumed to represent a complete solid suspension, it follows that the 10% 
w/w solid dispersion contains 55% of CsA as a solid solution and 45% of a 
solid suspension. The 20%, 30% and 50% w/w solid dispersion would then 
contain 54%, 63% and 90% of the CsA as a solid suspension, respectively. 
 
Aerosol characteristics 
Spray freeze drying results in log-normal geometrical particle size 
distributions with relatively large volume median diameters (x50) (Table 
3). The GSD of the spray freeze dried solid dispersions, as calculated with 
equation 1, are between 1.87 and 2.97 (Table 3).  
In order to evaluate the aerodynamic behavior and measure the mass 
median aerodynamic diameter (MMAD), the powder was analyzed with 
cascade impactor analysis. As the powder showed rather cohesive 
behavior, a test inhaler which is able to generate relatively high 
deagglomeration forces was used (31). 
 
Table 3. Particle size analysis: x16, x50 and x84 undersize values of the cumulative 
geometric size distributions, MMAD and GSD of the spray freeze dried powders. 
Formulation  x16  x50  x84  GSD  MMAD 
   (µm)  (µm)  (µm)  (-)  (µm) 
10% w/w CsA  3.08  7.10  17.10  2.36  - 
20% w/w CsA  3.53  7.29  15.29  2.08  - 
30% w/w CsA  3.52  6.84  12.32  1.87  3.50 
50% w/w CsA  2.46  8.44  21.74  2.97  3.39 
Pure spray-freeze dried CsA  2.94  8.81  19.43  2.57  - 
 Chapter 3 
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Both the 30 and 50% solid dispersions exhibit excellent inhalation 
characteristics (Figure 6). The spray freeze dried CsA solid dispersions 
show a low inhaler retention of ~ 4%, which leads to a high emitted 
fraction of ~ 96% for both solid dispersions (Figure 6). The solid dispersion 
powders furthermore show good dispersion characteristics as indicated by 
the respirable fraction of higher than 75%, as calculated by the sum of 
deposition on stages 2, 3 and 4 plus the filter. Furthermore, the FPF is 
higher than 50% of the metered dose, indicating that the solid dispersions 


















Figure 6. Cascade impactor analysis of the 30% (black bars) and 50% (grey bars) 
w/w solid dispersion at a flow rate of 60 l/min through an air classifier-based 
test inhaler. Error bars represent standard deviations (n=3). 
 
Since a volume median diameter (x50) is measured with laser diffraction 
and the particles were found to be spherical (scanning electron 
microscopy, data not shown), we can assume that de equals x50 as 
obtained with laser diffraction. The MMAD can be measured by using the 
mean of the cut off diameters (i.e. 4.95 and 2.4 µm for 3
rd and 4
th stage, 
respectively, as calculated according to the European Pharmacopeia (39)) 
and cumulative mass percentage (40). The intercept at the 50% mass Cyclosporine A formulation 
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p x MMAD ρ 50 =
percentile of the cumulative mass percentage with cut off diameter 
corresponds to the MMAD. Thus, we can rewrite eq. 2 to: 
 
        ( 3 )  
 
In other words, by comparing the data obtained from laser diffraction and 
cascade impactor analysis, we can calculate the true particle density. 
The true particle density can be determined from the MMAD and volume 
median diameter if a log-normal distribution, a dynamic shape factor of 1 
and a particle size independent density is assumed (equation 3). The 
measured MMADs are 3.50 and 3.39 µm for the 30% and 50% drug load 
solid dispersions, respectively (Table 3). Given equation 3 it is possible to 
combine laser diffraction (x50=de) with cascade impaction data (MMAD) to 
calculate the density (ρp) of the particles. The comparison results in a 
calculated density of 0.26 and 0.16 g/cm
3 for the 30% and 50% drug load 
solid dispersions, respectively. Since the true densities of CsA and inulin 
are around 1.5 g/cm
3, the calculated density indicates the high porosity 
of the spray freeze dried particles.  
Spray freeze drying of CsA and inulin resulted in relatively large (x50 ~ 7.5 
µm) but porous (low density) particles. In literature (40-43), several 
advantages are ascribed to the use of (large) porous particles for 
pulmonary administration such as high emitted dose (fraction that is 
released from the inhaler), good dispersion characteristics and high – 
deep – lung deposition, which  was confirmed in this study. 
 
Dissolution 
The dissolution rate of CsA formulated as a solid dispersion was 
significantly increased compared to the physical mixture, which consisted 
of pure spray freeze dried CsA (Figure 7) and spray freeze dried inulin. In 
the 10% and 20% w/w CsA-containing solid dispersions, inulin dissolves 
slightly faster than CsA (Figure 7A). The faster dissolution of inulin 
indicates that inulin dissolves first, followed by CsA. All solid dispersions 
dissolve faster than the physical mixture, albeit without a clear 
correlation between drug load and dissolution rate (Figure 7B). After 30 
minutes all solid dispersions have dissolved for more than 80% compared 
to only 50% of the physical mixture. 





























Figure 7. Dissolution behavior of the solid dispersions. (A) Dissolution behavior of 
a 10% (represented by circles) and 20% w/w (represented by triangles) solid 
dispersion. Open symbols represent inulin, closed symbols represent CsA. Squares 
represent the dissolution behavior of CsA from the physical mixture (30 mg CsA + 
70 mg inulin). (B) Dissolution of CsA from the 10% (black circles), 20% (white 
circles), 30% (black triangles), 50% (open triangles) solid dispersion and from the 
physical mixture (squares). 
 
The improved dissolution rate of the solid dispersion powder can be 
ascribed to the presence of inulin in the solid dispersions for two reasons. 
Firstly, the higher specific surface area of the solid dispersions, compared 
with pure spray freeze dried CsA, will have contributed to the higher Cyclosporine A formulation 
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dissolution rate. Secondly, inulin improves wetting of CsA, even at drug 
loads up to 50%.  
 
CONCLUSION 
In this study a dry powder formulation containing CsA was developed for 
local administration in lung transplant patients. The presented dry 
powder formulations contain large porous particles which dissolve rapidly, 
even at high drug loads. The type of dry powder formulation was a solid 
dispersion. The solid dispersion, as investigated with FTIR, was found to 
be a mixture of a solid solution and a solid suspension, the ratio of which 
depended on the drug load. For inhalation the high drug load formulations 
are especially favorable, since with these a lower amount of powder has 
to be inhaled by the patient. Future studies will be performed to 
investigate whether this powder is a feasible alternative to nebulization 
and is able to improve therapeutic efficacy of treatment of lung 
transplant patients without increasing local and systemic side effects. 
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Background. The aim of this pilot study was to determine the 
pharmacokinetics of cyclosporine A powder for inhalation (iCsA) and 
its efficacy in preventing rejection in experimental lung 
transplantation in rats.  
Methods. Single dose pharmacokinetics (10 mg/kg) of pulmonary and 
orally administered cyclosporine A was determined in whole blood and 
in lung and kidney tissue. The efficacy of iCsA (2.5 and 5 mg/kg) in 
inhibiting rejection was determined in an orthotopic left lung 
transplantation rat model and compared with orally administered CsA 
(5 and 10 mg/kg). The ventilation score of lung allografts was assessed 
with roentgenograms. At day 10 post-operative, the rats were 
terminated and lungs were prepared for histological analysis. 
Results. In the pharmacokinetic study, AUC0-48 values in blood for iCsA 
and oral CsA were similar (47,790±1,739 and 46,987±2,439 ng·h·mL
-1, 
respectively). In contrast, iCsA levels in lung tissue were much higher 
than oral CsA levels (AUC: 9,152,977±698,920 versus 84,149±8,134 
ng·h·g
-1, respectively), showing the effectiveness of the pulmonary 
administration. In the rejection study, non-treated animals showed 
complete rejection after 8 days on roentgenograms. Treatment with 5 
mg/kg iCsA reduced rejection on day 10, while the 2.5 mg/kg dose did 
not inhibit rejection. Oral CsA
  10 mg/kg strongly reduced rejection, 
while the 5 mg/kg dose showed hardly any effect on rejection. 
Conclusions. We conclude that iCsA is an effective immunosuppressive 
formulation, which might become a valuable asset for clinical use in 




Lung transplantation is an effective treatment for end-stage lung disease, 
since it improves quality of life and prolongs survival. Oral treatment with 
calcineurin inhibitors such as cyclosporine A (CsA) is a cornerstone of the 
current immunosuppressive strategies. To reduce the notorious adverse 
effect profile of CsA, newer strategies are employed such as exchanging 
CsA for Tacrolimus (1), improved pharmacokinetic monitoring and 
subsequent dosing based on the 2 hours post-dose CsA concentration (C2) 
instead of the trough (C0) concentration (2-5), delayed initiation of CsA 
therapy through induction therapy with Basiliximab (6), combination 
therapy with Everolimus (Certican®) to allow a lower CsA dose with 
similar efficacy and less adverse effects (7-12) or pulmonary delivery of 
CsA (13, 14). Pulmonary delivery of CsA by nebulization has shown to 
improve the therapeutic efficacy in lung transplantation in animal models 
(15-17) and humans (14, 18-20). In humans, aerosolized CsA resulted in 
lower rejection rates in patients with acute (13) and chronic (14, 20) 
rejection, resulting in improved survival.  
In the clinical studies, a propylene glycol solution that contained CsA was 
used (13, 18, 20, 21). Unfortunately, inhalation of the CsA solution was 
accompanied by severe complications. First, patients had to be 
pretreated with aerosolized lidocaine and albuterol to reduce side effects 
like dyspnea, cough and pharyngeal soreness (14). Secondly, nebulization 
resulted in a lung deposition of only 5.4 - 11.2% of the metered dose in 
the lung (21). Since Corcoran showed that doses of at least 5 mg CsA are 
needed in the peripheral part of the lung to obtain a significant 
improvement in lung function (18), it is clear that with conventional 
administration, high nebulized doses are necessary for effective 
treatment. As detailed above, higher dosing is limited by local side 
effects.   
To avoid the difficulties faced with propylene glycol nebulization, we 
developed CsA as a powder for inhalation (iCsA) using an inulin-based 
solid dispersion formulation technique (22). A major advantage of dry 
powder inhalation over fluid nebulization is that no solvent is needed, 
which could make the premedication redundant. Other advantages are 
the higher pulmonary deposition efficiency and ease of administration 
(23).  
Since this is the first study of iCsA in animals, the purpose of this study 
was to investigate 1) single dose pharmacokinetics for dose determination Chapter 4A 
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i n  t h e  e f f i c a c y  p a r t  o f  t h i s  s t u d y  a n d  2 )  t h e  e f f e c t i v e n e s s  o f  i C s A  i n  
preventing rejection in orthotopic left-lung transplantation in rats.  
 
MATERIALS AND METHODS 
Materials 
Neoral
® was obtained from Novartis, Basel, Switzerland. Cyclosporine as a 
powder for inhalation (iCsA) was compounded at the Hospital Pharmacy of 




Brown-Norway (BN) and Albino-Oxford (AO) male rats (200-260 gram) 
were purchased from Harlan (Horst, the Netherlands). Our studies 
conformed to the Dutch Law on Experimental Animal Care and were 
approved by the Institutional Animal Care and Use Committee of the 
University of Groningen. During all experimental procedures, rats were 
under isoflurane anesthesia.  
Single dose (10 mg/kg) pharmacokinetics (iCsA) and oral CsA (Neoral
®, 
Novartis, Basel, Switzerland) were determined in BN rats (n=18 per 
treatment). iCsA was administered by insufflation (model DP-4, Penn-
Century, Philadelphia, PA, USA) after orotracheal intubation. Oral CsA 
was administered undiluted by oral gavage. Blood was collected at t= 0, 
0.5, 1, 2, 4, 6, 8, 12, 24 and 48 hours after administration; kidneys and 
lungs were harvested at t= 0, 2, 6, 12, 24 and 48 hours.  
Orthotopic, left lung transplantation was performed across a major 
histocompatibility barrier with AO (RT1
u) as donor and BN (RT1
n) as 
recipient (24, 25). In total, twenty-one transplantations were performed 
(table 1). Rats were treated with 2.5 or 5 mg/kg iCsA on day 0, 2, 4, 6 
and 8. Reference treatment was oral CsA in a dose of 5 or 10 mg/kg. 
Isogenic and allogenic transplantation served as untreated transplantation 
controls. Non-transplanted BN rats served as treatment controls and 
received 5 mg/kg iCsA or 10 mg/kg oral CsA. Determination of systemic 
CsA trough levels and ventilation score was performed at day 2, 4, 6, 8 
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Table 1. Experimental groups in lung allograft rejection study. 
Group  n
  Transplantation  Treatment  Dose  Ischemia time 
    (Donor-recipient)    (mg/kg)  (min ± SD) 
1  5
*  AO-BN  iCsA  2.5  34.2  ±  5.2 
2  4
*  AO-BN  iCsA  5  32.7  ±  1.5 
3  3  AO-BN  Oral CsA  5  33.0  ±  3.5 
4  3  AO-BN  Oral CsA  10  34.0  ±  1.7 
5  3  BN-BN  -  -  37.0  ±  7.9 
6  3  AO-BN  -  -  37.3  ±  4.0 
7  3  BN  iCsA  5  - 
8  3  BN  Neoral, orally  10  - 
* In group 1, 2 animals died during iCsA treatment and 1 animal died during the 
transplantation procedure. In group 2, 1 animal died during iCsA treatment. 
Autopsy revealed that the three deaths during treatment of iCsA were caused by 
destruction of the larynx as a consequence of the intubation procedure. 
 
Analyses 
Cyclosporine concentrations were determined using a fluorescence 
polarization immunoassay (AxSym
®, Abbott Laboratories, Chicago, USA) 
(26). CsA blood levels were fitted with first-order kinetics (equation 1), 
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where C(t) is the concentration in the compartment (ng/mL), C0 a 
constant (ng/mL) representing the maximum compartment concentration 
obtained by only absorption at t=0 and ka and kel the absorption and 
elimination rate constants, respectively (h 
-1). Bailer’s method was used 
to calculate the area under the curve (AUC) and standard error from 0 to 
48 hours (27). 
CsA tissue levels were determined by mixing an aliquot EDTA blood with a 
known amount of tissue sample extract and processed similarly to a whole 
blood sample.  
Rejection was determined by two blinded and independent observers on 
basis of roentgenograms and histology (24, 25). Ventilation scores of 
roentgenograms ranged from 6 (normal looking lungs) to 0 (opaque, fully Chapter 4A 
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rejected lungs). Histological scores ranged from 0 (normal looking lungs) 
to 4 (completely rejected lungs). 
 
Statistical analysis 
All results are expressed as mean ± standard error of the mean (SEM), 
unless mentioned otherwise. Statistical comparisons between groups were 




























Figure 1. Cyclosporine whole blood levels after single 10 mg/kg dose. (A) iCsA 10 
mg/kg and (B) oral CsA 10 mg/kg. Each circle represents an individual data point 
and lines represent the fit of the data points. 





Inhalation and oral administration of CsA resulted in substantial systemic 
blood levels (figure 1). Insufflation of CsA (figure 1A) led to a lower 
variation of individual whole blood levels compared to orally administered 
CsA (figure 1B).  
 
Table 2. Summary of fitting parameters, calculated Cmax, tmax and t½el by using 
eq. 1 and Calculated area under the curve in whole blood, kidney and lung 
tissue. Targeting index was calculated by dividing tissue AUC’s by whole blood 
AUC. C0 is a constant (ng/mL) representing the maximum compartment 
concentration obtained by only absorption at t=0, ka the absorption rate constant 
and kel the elimination rate constant. 
   iCsA  Neoral 
Administration  Insufflation  Oral gavage 
Dose (mg/kg)  10  10 
Results of fit     
C1 (ng·ml
-1)  1,201.59  1,727.05 
ka (h
-1)  1.474  0.653 
L1 (h
-1)  0.00968  0.03309 
Pharmacokinetic parameters     
Cmax (ng·ml
-1)  1,162.32  1,472.78 
tmax (h)  3.4  4.8 
t½el (h)  71.6  20.9 
AUC0-48     
Whole blood (ng·h·ml
-1 ± SD)  47,790  ±  1,739  46,987  ±  2,439 
Kidney (ng·h·g
-1 ± SD) *  166,679  ±  8,371  130,962  ±  8,541 
Lung (ng·h·g
-1  ± SD) *  9,152,977  ±  698,920  84,149  ±  8,134 
Targeting index     
Kidney (-)  3.5  2.8 
Lung (-)  191.5  1.8 
* Significant difference, P<0.05 
 
Pharmacokinetic parameters (table 2) were calculated using equation 1, 
and curve fitting resulted in the levels given in figure 1. Inhalation of iCsA 
resulted in similar whole blood AUC0-48 as oral CsA (table 2), despite a 
lower peak level (Cmax of 1,162 vs. 1,472 ng/mL), which was reached Chapter 4A 
 
108 
earlier (tmax of 3.4 vs. 4.8 hours) (table 2). Furthermore, the elimination 
half-time in blood (t½el) of iCsA was substantially longer than of oral CsA 
(72 vs. 21 hours, respectively). The low tmax demonstrates that CsA after 
inhalation is rapidly absorbed into the systemic circulation, while the long 






























Figure 2. (A) CsA tissue levels after administration of 10 mg/kg iCsA (lung: 
────; kidney: ••••••••) and oral CsA (lung: ─  ─  ─; kidney: ─ •• ─). (B) AUC0-
48 of CsA in tissue (lung: black bars; kidney: grey bars) and blood (white bar). 
Error bars represent standard deviation calculated according to Bailer’s method. In vivo efficacy of iCsA 
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The small difference of the AUC0-48 in blood for iCsA and oral CsA suggests 
that the absolute bioavailability in the systemic compartment was similar 
over a 48-hour period. 
In contrast, iCsA resulted in a 109-fold higher lung availability (AUC0-48) 
compared to oral CsA (table 2 and figure 2). During the complete period, 
the lung tissue level after insufflation of iCsA was much higher than after 
oral CsA (figure 2A). In kidney tissue, the AUC0-48 was 27% higher for iCsA 
than for oral CsA, demonstrating that the lung:kidney ratio was much 
higher for iCsA than for oral CsA. The increased availability of iCsA in the 
lung after insufflation is clearly seen in figure 2B. The lung targeting 
index, calculated by dividing lung tissue AUC by whole blood AUC, was 
191.5 and 1.8 for iCsA and oral CsA, respectively, again demonstrating 
that insufflation of iCsA has higher availability in the lung compared to 
oral CsA administration.  
 
Allograft rejection study 
Ventilation 
Treatment of transplanted animals with iCsA as monotherapy (groups 1 
and 2) prevented rejection up to 10 days, but only at a 5 mg/kg dose 
(figure 3A). Up to 6 days post transplant, no difference between the 2.5 
and 5 mg/kg dose was observed while after 6 days a substantial decrease 
in ventilation score was observed in the 2.5 mg/kg group, leading to full 
loss of ventilation at day 10. Compared to allogenic transplantation 
without treatment (group 6), inhalation of 5 mg/kg iCsA was effective in 
maintaining ventilation (p=0.026), indicating that monotherapy with iCsA 
inhibits the underlying rejection. Inhalation of 2.5 mg/kg did not differ 
significantly from allogenic transplantation without treatment. 
Treatment with 5 or 10 mg/kg oral CsA (groups 3 and 4) prevented 
rejection compared to allogenic transplantation (p=0.01 and p=0.002, 
respectively) (figure 3B). The higher dose (10 mg/kg) was more effective 
than 5 mg/kg in preventing rejection (p=0.01). Treatment with 5 or 10 
mg/kg oral CsA did not differ from treatment with 5 mg/kg iCsA (group 2) 
(p=0.352 and p=0. 937, respectively). 
In isogenic control animals (group 5), orthotopic left lung transplantation 
resulted in a reversible ischemia-induced decrease in the ventilation 
score at post-operative day 2, which surprisingly was especially seen in 
the untreated isogenic control group (figure 3C).  




























Figure 3. Rejection of the left lung as measured with ventilation scores (6: 
normal looking lungs; 0: opaque, fully rejected lungs) and histologic rejection 
score (0: normal looking lungs; 4: fully rejected lungs). (A) Ventilation score of 
animals that received allogenic transplantation and were treated with iCsA (black 
squares: 5 mg/kg; open squares: 2.5 mg/kg). (B) Ventilation score of animals that 
received allogenic transplantation and were treated with oral CsA (black 
triangles: 10 mg/kg; open triangles: 5 mg/kg). (C) Control animals that did not 
receive cyclosporine (black circles: isogenic transplantation BN-BN; open circles: 
allogenic transplantation AO-BN). (D) Histologic rejection score at day 10 post-
operative. Error bars represent SEM (n=3). Statistically significant difference: 
allogenic control versus 5 mg/kg iCsA (*; P=0.026), allogenic versus 5 mg/kg (***; 
P=0.01) and 10 mg/kg oral CsA (**; P=0.002), isogenic versus 2.5 mg/kg iCsA (†; 
P=0.01) and isogenic versus 5 mg/kg oral CsA (††; P=0.01).  In vivo efficacy of iCsA 
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After 10 days, the ventilation score normalized. In allogenic left lung 
transplantation without treatment (group 6), the ventilation score 
decreased to 0 at  day 8 after transplantation, which indicated complete 
rejection after 8 days. Despite full loss of ventilation of the left lung, the 
rat functioned normally due to the unaffected right lung. The non-
transplanted groups treated with 5 mg/kg iCsA (group 7) or 10 mg/kg oral 
CsA (group 8) did not show any loss of ventilation (data not shown), 
proving that the treatment itself did not have an influence on the 
ventilation score. 
 
The ventilation score of isogenic transplants didn't differ significantly 
from allogenic transplants treated with 5 mg/kg iCsA or 10 mg/kg oral 
CsA (p=0.589 and p=0.699, respectively). In contrast, isogenic 
transplantation was significantly different compared to 2.5 mg/kg iCsA 
(p=0.01) and 5 mg/kg oral CsA (p=0.01). These results show that 
monotherapy with 5 mg/kg iCsA or 10 mg/kg oral CsA effectively prevents 
rejection as measured by the ventilation score. 
 
Histology 
After 10 days the animals were sacrificed and the histology of the lungs 
was analyzed (figure 4). After treatment with 5 mg/kg iCsA, the allografts 
exhibited some perivascular, peribronchial and interstitial infiltrates, 
while the pulmonary architecture and alveolar integrity were preserved. 
On average, administration of 5 mg/kg iCsA resulted in a grade 2.7 
rejection (figure 3D). The lower dose of 2.5 mg/kg iCsA was not effective 
in suppression of rejection (grade 4, figure 3D).  
Oral administration of CsA in a 5 mg/kg dose resulted in almost complete 
rejection similar to 2.5 mg/kg iCsA but with edematous alveoli and more 
infiltrates. These allografts showed grade 3.5 rejection on average (figure 
3D). At a 10 mg/kg oral dose, the allografts exhibited some perivascular 
inflammation and had a mild grade 1.3 rejection score.  
Control recipients with isogenically transplanted lungs (group 5) showed 
no signs of rejection. In contrast, allografts from non-treated control 
recipients exhibited full rejection grade 4 rejection. The alveoli of the 
allografts were obliterated and contained necrotic debris. In addition, 
interstitial destruction and vascular thrombosis was observed. Histological 
analysis revealed that inhalation of 5 mg/kg iCsA in non-transplanted 
animals (group 7) resulted in some alveolar, perivascular and interstitial Chapter 4A 
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reaction which differed from reaction typically seen with rejection. Focal 
infiltrates of macrophages, lymphocytes and polymorphous nuclear cells 
were visible (data not shown). However, this reaction was not visible on 
roentgenograms. The control animals that received 10 mg/kg oral CsA 
(group 8) did not show such signs of reaction in the lungs. 
 
Systemic trough CsA blood levels 
Trough CsA blood levels were determined in rats that received lung 
transplantation and were treated with iCsA or oral CsA systemic (figure 
4). Generally, rats treated with 2.5 mg/kg iCsA had relatively lower 
trough levels (average 93±26 ng/mL) than 5 mg/kg iCsA (average 243±54 
ng/mL). In line with the findings in the pharmacokinetic study, treatment 
with 5 mg/kg iCsA resulted in lower trough blood levels than treatment 
with 5 mg/kg oral CsA (average 439±207 ng/mL). Treatment with 10 
mg/kg oral CsA led to highest systemic trough levels (average 687±258 
ng/mL). Furthermore, treatment with iCsA led to more constant trough 
levels compared to oral treatment, a finding that was also observed in 
















Figure 4. Systemic CsA trough levels of rats that received allogenic lung 
transplantation and were treated with 2.5 mg/kg iCsA (black bars), 5 mg/kg iCsA 
(dark grey bars), 5 mg/kg oral CsA (grey bars) or 10 mg/kg oral CsA (white bars). 
Time point “Average” represents the average systemic CsA trough level per group 




In this study, a new cyclosporine powder formulation suitable for 
pulmonary administration (iCsA) was effective in preventing rejection 
after lung transplantation in rats as single therapy. A trend was observed 
between suppression of rejection and CsA dose, irrespective of the 
administration route, with 10 mg/kg being most effective, followed by 5 
mg/kg. A dose of 2.5 mg/kg was not effective in suppression of rejection. 
In equal doses (5 mg/kg), iCsA showed suppression of rejection at lower 
trough blood levels than orally administered CsA. Therefore, the efficacy 
of iCsA appears to be related to both systemic and pulmonary 
concentrations.  
Inhalation of iCsA resulted in much higher lung tissue levels than oral CsA. 
The high lung tissue levels after insufflations may have led to local 
pulmonary reaction as observed in the 5 mg/kg iCsA control group. Such 
reaction was not reported previously and may be the consequence of the 
extremely high tissue levels. This reaction requires further investigation. 
In the literature (15-17, 28) lower doses for effective suppression of 
rejection have been found, albeit in different animal models. The 10 
mg/kg oral CsA group (group 8) displayed normal lung histology without 
signs of pulmonary reaction. Therefore, less, or even no pulmonary 
reaction is expected when iCsA would be given in lower doses. 
The difference in lung tissue levels after inhalation and oral 
administration (lung targeting index) were about 7- to 14-fold higher in 
this study than Blot et al. (15) and Mitruka et al. (29) previously reported, 
which may have been due to the different administration method used in 
this study. Both Blot et al. and Mitruka et al. used nose-only exposure to 
the aerosol, while in this study insufflation was used. With nose-only 
exposure, a small part of the dose is inhaled; of the inhaled dose a 
portion is possibly swallowed, leading to systemic absorption. In contrast, 
the complete dose is given to the lungs with insufflation, which would 
result in much higher deposition and lower systemic exposure. As a 
consequence, the different administration method may have contributed 
to the occurrence of the local reactio n  b y  e n a b l i n g  m u c h  h i g h e r  l o c a l  
doses. 
The pharmacokinetics show that iCsA was for the largest part absorbed in 
the lung. After tmax has been reached, the lung tissue level declines very 
slowly, as well as the corresponding blood levels as shown by the high 
t½el. This indicates that CsA is only gradually released into systemic Chapter 4A 
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compartment. The systemic blood levels after administration iCsA are 
more reproducible than after oral administration of CsA, which is the 
result of the less complicated route of entrance into the systemic 
compartment: directly from the lungs. In contrast, oral administration of 
CsA is influenced by gastrointestinal transit, food and first-pass 
metabolism, resulting in a reported bioavailability of 27% (30). 
Consequently, the availability in the target organ is much higher for iCsA.  
The side effects of iCsA are limited. The kidney tissue level, was not 
different for iCsA and oral CsA and indicates comparable safety of both 
products. On the other hand, the ratio of lung to kidney tissue level (in 
fact an efficacy/safety parameter) is much higher for iCsA than for oral 
CsA. Therefore,  iCsA as add-on therapy over conventional oral therapy 
would not drastically increase the systemic exposure and thereby the risk 
of nephrotoxicity. 
To conclude, our study indicates that results of lung transplantation may 
be improved by combination therapy of iCsA with standard oral 
immunosuppressive therapy. In addition to other approaches to improve 
the efficacy/safety balance of immunosuppressive therapy with 
calcineurin inhibitors, iCsA may be an option. The different route of 
administration of iCsA in lung transplantation in combination with oral 
therapy may lead to more effective local immune suppression than can be 
reached by oral therapy only. Lower doses of iCsA would only have a 
limited effect on the systemic CsA levels, which would not increase the 
risk of side effects. Future studies should focus on establishing the safety 
of iCsA in pre-clinical studies and establishing the appropriate dose in 
combination with oral treatment. 
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Background: The aim of this study was to compare the pulmonary side-
effects of high dose cyclosporine A solid dispersion for inhalation 
(iCsA) with low dose and with controls. 
Methods: Rats were orotracheally intubated and given either 5 or       
0.8 mg/kg iCsA by insufflation, 5 or 0.8 mg/kg placebo (inulin) powder 
by insufflation, insufflation without powder, or no insufflation. Dosing 
was performed on alternate days. On day 10, lungs were harvested for 
histological analysis. 
Results: Insufflation of 5 mg/kg iCsA resulted in some alveolar, 
perivascular and interstitial reaction. The reaction after low-dose iCsA 
(0.8 mg/kg) did not differ from both placebo doses  dose. 
Furthermore, the reaction observed after 0.8 mg/kg iCsA did not differ 
materially  from untreated, but insufflated control groups. 
Conclusion: The absence of an additional reaction after treatment with 
low-dose iCsA compared with placebo indicates that inhalation of iCsA 




Lung transplantation has become a therapeutic option for end-stage 
pulmonary disease. Oral treatment with calcineurin inhibitors, such as 
cyclosporine A or tacrolimus, is the cornerstone of current 
immunosuppression. However, calcineurin inhibitors are known for their 
side effects, such as neuropathy and nephrotoxicity, which narrows the 
therapeutic window (1-4). 
Currently, calcineurin inhibitors are only available as formulations for 
parenteral or oral administration. After oral administration, the systemic 
concentration determines the tissue concentration in the target organ. To 
improve therapeutic efficacy, it has been suggested to increase the drug 
tissue levels in the lung via pulmonary administration. Iacono et. al. (5) 
have demonstrated in a single center study that liquid nebulization of CsA 
resulted in improved survival after lung transplantation compared with 
placebo. Unfortunately, patients had to be pretreated with local 
anesthetiscs to make the inhalation maneuver tolerable. 
To improve the administration of CsA by inhalation and to avoid the 
pretreatment with local anesthetics, a dry powder formulation containing 
CsA (iCsA) has been developed based on inulin solid dispersion technology 
(6). In a previous study, the pharmacokinetics and efficacy of iCsA have 
been compared with oral administration of CsA (Neoral
®) (7). iCsA 
resulted in much higher tissue levels in the lung than oral CsA, whereas 
the systemic exposure was similar. Furthermore, the lung tissue levels of 
iCsA remained higher for a longer period than those found after oral CsA. 
Inhalation of 5 mg/kg iCsA resulted in improved suppression of rejection 
in a transplantation model in rats compared to oral administration of               
5 mg/kg CsA: on day 10 after transplantation, the ventilation score, 
which ranged from 6 (normal lungs) to 0 (opaque, fully rejected lungs), 
was 4.1 versus 2.5 for 5 mg/kg iCsA and oral CsA, respectively. The 
histologic score, which ranged from 0 (normal looking lungs) to 4 (fully 
rejected lungs), was 2.7 versus 3.5 for 5 mg/kg iCsA and oral CsA, 
respectively. However, inhalation of 5 mg/kg iCsA in control animals 
resulted in some alveolar, perivascular and interstitial reaction which 
differed from the reaction typically seen with rejection. Focal infiltrates 
of macrophages, lymphocytes and polymorphous nuclear cells were 
visible. This reaction was not visible on roentgenograms. The conclusion 
of that study was to use iCsA in combination with systemic treatment, but 
with a lower iCsA dose (7). Chapter 4B 
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Therefore, the purpose of the current study was to investigate the (side-
)effects of a lower iCsA dose and the effects of placebo (inulin) on the 
histology of the lung. Rats were treated according to the same protocol as 
in the study mentioned above. End point of this study was histologic 
analysis. 
 
MATERIALS AND METHODS 
Materials 
Cyclosporine as a powder for inhalation (iCsA) and inulin (placebo) were 
formulated as described before (6). For iCsA, a co-solvent solution of 
tert-butanol and water (40/60 v/v) containing CsA and inulin was spray 
freeze-dried to obtain a solid dispersion of 50% w/w CsA in inulin (iCsA). 
The placebo powder was prepared similarly, only the inulin concentration 
was increased to have the same amount solid concentration. 
 
Animals 
Specific pathogen free, male Brown-Norway rats (BN/RijHSD), weighing 
200 to 260 gram, were purchased from Harlan (Horst, the Netherlands). 
The rats were conventionally housed at the animal facility of the 
University of Groningen. The experimental protocol was approved by the 
institutional animal care committee of the University of Groningen. Prior 
to any experiment, the rats were allowed to acclimatize for a period of 
minimally 7 days. Throughout the experiment the rats were allowed to 
eat and drink ad libitum. The animals received human care in compliance 




Rats were anesthetized with 4% isoflurane at an O2 flow of 0.6 L/min and 
given atropine (0.05 mg/kg SC). Next, they were orotracheally intubated 
for the insufflation procedure. The powder for inhalation (iCsA) or 
placebo was administered by insufflation (Model DP-4, Penn-Century, 
Philadelphia, PA, USA).  
 
Experimental groups and treatment regimen 
All rats in this study were exposed to the same experimental procedures. 
All rats were anesthetized, followed by intubation. These procedures 
were repeated on alternate days for a period of 10 days. Depending on In vivo safety of iCsA 
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the experimental group, additional insufflation with or without powder 
could be performed as detailed in Table 1.  
We randomly divided rats into 6 Groups. Rats in Group 1 and 2 were given 
5 mg/kg iCsA or 5 mg/kg placebo (inulin), respectively. Groups 3 and 4 
were given 0.8 mg/kg iCsA or 0.8 mg/kg placebo, respectively. Rats in 
Group 5 and 6 served as controls: rats in Group 5 received insufflation 
without powder, while rats in group 6 were only intubated.  
On day 10, all rats were euthanized by puncture of the aorta while they 
were under isoflurane anesthesia. The lungs were fixated with formalin, 
dissected and stored for histologic analysis.  
 
Table 1. Experimental groups 
Group  n  Treatment 
1  3  5 mg/kg iCsA 
2  4  0.8 mg/kg iCsA 
3  4  5 mg/kg placebo 
4  4  0.8 mg/kg placebo 
5  4  Insufflation 
6  4  - 
 
Histologic analysis 
The formalin-fixated lungs were embedded in paraffin and cut into 3 μm 
sections followed by hematoxylin-eosin (HE) staining. Sections were 
analyzed as previously described (8).  
 
RESULTS 
Insufflation of 5 mg/kg iCsA on alternate days for a duration of 10 days 
did not result in macroscopic (i.e. on X-rays) reactions, but as in our 
former experiment (7), did result in a measurable microscopic 
inflammatory reaction (Figure 1). Microscopically, focal infiltrates of 
macrophages, lymphocytes and polymorphous nuclear cells were visible in 
all rats treated with 5 mg/kg iCsA (Table 2).  
In contrast, insufflation of 0.8 mg/kg iCsA using the same dosing scheme, 
only resulted in a minor reaction as compared to 5 mg/kg iCsA (Table 2): 
in most cases, the alveoli were clean, in one rat some alveolar 
macrophages were seen. In two rats, polymorphous nuclear cells were 
visible in the interstitium. In a single rat, some infiltrates were observed 




Figure 1. Hematoxillin and eosin stainings of lung tissue from rats treated with 5 
mg/kg (upper part) and 0.8 mg/kg iCsA (lower part). Each representative 
photograph is taken from the lung of a different rat. Magnification was 4x for 5 
mg/kg iCsA and 5x for 0.8 mg/kg iCsA doses. 
 
In the control groups that received inulin (placebo) by insufflation of 
similar doses as iCsA (5 and 0.8 mg/kg), minor histologic reactions were 
also found. These were far less than observed after insufflation of                     
5 mg/kg iCsA insufflation (Figure 2), yet similar as 0.8 mg/kg iCsA 
insufflation (Table 2). At a 5 mg/kg inulin dose, a few small infiltrates 
consisting of polymorphous nuclear cells were perivascularly seen in two 
rats. In one rat, some macrophages were observed perivascularly and 
peribronchially. At a 0.8 mg/kg inulin dose, a few polymorphous nuclear 
cells were found in one rat in the alveoli and perivascularly, while in two 
rats alveolar macrophages were found. 
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In the control group that received insufflation without powder, a single 
small infiltrate of polymorphous nuclear cells in the interstitium and 
peribronchially was observed in a single rat. In addition, a few alveolar 
macrophages were found in another rat (Figure 3). Control rats that did 
not receive insufflation but were treated according to the same 
experimental procedures, showed a similar picture as the insufflation 
group (Table 2). 
 
Table 2. Semiquantitative histologic observations in the experimental groups 





















































      Neutrophils  ++  +/-  +/-  +/-  ++ 
1  5  mg/kg  iCsA  Macrophages  +++  +/- ++ ++ ++ 
      Lymphocytes  +++  +/-  ++  ++  ++ 
      Neutrophils  +  +/-  -  -  - 
2  0.8 mg/kg iCsA  Macrophages  +  -  -  -  +/- 
        Lymphocytes - - - - - 
      Neutrophils  -  ++  -  +/-  - 
3  5 mg/kg placebo  Macrophages  -  +/-  -  -  - 
        Lymphocytes - - - - - 
        Neutrophils  - +/- -  - +/- 
4 0.8  mg/kg  placebo  Macrophages  - - - - + 
        Lymphocytes - - - - - 
        Neutrophils  +/- -  - +/- - 
5 Insufflation  Macrophages  - - - -  +/- 
        Lymphocytes - - - - - 
      Neutrophils  -  +  -  +/-  - 
6 -  Macrophages  - - - - - 
        Lymphocytes - - - - - 
Note: The signs denote in how many rats in the experimental a certain cell type 
was observed: - correlates to no observations, +/- correlates to an observation in 
1 rat, + correlates to 2, ++ correlates to 3 and +++ correlates to observations in 
all rats of a specific group. 
 




Figure 2. Hematoxillin and eosin stainings of lung tissue from rats treated with 
placebo (inulin) in a 5 mg/kg (upper part) and 0.8 mg/kg dose (lower part). Each 









Figure 3. Hematoxillin and eosin stainings of lung tissue from control rats treated 
with insufflation without powder (upper part) and untreated rats (lower part). 
Each representative photograph is taken from the lung of a different rat. 
Magnification was 5x. 
 
DISCUSSION 
iCsA in a low dose (0.8 mg/kg) does not result in a local pulmonary 
reaction as observed after 5 mg/kg inhalation. The reaction after                 
0.8 mg/kg iCsA was not different from that observed after 5 or 0.8 mg/kg 
placebo. Furthermore, the reaction observed with 0.8 mg/kg iCsA does 
not differ essentially from the untreated, but insufflated control groups. 
As a summary measure, the cumulative number of histologic 
abnormalities ranked as follows: 5 mg/kg iCsA (27 abnormalities) >>         
0.8 mg/kg iCsA (6 abnormalities) > 5 or 0.8 mg/kg inulin (4 abnormalities) 
> insufflation or placebo (3 abnormalities). Additionally, the intensity of 
observed histologic reaction was much less intense than the reaction 
caused by insufflation of 5 mg/kg iCsA, indicating that the lower iCsA 
dose is safe. Inulin insufflcation appeared to be safe at both doses.  
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Our results suggest that the high CsA levels locally in the lung after                 
5 mg/kg iCsA are the main reason for the observed pulmonary reaction. In 
the previous study (7), only the 5 mg/kg dose was effective in preventing 
allograft rejection while a lower dose did not inhibit rejection. 
Therefore, demonstrating that 0.8 mg/kg is safe may seem irrelevant. 
Nevertheless, the animal model used in the allograft rejection study was 
very acute because of the incompatibility between the major 
histocompatibility complexes of the donor and recipient. This 
incompatibility necessitated the use of high iCsA doses, administered via 
the pulmonary route as single treatment, for effectiveness. In contrast, in 
the human transplantation setting, the donor and recipient are matched 
to prevent acute rejection as much as possible. Consequently, 
immunosuppresive therapy is given for a long time via the oral route, with 
a combination of immunosuppressive drugs. If iCsA was to be used in 
humans then iCsA would be given on top off the current treatment 
regimen, and never as a single treatment. For that situation, the 0.8 
mg/kg dose administered in the rat will probably be too high as the 0.8 
mg/kg iCsA dose in rats corresponds to 64 mg CsA given by inhalation in 
humans. In the currently scheduled clinical trial, we envisage to use a 
dose of 6.25 mg CsA, equivalent to 12.5 mg powder. This dose is based on 
a study performed by Corcoran et. al. (9), who reported that for 
nebulized CsA, a deposition of at least 5 mg in the peripheral lung led to 
improvements in lung function after lung transplantation. The 6.25 mg 
CsA dose is based on our intention to administer iCsA twice daily and the 
assumption that we will be able to obtain about 40% deep lung deposition 
with this powder and administration device (Twincer
®). Adverse side 
effects as seen with the 5 mg/kg dose in the rat are not expected with 
the 6.25 mg iCsA human dose since the human dose is over 60 times lower 
(and even 10 times lower than the 0.8 mg/kg rat dose tested in this 
study). 
In the previous study we concluded that in humans inhalation of iCsA as a 
single treatment would not be feasible while a lower iCsA dose in 
combination with systemic immunosuppression could have a place in 
therapy. As shown in this study, a lower iCsA dose led to a reaction at the 
level of placebo. More important, the similarity in reaction between 0.8 
mg/kg iCsA, placebo and controls suggests that the observed effects at 
this dose are merely the result of the experimental setup rather than the 
administered drug. In vivo safety of iCsA 
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To conclude, the results described in this chapter demonstrate that a 0.8 
mg/kg dose of iCsA does not give the pulmonary adverse reaction found 
with a 5 mg/kg dose (7). This indicates that there are no major safety 
objections against the use of this 0.8 mg/kg dose in man. Although in the 
previous study a lower dose of inhaled CsA was not effective in 
suppressing rejection in a very acute animal model of rejection, a study 
that combines systemic (oral) with pulmonary CsA administration may 
demonstrate the benefits of a cyclosporine powder for inhalation while 
preventing at least large part of the associated nefrotoxicity. 
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A formulation and process development study was performed to 
formulate recombinant human deoxyribonuclease I as a powder for 
inhalation. First, excipient compatibility (with bovine DNase as a 
model substance) was examined with a stability study at stressed 
conditions (60 and 85 °C) while monitoring for occurrence of the 
Maillard reaction. Next, powders for inhalation were prepared by 
spray drying and spray freeze drying. We found that spray drying with 
inulin as stabilizer resulted in the best powder for inhalation. Finally, 
an ex-vivo test with the spray dried rhDNase I/inulin powder 
significantly decreased elastic and viscous moduli of sputum from 5 





® is a solution for nebulization containing 2.5 mg/mL 
recombinant human deoxyribonuclease I (rhDNase I). RhDNase is used to 
decrease the viscoelastic properties of sputum in cystic fibrosis (CF) 
patients which results in an improved lung function (1, 2). In CF, repeated 
respiratory tract infections lead to high concentrations of DNA from 
degenerating polymorphonuclear leucocytes in the lung (3, 4). The 
presence of DNA increases the viscosity of sputum and makes it more 
difficult to clear the sputum from the respiratory tract. This increases the 
susceptibility to infection which, in turn, provokes an inflammatory 
response. The cycle of infection, inflammation and obstruction leads to 
progressive destruction of lung tissue and reduced life expectancy (5, 6). 
Pulmozyme is one of the therapeutic options in CF. In a double-blind, 
randomized, placebo-controlled phase III study, which involved 51 CF 
centers and 968 CF patients, patients were randomized to receive 2.5mg 
rhDNase once or twice daily, for 6 months (7). Administration of rhDNase 
either once or twice daily reduced the risk of a respiratory infection 
requiring antibiotics by 22% and 34%, respectively. At the end of the 6-
month period the improvement in forced expiratory volume in 1 second 
(FEV1) was 0% for the placebo group, 5.8% for the once-daily group, and 
5.6% for the twice-daily group, showing that both the incidence of 
respiratory tract infections and lung function is improved by rhDNase. 
Pulmonary administration of drugs by nebulization is a process with 
several drawbacks. One of the major drawbacks is low deposition 
efficiency, especially with traditional nebulizers which for instance have 
high residual volumes. For Pulmozyme, the pulmonary deposition was 
reported to range between 7.8% and 31.2% (8). Furthermore, the 
nebulization (including cleaning of the equipment) is time consuming and 
requires complex equipment using electricity or compressed air. Finally, 
the solution for nebulization has to be stored in the refrigerator (2-8ºC). 
All these aspects reduce patient compliance to therapy and may reduce 
the success of rhDNase therapy.  The development of a stable dry powder 
inhalation formulation containing rhDNase may improve the 
administration. Major advantages are the potentially higher lung 
deposition (which would also reduce costs),  a reduced administration 
time and no need to store the rhDNase solution at low temperatures to 
prevent degradation (8-12). These advantages may results in an improved 
compliance which positively affects the therapeutic outcome.  Chapter 5 
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Major aspects that have to be taken into account when a protein 
containing dry powder for inhalation is to be developed are: 
•  the excipients in the formulation should stabilize the protein during 
drying and subsequent storage, 
•  the powder characteristics should, in combination with the used 
inhalation device, allow for the generation of an aerosol with an 
aerodynamic particle diameter within the 1 to 5 µm range (preferably 
2 µm) (13). 
•  ex vivo experiment should guarantee the activity of the protein in the 
therapeutic setting. 
Drying of pure proteins often leads to partial or total inactivation due to 
degradation. However, recently several technologies have been described 
that allow for the production of a dry and stable powder formulation of 
proteins for inhalation (14-17). To withstand the degradation during 
processing and storage, stabilizing excipients should be used (18-21). The 
most common types of protectants are carbohydrates or polyols (e.g., 
mannitol,  sucrose, trehalose, inulin). Spray (freeze) drying of aqueous 
solutions of rhDNase has been reported previously as a successful drying 
technique (14, 16). Maa et al.(16) have compared spray drying with spray 
freeze drying and found that with their inhaler (Dryhaler®) spray freeze 
drying was better suited to produce a rhDNase powder for inhalation. 
However, their findings may be rather specific for the used inhaler and 
spray freeze drying, in contrast to the spray drying, is difficult to upscale 
to an industrial process (22). 
Quan et al. (23) have demonstrated that rhDNase is prone to the Maillard 
reaction when intimately co-formulated with reducing sugars, such as 
lactose. Hence, reducing sugars should be avoided as excipient for 
proteins in spray dried and freeze dried formulations. In a different study, 
Chan et al. (14) have spray dried pure rhDNase solutions and subsequently 
mixed the powder with lactose carrier, thereby keeping the number 
contact points between rhDNase and lactose low. However, for long term 
storage, a glassy formulation may be preferred.  
The purpose of this study was to investigate whether spray drying of a 
(rh)DNase powder for inhalation with the Novolizer
® dry powder inhaler is 
feasible. In this study the performance of spray dried DNase powder is 
evaluated in comparison with freeze dried and spray freeze dried powders 
regarding stabilization effectiveness, maintenance of enzymatic activity 
and dimerization of (rh)DNase. In contrast with previous studies, the Preclinical development of rhDNase 
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aerosol generation of the differently produced powders was studied 
without mixing the powders with additional excipients (e.g. crystalline 
lactose) to improve dispersion. Working without additional excipients 
reduces the amount of material to be inhaled. Finally, an ex vivo test, 
measuring the effect of rhDNase powder on the viscoelasticity of CF 
sputum, was performed. 
 
MATERIALS AND METHODS 
Materials 
Pancreatic bovine deoxyribonuclease I (DNase, ~3000 units per mg, purity 
>80%) was purchased from Sigma-Aldrich. DNase was used as a model 
drug, since bovine DNase has a homology of ~80% in its amino acid 
sequence compared to rhDNase (24). DNase was the test drug for the 
entire study, with the exception of the ex vivo proof of principle, where 
recombinant human deoxyribonuclease I (rhDNase) was used, which was 
obtained as Pulmozyme
® from Roche (Basel, Switzerland). Inulins with a 
degree of polymerization (DP) of 14 and 23 were a generous gift of Sensus 
(Roosendaal, the Netherlands). All other chemicals were either of reagent 
or of analytical grade and purchased from commercial suppliers. 
 
Methods 
Powder preparation methods 
For all processes used to produce bovine DNase powders, the starting 
solutions were made in the same way. Each solution contained 2.5 mg/ml 
DNase, 0.375 mg/ml CaCl2 and 11.0 mg/ml NaCl and the pH was adjusted 
to 6.3 with 0.2N HCl. CaCl2 was added to the DNase-solution because it 
has been reported that this salt stabilizes two disulfide bridges in the 
protein (23).  NaCl was added to ensure that DNase remained in its 
tertiary structure in the solution. Carbohydrates were added to the DNase 
solution in a final concentration of 22.5 mg/ml before drying. 
 
Spray drying 
Sucrose, trehalose, inulin DP14 and inulin DP 23 were initially tried in the 
spray drying process. For the inhaler experiments inulin DP23 was used as 
stabilizer. The solution was spray dried with a Büchi 190 Mini Spray Dryer 
(Büchi, Flawil, Switzerland) equipped with a two-fluid nozzle (0.5 mm). 
The process conditions were: pump 2.37 mL/min (setting 3), aspirator       
75 mbar (setting 18), heating inlet temperature 135 °C, outlet Chapter 5 
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temperature between 55 - 75 °C (setting 9) and the atomizing airflow was 
set at 400, 600 or 800 Ln/h. The obtained powder was subsequently stored 
at 20 °C and 50% relative humidity (RH). 
To spray dry rhDNase, Pulmozyme
® was used as starting material and the 
preparation of the solution was adapted to obtain similar concentrations 
as during DNase experiments. Firstly, Pulmozyme
® was centrifuged with 
an Ultrafree
© centrifugal filter device with a molecular weight cut-off of 
10 kD (Millipore Corporation, Bedford, MA 01730) to obtain a more 
concentrated solution. After centrifugation, the concentration of rhDNase 
was measured with a Lowry assay (25). The CaCl2 concentration was 
adjusted to the rhDNase concentration with microdialysis using a pH of 
6.3. Afterwards, inulin DP23 was added to obtain a ratio of rhDNase:inulin 
of 1:9. The total concentration of inulin and rhDNase was 40 mg/mL and 
contained 0.6 mg/mL CaCl2 at a pH of 6.3. The solution prepared in this 
way was similar to the solutions used for bovine DNase, only the 
concentration was slightly higher because centrifugation led to higher 
rhDNase concentrations. A similar solution was prepared without rhDNase 
to obtain a placebo powder.  
 
Freeze drying 
Sucrose, trehalose, inulin DP14 and DP 23 were used as stabilizers in the 
freeze drying process; a sample without carbohydrate was produced as 
reference material. The sample without carbohydrate thus only contained 
DNase (2.5 mg/ml), CaCl2 (0.375 mg/ml) and NaCl (11.0 mg/ml). Freeze 
drying was performed using a Christ model Alpha 2-4 lyophilizer (Salm en 
Kipp, Breukelen, the Netherlands). For the  freeze  drying  experiments,     
4 mL glass vials were filled with 400 μl aqueous solution. The aqueous 
solutions were frozen in liquid nitrogen and subsequently dried at a 
condenser temperature of -53 ºC and a shelf temperature of -35 ºC at a 
pressure of 0.220 mbar. After 21 hours the shelf temperature was 
increased incrementally over 3 hours to 20 ºC and the pressure was 
decreased to 0.060 mbar. Secondary drying was continued for another       
24 hours under these conditions. 
After lyophilization the dried samples were transferred to a vacuum 
desiccator and stored for at least 1 day before using the samples in 
experiments. 
 Preclinical development of rhDNase 
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Spray freeze drying 
For the spray freeze drying process (with inulin DP23) the solution was 
sprayed into a bowl of liquid nitrogen with the two-fluid nozzle (diameter 
0.5 mm). The same nozzle as used in the Büchi Mini Spray Dryer. The 
nozzle was placed approximately 10 cm above the surface of the liquid 
nitrogen and the solution was atomized with an atomizing air flows of 
400, 600 and 800 Ln/h at a pump flow 2.37 mL/min. After the spraying 
was completed, the bowl with liquid nitrogen was transferred to a Christ 
model Alpha 2-4 freeze dryer (Salm & Kipp, Breukelen, The Netherlands) 
and the liquid nitrogen was allowed to evaporate. For drying, exactly the 
same regime was used as described for the freeze dried samples The 
obtained powders were subsequently stored at 20 °C and 50% RH. 
 
Stability testing of the powders 
Freeze dried samples were transferred to a vacuum desiccator for at least 
one day before using the samples in experiments. Long term storage of 
the freeze dried samples was at 0% RH and two different temperatures: 
60 and 85 °C. The climates were controlled with a Hygrocontrol 
temperature and humidity transmitter (Hygrocontrol, Hanau, Germany). 
 
DNase activity 
The effect of freeze drying in the absence or presence of carbohydrates 
followed by storage at elevated temperatures on the enzymatical activity 
of DNase was determined as described by Sinicropi (26). Samples were 
reconstituted with 2.5 mL of HEPES buffer (containing 25 mM HEPES,             
4 mM CaCl2, 4 mM MgCl2, 0.1% BSA, 0.01% thimerosal and 0.05% Tween 20) 
and diluted to DNase concentrations of 2000 ng/mL, 1000 ng/mL and       
500 ng/mL. A calibration curve of unprocessed DNase was simultaneously 
prepared in HEPES buffer with a concentration range of 0-1000 ng/mL. 
The substrate was prepared by mixing 8.47 mL buffer A (25 mM Hepes and 
1 mM EDTA, pH 7.5) with DNA from salmon testes (Sigma), 0.42 mL buffer 
B (20 mM acetate-NaOH, pH 4.2) containing 0.4% methylgreen and             
2.21 mL buffer C (25 mM Hepes, 4 mM CaCl2, 4 mM MgCl2, 0,1% BSA, 0,01% 
thimerosal, 0,05% Tween 20, pH 7.5).  
Next, the wells of a 96 wells plate were filled with 100 μl of the diluted 
sample and 100 μL substrate was added. The reaction was performed at 
room temperature. After 90 minutes the reaction was quenched by adding 
50 μL of a solution containing 50 mM EDTA and 50 mM H2O2. After another Chapter 5 
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90 minutes the absorption was measured with a Biorad Microplate Reader 
Benchmark (Biorad, Hercules, United States) at 630 nm. The difference in 
absorption between 5 and 180 minutes was used to calculate the activity 
of the samples relative to unprocessed DNase. 
 
Glass transition temperature 
The glass transition temperature of freeze dried samples was determined 
with modulated differential scanning calorymetry (mDSC; DSC2920 
differential scanning calorimeter, TA Instruments, Ghent, Belgium).  The 
sample was preheated at 40 °C for 15 minutes and then heated to 200 °C 
at a rate of 2 °C/min and a modulation of ±0.318 °C/min. The midpoint 
of the deflection in the reversing heat flow – temperature curve was 
determined as the Tg. During the measurements, the cell was purged with 
nitrogen (35 mL/min). 
 
Reducing groups 
The amount of reducing groups in the carbohydrates was determined with 
the Sumner assay (27). In short, 100 mL of a solution with 20 g NaK-
tartrate tetrahydrate, 1 g dinitrosalycylic acid, 1 g NaOH and 200 mg 
phenol was prepared. Subsequently, 1.2 mL of this solution was added to 
0.8 mL of the carbohydrate solution. To this solution, 80 µL of a freshly 
prepared solution of 3 g Na2SO3 in 100 mL demineralised water was 
added. The resulting mixture was immediately vortexed and placed in a 
water bath of 95 °C. After 15 minutes the samples were removed from 
the water bath and allowed to cool down to room temperature. Finally, 
the absorbance of 200 µL was measured at 630 nm using a Biorad 
Microplate Reader Benchmark (Biorad, Hercules, United States). A 
calibration curve of glucose in a concentration range of 0.09 – 0.9 mg/mL 
was used in all experiments. The number of reducing groups was 
expressed as the percentage of sugar units containing reducing groups. 
 
Monitoring of the Maillard reaction 
The Maillard reaction occurs in three steps. In the first step the reaction 
between the carbonyl and free amino groups leads to a condensation 
product N-substituted glycosylamine, which transforms into the Amadori 
rearrangement product (ARP). Under acidic conditions, the ARP undergoes 
mainly 1,2-enolisation with the formation of furfural (when pentoses are 
involved) or 5-hydroxy-2-methylfurfural (when hexoses are involved). In Preclinical development of rhDNase 
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the intermediate step colorless Maillard intermediates are formed, such 
as 5-hydroxymethylfurfural and pyrazines. In the last step of the Maillard 
reaction the advanced glycation end-products are formed which can be 
noticed by their brown color (nonenzymatic browning) (28). The 
formation of 5-hydroxymethylfurfural and pyrazynes was investigated by 
measuring the absorbance of reconstituted samples at 280 nm using a 
Unicam UV 500 UV-VIS spectrophotometer (Thermospectronic, Cambridge, 
UK) (29, 30).  
 
Dimeric aggregation 
Size exclusion chromatography was performed on all DNase-carbohydrate 
samples stored for 0, 6, 14, 21 and 28 days at 85 °C. Prior to analysis, 
samples were dissolved with 1.0 mL HEPES buffer (as described under 
DNase activity) and filtered using a 0.45 µm filter. Subsequently, all 
solutions were placed in a Perkin-Elmer 200 series equipped with a Bio-Sil 
SEC250 column and a Bio-Sil 250 guard. As mobile phase 0.1 M sodium 
phosphate and 0.1 M sodium sulphate with a pH of 6.8 was used at a flow 
rate of 1.0 mL/min. For each run 20 µL sample solution was injected . 
Detection was performed with an ultraviolet detector (Applied Biosystems 
model 785A) at 215 nm. For calibration a GPC standard (Bio-Rad 
Laboratories, Hercules, USA) was used which contained bovine 
thyroglobulin (670 kDa), bovine γ-globulin (158 kDa), chicken ovalbumin 
(44 kDa), horse myoglobin (17 kDa) and vitamin B12 (1.35 kDa). The 
molecular weight of DNase is 31 kDa. 
 
Scanning electron microscopy 
Scanning electron micrographs (SEM) were recorded with a JEOL JSM 
6301-F Microscope (JEOL, Japan). The powder was dispersed on top of 
double-sided sticky carbon tape on metal disks and coated with 150 nm of 
gold/palladium in a Balzers 120B sputtering device (Balzers UNION, 
Liechtenstein). 
 
Laser diffraction analysis 
Particle size distributions of the powders were measured in duplicate (the 
difference between the duplicates was less than +1% for all samples) with 
a HELOS Compact model KA laser diffraction apparatus (Sympatec GmbH, 
Clausthal-Zellerfeld, Germany: 100 mm lens and the Fraunhofer theory) Chapter 5 
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equipped with a RODOS disperser. The powders were dispersed at a 
pressure of 3 bar and the median volume diameters (X50) were calculated.  
 
Cascade impactor analysis 
Cascade impactor analysis was carried out with a glass constructed four 
stage liquid impactor of the Fisons type (Elgebe, Leek, The Netherlands). 
The Novolizer
® inhaler was attached to a dry bent induction port using a 
coupling flange with rubber seal ring. A solenoid valve was used in 
combination with a timer to control the flow rate through the inhaler and 
the cascade impactor for the duration of 3 seconds. The airflow through 
the inhaler, corresponding with a pressure difference of 4 kPa, was               
71 Ln/min. The amount of drug deposited on the different stages was 
determined by the Lowry assay (25). Deposition was expressed as a 
percentage of the metered dose. The fine particle fraction (FPF), defined 
as a percentage of particles with an aerodynamic diameter less than               
5 μm, was calculated by intrapolation of the cumulative mass plot versus 
effective cut-off diameter and expressed as a percentage of the metered 
dose. The mass median aerodynamic diameters (mmad’s), were 
calculated from the cumulative mass percentages derived from the 
impactor stages 2, 3 and 4 (31), using the theoretical cutpoints for the 
different impactor stages.  
Cascade impactor measurements were performed in triplicate. 
 
Ex vivo rhDNase activity analysis 
Approval for the collection of sputum of CF patients was obtained from 
the ethics committee of the University Hospital of Ghent. The sputum was 
expectorated spontaneously by CF patients (n=5) during chest 
physiotherapy sessions. After collection, sputum samples were 
immediately frozen at -20 °C (32, 33). The prepared placebo and rhDNase 
powder was mixed in a 1:10 ratio with sucrose to obtain a weighable dose 
of rhDNase. In total, rhDNase-dose was 30 µg (15 IU). 
After thawing, a single sample of sputum was divided into 4-6 portions, 
depending on the volume of the sample. First, the viscoelasticity of 
untreated sputum was determined as 100% reference. Next, 30 mg of 
placebo powder or rhDNase powder was added and the viscoelasticity of 
the sputum was determined after 20 minutes of incubation at room 
temperature. This procedure was performed in such a way that at least Preclinical development of rhDNase 
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duplicate measurements were determined on a single sputum sample of 
placebo and DNase powder. 
Sputum viscoelasticity was measured with a controlled-stress rheometer 
(AR 1000-N; TAInstruments, Ghent, Belgium) at 20 °C, using a cone-plate 
geometry. The angle between the cone and the plate was 2 degrees, and 
the sample volume required was approximately 0.9 mL. Dynamic 
oscillatory measurements were made at a constant frequency of 1 Hz, 
with a stress ranging from 0.01 to 0.1 Pa. To avoid disruption of the weak 
biopolymer network in sputum, the elastic (G’) and viscous (G”) moduli of 
the sputum samples were determined in the linear viscoelastic region. 
 
RESULTS 
Excipient compatibility and stability 
To determine the effect of different excipients on the stability of bovine 
DNase the material was freeze dried in the presence of the four different 
carbohydrates. Figure 1 shows that freeze drying reduces the activity of 
bovine DNase by approximately 20% when no carbohydrate is present in 
the formulation. Drying in the presence of a carbohydrate reduces the 
activity loss to about 10%.  
When stored at 60 °C all carbohydrates protected DNase from further loss 
of activity for a period of 6 weeks, whereas the DNase freeze dried 
without carbohydrate lost another 40% of activity within the same period. 
The type of carbohydrates did not seem to have a substantial effect at 
this storage temperature.  
 
Table 1. Glass transition temperature and the percentage of reducing groups 
found for the different carbohydrates (freshly prepared freeze dried samples, 
n=3). 
Sample Tg (°C) Reducing  groups  (%) 
Sucrose  76.1 ± 1.1  0.09 ± 0.01 
Trehalose *  121.6 ± 0.7  0.14 ± 0.04 
Inulin DP14 *  139.7 ± 1.7  2.1 ± 0.1 
Inulin DP23  157.1 ± 1.3  5.2 ± 0.2 
* Data from Hinrichs et al. 
[21] 
































Figure 1. DNase activity of the different formulations after freeze-drying and 
storage at 60 °C or 85 °C. Storage times were 0 days (black bars), 2 weeks (grey 
bars), 4 weeks (dark grey bars) or 6 weeks (light grey bars). Results are expressed 
as averages (n=3) ± standard deviation.  
 
When stored at 85 °C, DNase freeze dried without carbohydrates rapidly 
lost all of its activity. The sucrose formulation lost its activity even faster 
under these conditions. However the degradation rates of the trehalose 
and inulin formulations were clearly reduced compared to the reference Preclinical development of rhDNase 
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and the sucrose formulation. The formulations with inulin showed a faster 
loss of activity than the trehalose formulation, despite the higher Tg’s of 
inulin (Table 1). In a control experiment, the presence of NaCl in the 
formulations did not change the Tg of the pure carbohydrate (data not 
shown). Visual observation of the stored cakes showed a dramatic volume 
contraction and browning, which was dependent on storage time. This 
effect was most pronounced for the sucrose-containing formulation stored 
at 85 °C. At this temperature, the sucrose formulation was stored above 
its Tg. 
The Sumner assay revealed that sucrose and trehalose contain only minor 
levels of  reducing groups whereas somewhat higher levels were found in 
the inulins (Table 1).  
The intrinsic absorbance of DNase at 280 nm in all formulations 
immediately after freeze drying (t = 0) was found to be 0.18 (Figure 2A). 
During storage at 85 °C, the absorbance increased dramatically for the 
sucrose formulation, indicating a dramatic increase in the formation of 5-
hydroxymethylfurfural and pyrazines (intermediates of the Maillard 
reaction). The increase was much less pronounced for both inulins, 
whereas the trehalose formulation showed no significant increase in 
absorption at 280 nm. 
Upon reconstitution, approximately 10% of DNase was found as dimeric 
aggregates immediately after freeze drying, irrespective of the 
formulation (Figure 2B). During storage at 85 °C, the sucrose formulation 
resulted in the highest increase in the amount of dimeric aggregates. 
Also, the inulin formulations and the carbohydrate-free DNase showed a 
slight increase in the amount of dimeric aggregates during storage 
whereas this increase for the trehalose formulation was almost negligible.  
 
Drying processes 
In this study spray drying was chosen as process of first choice for the 
production of a dry DNase powder for inhalation. However, when spray 
drying was performed it was found that the sucrose formulation can not 
be processed properly at the conditions tested in our study. The particles 
immediately coalesced in the collection vessel. The trehalose and inulin 
formulations could successfully be spray dried but the trehalose 
formulation could not be stored adequately at ambient conditions               
(20-25 °C and 40-60% RH), due to coalescence of the particles, rendering 
an unsuitable formulation for inhalation. The inulin formulations showed Chapter 5 
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no coalescence during storage at ambient conditions, but in further spray 
drying experiments, we decided to investigate only the inulin DP23 
formulation. The enzymatic activity of both the bovine DNase as well as 





























Figure 2. A: UV absorption at 280 nm of reconsituted freeze dried formulations 
after storage at 85 °C. B: percentage dimeric aggregates as found with size 
exclusion chromatography of reconstituted freeze dried formulations after 
storage at 85 °C: pure DNase (z), DNase-sucrose ({), DNase-trehalose (T), 
DNase-inulin DP14 () and DNase-inulin DP 23 (U). Results are expressed as 
averages (n=3), error bars represent standard deviation. Preclinical development of rhDNase 
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Because inulin was the only carbohydrate to be processed successfully 
with spray drying, inulin (only DP23) was also selected for the preparation 
of a spray freeze dried powder in order to investigate the effect of 
process (spray drying vs. spray freeze drying) on the aerosol formation 




























Figure 3. Effect of atomizing air flow on the powder particle size distribution of 
the DNase-inulin DP23 formulation after spray drying (A) or spray freeze drying 
(B) as determined by laser diffraction. Solid line represents 400 Ln/h, dotted line 
600 Ln/h and crossed line 800 Ln/h. 
 


































Figure 4. Scanning electron micrographs of spray dried (left) or spray freeze 
dried (right) of the DNase-inulin DP23 formulation. From top to bottom: 
atomizing air 400 Ln/h, 600 Ln/h and 800 Ln/h, respectively. Magnification factor 
of the spray dried formulation was 2000x and for the spray freeze dried 
formulation 500x. 
 Preclinical development of rhDNase 
 
147 
Physical characteristics and in vitro deposition of the powders 
Laser diffraction experiments revealed that spray drying at a higher 
atomizing air flow results in smaller particles (Figure 3A). The same 
effect was also found for spray-freeze drying (Figure 3B). Furthermore, 
spray freeze drying produced larger particles than spray drying at similar 
atomizing air flows (see also table 2). The morphologies of the particles 
obtained by spray drying and spray freeze drying are shown in Figure 4. 
Spray drying resulted in basically round, slightly dimpled particles. Spray 
freeze drying resulted in larger particles. At an atomizing air flow of 400 
Ln/h, round intact spheres were produced, while at 600 and 800 Ln/h, the 
particles consisted of fragments of these spheres. These fragments 
tended to agglomerate and form larger “secondary” particles. 
To determine the fine particle fraction from a marketed inhaler 
(Novolizer
®) we performed a series of cascade impactor analyses with the 
spray dried powders. Figure 5A shows that a significant fraction of all 
three samples produced at different processing conditions deposited in 
the inhaler and induction port. Formulations prepared at increasing 
atomizing air flow showed an increased FPF.  
From the cascade impactor data, mass median aerodynamic diameters 
were calculated (Table 2). Spray drying at higher atomizing air flows 
resulted in a powder having a smaller aerodynamic diameter (da). The 
mass median aerodynamic diameters of the powders prepared by spray 
drying and spray freeze drying at 600 Ln/h differed substantially, despite 
the fact that the same solutions and nozzles were used to produce the 
powders (Table 2).  Yet, the fine particle fractions of the spray dried and 
spray freeze dried powders were comparable, 39.2 and 41.8%, 
respectively The difference in terms of dispersion and aerosol behavior 
between the powders was considerable (Figure 5B). The spray freeze 
dried powder displayed less deposition in the inhaler and induction port. 
In the cascade impactor, the spray freeze dried powder deposited mainly 
on the first and second stage, whereas for the spray dried powder the 
highest fractions were recovered from the third and fourth stage. The 
difference in the size distributions within the fine particle fractions is 
reflected by the mass median aerodynamic diameters, being 2.31 µm for 
the spray dried and 3.70 µm for the spray freeze dried product (Table 2).  
 
 
































Figure 5. A: Cascade impactor analysis (4 kPa pressure drop) of the DNase-inulin 
DP23 formulation spray dried at 400 Ln/h (black bars), 600 Ln/h (grey bars) or 800 
Ln/h (dark grey bars). B: Cascade impactor analysis (4 kPa pressure drop) of the 
inulin DP23 formulation spray dried (black bars) or spray freeze dried (grey bars) 
at 600 Ln/h. Results are expressed as averages (n=3) ± standard deviation.  Preclinical development of rhDNase 
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Table 2. Particle size and aerosol performance of spray (freeze) dried DNase-





air flow  x50 MMAD  FPF 
 (Ln/h) (µm)  (µm)  (%) 
Spray drying  400  9.15  ±  0.38  3.57 ±  0.01  30.0 ±  1.1 
Spray drying  600  7.50  ±  0.92  2.31 ±  0.10  41.8 ±  0.7 
Spray drying  800  4.95  ±  0.55  1.52 ±  0.02  51.9 ±  0.8 
Spray freeze drying  600  18.67  ±  3.92  3.70 ±  0.01  39.2 ±  0.7 
X50: median volume diameter 
MMAD: Mass median aerodynamic diameter 




















Figure 6. Effect of placebo (inulin DP23) or spray dried rhDNase-inulin DP23 
formulation on elastic modulus (G’) and viscous modulus (G”) of CF sputum. 
Results are expressed as averages (n= 5) ± standard deviation. Statistics: Effect 
on elasticity of placebo versus rhDNase-inulin (*, p=0.025), effect on viscosity of 
placebo versus rhDNase-inulin (**, p=0.016). Chapter 5 
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Ex vivo rhDNase activity analysis 
The effect of a spray dried rhDNase powder on the viscoelastic properties 
of sputum which was expectorated by 5 CF patients was determined 
(Figure 6). Addition of placebo powder to the sputum resulted in a 20% 
increase in elasticity (G’) and viscosity (G”) compared to the reference 
measurement. This increase is likely to be caused by partial evaporation 
of water from the sample due to the length of the measurement. 
However, addition of powder containing 15 Units rhDNase resulted in a 
significant decrease of around 40% compared to placebo of both the 
elasticity (G’; p=0.025) and viscosity (G”; p=0.016). This indicates that 
the rhDNase powder dissolved upon contact with the viscous sputum and 
that the reconstituted rhDNase was able decrease the viscoelasticity of 
the sputum. For Pulmozyme a similar effect has been described (6, 34). 
 
DISCUSSION 
In this study several major aspects related to the preclinical development 
of a rhDNase containing powder for inhalation were investigated. 
Since the spray drying of the sucrose powders was not successful and 
trehalose rendered powders that showed rapid coalescence at ambient 
conditions, spray drying was not considered a suitable preparation 
method for the stability testing. Freeze drying is a suitable alternative 
since this process, like spray drying, produces powders in which contact 
between the protein and carbohydrate exists on a molecular scale. 
Moreover, it was found in this study that after both spray drying and 
freeze drying (for trehalose and inulin) DNase activity is still around 80%. 
To compare the effects of the four carbohydrates on the stability of 
DNase during drying and storage, freeze dried materials were stored 
under accelerated stress conditions. Fig. 2 shows that all four 
carbohydrates are suitable stabilizers for DNase at 60 °C. However, at the 
higher stress condition of 85 °C differences between the carbohydrates 
are found. The sucrose formulation led to extreme Maillard reaction when 
stored at 85 °C. This is explained by the fact that at 85 °C the sucrose 
system is in the rubbery state and the combination with the elevated 
temperature could have led to the formation of reducing degradation 
products which subsequently reacted with DNase. On the other hand, for 
the trehalose formulation no indication of the occurrence of a Maillard 
reaction was observed. Neither did the absorption at 280 nm increase nor 
did the amount of dimeric aggregates increase. The degradation found at Preclinical development of rhDNase 
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85 °C is only heat induced degradation of the DNase. The absence of any 
interaction of the DNase with trehalose is explained by the high glass 
transition temperature of the trehalose and the absence of reducing 
sugars in this material. Both inulin based products show some degradation 
at 85 °C. Although the degradation rates were considerable slower than 
in the sucrose product, they were somewhat faster than in the trehalose 
product. The small increase in the 280 nm absorption and amount of 
dimeric aggregates shows that the Maillard reaction is to some extent 
responsible for this degradation. Because of the high glass transition 
temperature of the inulins (139.7 °C and 157.1 °C for inulin DP14 and 
inulin DP23, respectively) it is unlikely that reducing degradation products 
are formed at 85 °C, which indicates that the reducing groups in the 
starting material are responsible for this degradation. In spite of the 
higher amount of reducing groups in the inulin DP23 there is no faster 
degradation compared to inulin DP14. This is explained by the higher glass 
transition temperature, since for amorphous systems, a low molecular 
mobility is favorable for storage stability (35). 
The spray drying studies revealed another disadvantage of the low glass 
transition temperature of sucrose. I t  w a s  f o u n d  t h a t  t h e  s u c r o s e  
formulation can not be processed properly at the conditions tested in our 
study. The particles immediately coalesced in the collection vessel, most 
likely due to a relatively high temperature and residual moisture in the 
powder by which the Tg was passed. By optimizing the settings, 
conditions may be found with which the sucrose formulation can well be 
spray dried, but this was not investigated because of the poor 
performance of the sucrose in the stability study. The trehalose and inulin 
formulations could be successfully spray dried. However, the trehalose 
formulation could not be stored adequately at ambient conditions (20-25 
°C and 40-60% RH), due to coalescence of the particles, rendering an 
unsuitable formulation for inhalation purposes. A similar finding was 
described by other authors (36). The inulin formulations showed no 
coalescence during spray drying and subsequent storage at ambient 
conditions. Based on this observation we decided to perform the further 
experiments with the inulin DP23 formulation. The inulin DP23 was 
chosen over the DP14 because of its higher glass transition temperature.  
Overall it was concluded that sucrose is not a suitable excipient because 
of its low glass transition temperature and the formation of reducing 
degradation products that interacted with the DNase. The high glass Chapter 5 
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transition temperatures of trehalose and both inulins make these 
carbohydrates better suited as stabilizer for DNase. Although it would 
have been preferable that inulin starting materials are free from reducing 
sugars. On the other hand, the six weeks stability at 60 °C indicates that 
both trehalose and inulin powders can be stored for more than 1 year at 
room temperature in the complete absence of water without significant 
degradation.  
 
During spray freeze drying droplets or fragments of the droplets are 
rapidly frozen in a rigid conglomerate of solid material and ice. Upon 
removal of the ice the original droplet dimensions are maintained. With 
spray drying, water evaporates from the surface of the droplet, resulting 
in droplet size reduction. At a certain point, a droplet surrounded by a 
rubbery shell is formed. Upon further drying, the pressure in the particle 
increases to such an extent that the shell disrupts and often collapses 
leading to rimpled particles. As a result, the size of the dry particle is 
often much smaller than the original droplet size. Since the solutions of 
which the droplets were made contained the same concentration of solid 
material irrespective of which drying process is used, it is obvious that 
the spray dried particles must have a higher apparent density. The SEM 
pictures and laser diffraction results show that an increasing atomizing air 
flow reduces the particle size when the material is spray dried. The 
smaller initial droplet size results in a smaller particle size (37).  
The large fractions of fragments observed in the SEM pictures of spray 
freeze dried particles that were produced at atomizing air flows of 600 or 
800 Ln/h indicate that the droplets are scattered upon impaction with the 
liquid nitrogen during the spraying process. Only at the lower atomizing 
air flow the droplets remain intact when sprayed into the nitrogen. 
The cascade impactor experiments clearly show that the reduced particle 
size of spray dried powders produced with higher atomizing air flows is 
reflected in an increased fine particle fraction. Also the MMAD decreased 
for the particles produced at higher atomizing airflows. The particles 
produced at 400 Ln/h  are certainly too large, since Geller et al. (13) have 
reported that nebulization of Pulmozyme in a droplet size distribution 
with a MMAD of 2.1 µm, resulted in larger improvement of FEV1 than a 
droplet size distribution of 4.9 µm: 4.3% vs. 2.5%, respectively. On the 
other hand, the powder with the MMAD of 1.52 μm may be too small to 
obtain the desired effects (38). Therefore, the powder produced at 600 Preclinical development of rhDNase 
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Ln/h which gives an MMAD of 2.31 μm from the Novolizer at 4 kPa seems 
preferable.  
The larger MMAD found for the spray freeze dried powder compared to 
the spray dried powder is remarkable. Since the spray freeze dried 
powder is formed from the same droplets (or fragments thereof) as the 
spray dried powder, the same MMAD or a slightly lower MMAD is expected. 
The higher MMAD indicates that powder de-agglomeration is incomplete 
for the spray freeze dried powder. This observation is in contrast with the 
findings of Maa et al. (16) who concluded that aerosol performance was 
superior with spray freeze dried particles. The reason for the better 
performance of the spray dried particles in this study may be linked to 
the powder de-agglomeration principle in the Novolizer, which makes use 
of inertial forces (39, 40). Differences in particle density may cause a 
difference in classifier payload (at the same dose weight) and this, in 
combination with a difference in the rate and mode of agglomerate 
break-up, may result in different effective cutpoints for the classifier. 
These findings clearly show that drug development for inhalation does not 
stop at powder formulation, but that inhaler design plays an important 
role too. Most currently marketed inhalers are not suited for effective de-
agglomeration of different types of inhalation powder. Besides, most 
inhalers do not perform well on powders in the micron range without 
processing them into adhesive mixtures.  
 
Finally, exposure of the preferred powder formulation to sputum from CF 
patients resulted in decreased viscosity and elasticity. Sputum from CF 
patients is extremely viscoelastic because of a low water content and an 
enhanced presence of extra cellular DNA and actin from degenerating 
neutrophils, serum proteins, and lipids (4, 41-44). It can be assumed that 
the mechanism by which the viscoelasticity is decreased by the rhDNase 
powder is similar to that of the liquid formulation: enzymatic break down 
of the DNA polymer network and thereby reduction of the typical 
viscoelasticity of the mucus (2).  
 
In summary,  this study shows that a stable rhDNase powder for inhalation 
can be designed. The stabilizing carbohydrate should be non-reducing and 
have a high glass transition temperature. Furthermore, utilization of the 
Novolizer inhaler (which generates high inertial de-agglomeration forces) 
allowed for the use of the spray drying process to produce the particles Chapter 5 
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with a high fine particle fraction having a desired MMAD of 2.3 μm. Future 
research should be directed to patient studies to investigate whether the 
dry powder inhalation system of rhDNase would indeed increase lung 
deposition and better fulfill patients’ needs in terms of improved ease of 
administration and compliance and whether this could reduce costs of the 
therapy (45). 
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For treatment of patients with cystic fibrosis, recombinant human 
deoxyribonuclease I (rhDNase) is widely used. RhDNase has a positive 
effect on the lung function and on the number of hospitalizations. 
RhDNase is currently administered by nebulization, which is an 
inefficient administration method. For expensive drugs, such as 
rhDNase, dry powder inhalation would be advantageous due to 
increased deposition efficiency, patient mobility and patient 
compliance. Furthermore, a significant cost reduction might be 
obtained. We therefore investigated the current status of rhDNase in 
the management of cystic fibrosis and gave special attention to 
developments in delivery systems as dry powder inhalation. We 
preliminarily estimated that if dry powder inhalation of rhDNase could 
be used, a reduction in the cost-effectiveness ratio of almost 40% can 




Recombinant human DNase (rhDNase) is a mucolytic agent, which reduces 
the viscoelasticity of sputum and is therefore a possible therapy in cystic 
fibrosis (CF) patients. RhDNase is currently administered by means of 
nebulization. However, nebulization is a rather inefficient delivery 
method. Improved administration of rhDNase would in several aspects be 
advantageous for CF patients. 
Dry powder inhalation (DPI) of rhDNase seems to be a promising example 
of a more efficient delivery method of rhDNase in CF patients. Because of 
the high costs of rhDNase, DPI of rhDNase could be cost-saving, compared 
to the nebulization of rhDNase.  
In this review, we evaluate the pharmacoeconomical aspects in the 
management of rhDNase of CF. Developments in nebulization and DPI 
delivery systems of rhDNase are compared. Furthermore, aspects with 
respect to efficacy, tolerability, safety and compliance of rhDNase 
(nebulization vs. DPI) are outlined. 
After weighting the advantages and disadvantages of rhDNase and the 
delivery systems, an expert opinion and a five-year view with respect to 
the rhDNase delivery in patients with CF, are described. 
 
CYSTIC FIBROSIS AND RECOMBINANT HUMAN DNASE (RHDNASE) 
Epidemiology and Pathofysiology 
CF is the most frequently observed genetic disorder in the white 
population with a potential lethal outcome. CF affects approximately 1 in 
every 2500-3400 live births and 3.3% is carrier of the defective gene 
among Caucasians (1-3).  
The disease is autosomal recessive, meaning that the gene relating to this 
disease is not present at the sex chromosome (autosomal) and that a 
person can carry a defect gene and not have the symptoms but can pass it 
on to the next generation (recessive). In the Netherlands about 1000 
patients have CF, while 1 in every 30 persons carries the defect gene (4). 
The defective gene is located on chromosome 7. Approximately 70% of 
the CF cases are caused by a 3 base-pair deletion (ΔF508). The remaining 
CF cases are arising from about 600 different mutations of the gene           
(3, 5). 
CF is a chronic disease that varies in the underlying systems involved and 
the severity of the symptoms. This is partly due to the genetic mutations, 
but also to environmental and treatment factors. In patients with CF Chapter 6 
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much variability is therefore seen and assessment of the efficacy and 
effectiveness of treatment strategies takes a long time because of 
uncertain progression (6). 
Complications of CF include pulmonary symptoms, pancreatic 
insufficiency (in 85% of the patients) leading to malabsorption of fat and 
malnutrition, diabetes mellitus, biliary cirrhosis, subacute bowel 
obstructions, arthritis and infertility. Although prevalence is relatively 
low, the treatment burden per patient may be quite high and can lead to 
chronic disability at any age (7-9).   
Over 85% of the CF patients die from progression of their lung disease   
(5, 10). Individuals with CF have a mean life span of about 30 years (8). 
Dietary strategies and new treatments of pulmonary symptoms have led 
to an increase in average survival of CF patients from only 6 years in the 
1960s to about 30 years in the 1990s (11-14). The quality of life for CF 
patients have also improved dramatically the last decades, due to regular 
periodic evaluations, monitoring for complications of the disease, and 
new interventions by physicians and other healthcare workers specifically 
trained in management of CF (11, 15). 
Respiratory Tract Infections (RTIs) are a major cause of hospitalization of 
CF patients. More than one-third of the CF patients are hospitalized each 
year, and 20% of the CF patients are hospitalized more than twice a year. 
Of all CF-related hospitalizations, more than 75% is for treatment of RTIs 
(16, 17). 
The high number of RTIs is a direct consequence of the genetic defect 
underlying CF. A mutation in the cystic fibrosis transmembrane 
conductance regulator (CFTR), a cAMP-dependent chloride channel, 
causes a defect in the transmembrane chloride transport. This leads to 
diminished transluminal chloride transport, which results in a relative 
dehydration of the luminal surface of the exocrine glands. In the lung, the 
dehydration causes a viscid mucus layer which inhibits a normal ciliary 
clearing and thus facilitates bacterial colonization of the respiratory 
tract. Bacterial colonization, most commonly with Staphylococcus aureus, 
Haemophilus influenza and Pseudomonas aeruginosa, accounts for much 
of the morbidity and virtually all mortality in CF patients by means of 
RTIs (1, 2, 7, 8, 16, 18, 19). 
After chronic pulmonary infection the viscoelastic properties of purulent 
airway secretions are primarily caused by DNA from degenerating 
neutrophils. The presence of DNA increases the viscosity of sputum and Preclinical development of rhDNase 
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makes it more difficult to clear the sputum from the respiratory tract. 
This increases the susceptibility to infection which, in turn, provokes an 
inflammatory response. Therefore, a cycle of infection, inflammation and 
obstruction leads to progressive destruction of lung tissue and reduced 
life expectancy (20, 21). 
The pulmonary inflammation in patients with CF begins in infancy, is 
present in babies of about 4 weeks (8), and is probably established when 
the child is 1 year old (22). The lower respiratory tract of 40% of the 
children with CF younger than 3 months, has been found to be colonised 
and in these, as well as in older children, airway DNA levels are also 
increased (8, 23). This suggests that early inflammation can cause lung 
injuries, which results in higher susceptibility for inflammation (8). 
 
Pharmacology and Therapy 
Patients with CF undergo complex, multidrug treatment aimed on 
treating the various symptoms of the disease. Alleviating the effects of 
chronic inflammation and infection in the airways is one of the major 
objectives. In the last 30 years, airway obstruction reducing agents, 
airway infection controlling agents, and agents that improve the 
nutritional status have become the cornerstone of successful treatment in 
patients with CF (8, 24). Next to these strategies aggressive symptomatic 
treatment of complications of the lung disease is also important. New 
treatment strategies are focussed on repair of the basic gene-defect and 
include manipulation of the ion-transport, activation of mutant CFTR and 
gene therapy (24, 25). 
An important aspect of CF-therapy is the use of mucolytic agents. An 
example is deoxyribonuclease, which hydrolyzes extracellular DNA and 
therewith reduces the viscoelasticity of sputum in patients with CF (26). 
In 1958, bovine pancreatic DNase Ι was approved in the United States for 
human use (Dornavac or Dornase). DNase showed a large reduction in 
viscosity in vitro and in one study it was suggested that bovine pancreatic 
DNase Ι was reasonably safe and effective in reducing the viscosity of lung 
secretions (27). 
However, for bovine pancreatic DNase Ι it has been reported that adverse 
reactions (possibly due to contaminating proteases in the final product) 
occurred after inhalation, causing the non-human protein to be no longer 
used (27, 28). Chapter 6 
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In 1990, recombinant human DNase Ι (rhDNase) was cloned, sequenced 
and expressed. RhDNase was in vitro shown to dramatically reduce the 
viscosity of the sputum of cystic fibrosis patients, transforming it within 
minutes from a viscous non-flowing gel to a flowing liquid (21, 27). Part 
of the action of rhDNase is explained by cleavage of highly polymerized 
DNA. Decreasing the chain length of DNA by rhDNase results in a lower 
viscosity (21). An in vitro study showed that the phospholipid 
concentration (phosphatidylglycerol, dipalmitoylphosphatidylcholine) is 
increased when the mucus is in its sol phase. The phospholipids are being 
liberated by rhDNase and then lubricate the mucus, thereby improving 
the effect of cough and ciliary clearance (28). 
In this review, we will focus on the therapy of recombinant human DNase 
(rhDNase) with special reference to development of delivery systems. 
Special attention is given to the rational development of RhDNase as a 
pharmacoeconomically effective drug. In the next section it is motivated 
that the delivery of rhDNase as a dry powder for inhalation would have 
enormous pharmaceutical and economical advantages over the current 
nebulization.  
 
Delivery systems of rhDNase 
In order to achieve high local and low systemic concentrations, inhalation 
is the most advantageous route of administration. Alternative routes of 
delivery would be very inefficient due to the poor permeation of rhDNase 
(~ 34 kDa) to airway lumen from the vascular system. 
Up to now, rhDNase is administred by means of nebulization. However, 
maintenance treatment of CF patients with nebulized rhDNase 
immobilizes the patient to a great extent: there is need for a compressor 
unit or pressurized air for the jet nebulizer or electricity if an ultrasonic 
nebulizer is used. Furthermore, the low efficiency is a major drawback. It 
has been reported that for the jet nebulizers, the type recommended for 
rhDNase, the efficiency (i.e. the percentage of drug that is available for 
therapeutic action after the inhalation manoeuvre) is only 2-12% (29). 
Although rhDNase delivered by nebulization is effective on the short (i.e. 
10 days (30, 31)), medium (i.e. 6 weeks (1), 12 weeks (2) and 6 months 
(32, 33)) and long term (2 years) (34, 35), improved administration would 
be advantageous for the patient and may have economic benefits. With 
dry powder inhalation (DPI) there is no need for pressurized air or 
electricity: the patient delivers the driving force for administering a dose Preclinical development of rhDNase 
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by means of an inhalation manoeuvre (29, 36). Moreover, DPI has the 
potential for a more efficient (deep) lung deposition, reports describing 
efficiency of up to 60% have appeared (37, 38) and new technologies are 
currently developed (39, 40). A switch from nebulization to DPI is 
therefore likely to increase patient compliance (dosing time, patient 
mobility) and therapeutic efficacy (29, 36).  
Although the development of a DPI-formulation of proteins is more 
complex, it is possible to develop such a formulation (41-44). In this 
review, we examined the consequences of the choice of type of 
formulation (nebulization vs. DPI) on healthcare costs. 
 
Cost of illness 
In the last decennia, new treatment strategies of CF increased median 
survival of this disease by a factor 5 (8). Cost estimates from developed 
countries indicate CF as a very expensive disease. Estimates of the annual 
cost per CF patient vary between €1,954 and €13,969 (45). For the Dutch 
situation the costs of CF were estimated to account for 0.07% of the 
health care budget (46). Life time costs for CF patients, assuming the life 
expectancy to be 25 years have been estimated to be approximately 
€225,000 (8). In another study, costs of care in patients with CF to the 
age of 35 were estimated to be €430,211 (47).  
Costs of a disease are divided in direct and indirect costs. For CF the 
clinical visit, hospital admission, outpatient drug costs (for example; 
rhDNase, antibiotics and dispensing fees) and laboratory tests are seen as 
direct costs. Direct non-medical costs include out-of-pocket expenses for 
dietary recommendations and travel costs to receive care. The indirect 
costs include for example productivity losses (48). These indirect costs 
were often disregarded in the reviewed publications on CF costs.  
Direct costs, such as costs for medication, account for most expenses of 
medical care in CF patients. Total costs were estimated to be around 
€5,250 per patient per year (49). Due to interindividual differences not all 
patients benefit from rhDNase (24, 48-51). The differences in costs 
depend on changes in respiratory function and possibility of 
exacerbations. The Dutch costs of rhDNase were estimated to be about 
2,5 million Euro’s in 1997 and were estimated to remain constant the 
following years (52).  
 Chapter 6 
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Next to medication, rates of exacerbations of CF and symptoms of this 
disease and hospitalization are the largest cost components. More than 1 
out of 3 patients with CF are hospitalized each year (16, 53). Over 3 out 
of 4 patients admitted are treated for pulmonary infections. The costs per 
admission were estimated to range from €7,840 to €28,000 (16, 53, 54). 
Different studies estimated the percentages of different cost-components 
for direct costs in CF. Table 1 shows these results 
 
Table 1. Direct costs of CF: percentage of distribution 
Reference:  (48) (45) (47) (55) 
Hospital care  33% - 42%  47% 
RhDNase  44% -  - 18% 
Clinic visits  12% -  - 12% 
Laboratory tests  8%  - - - 
Medication (other than rhDNase)  3% 57%  37%  10% 
Other  - 43%  21%  13% 
 
As can be seen in table 1, medication costs and hospital care are the 
largest component of the costs. RhDNase offers a therapeutic opportunity 
to reduce RTI-related health care use in CF patients. The objective 
behind therapy with rhDNase is improving health related quality of life 
and additionally lowering the costs of CF. As described above, several 
cost components (hospitalization, exacerbations, symptoms, therapy, RTI-
related, antibiotics, etc) have to be taken into account when estimating 
the cost-benefit ratio of rhDNase therapy in CF patients. RhDNase 
contributes significantly to the costs of treatment of CF (56). Therefore, 
if these costs can be reduced by development of a dry powder 
formulation for inhalation, significant benefits may be gained. 
 
Quality of Life considerations 
The respiratory symptoms of CF can adversely affect daily activities of 
the patient with CF, because of the unpredictability of these symptoms 
and serious consequences of exacerbations. It is difficult to predict the 
degree to which the quality of life of an individual can be affected by CF.  
Some studies mention that the great majority of CF patients live well in 
adulthood with an acceptable quality of life, due to basic therapies. New 
therapies can help to improve the quality of life (9, 57). However, all Preclinical development of rhDNase 
 
169 
patients suffer from deterioration in their disease, which leads to 
limitations and thus ultimately reduces quality of life significantly (9). 
The majority of morbidity and mortality in CF results from inflammation 
and infection of the airway lumen, which leads to a certain degree of 
disability in patients with CF (58). In one study, the impact of pulmonary 
exacerbations on quality of life in CF patients was studied (59). The 
objective was to compare health-related quality of life (HRQOL) of CF 
patients to general population and to determine the relationship between 
HRQOL and clinical and demographic factors.  
For measurement of HRQOL, five aspects of health were included: 
physical functioning, role functioning, mental health, social functioning 
and general health perceptions. HRQOL measures the individual ability to 
function in each area and the individuals evaluation of their functioning 
(59). 
The study of Britt et al. [56], showed that exacerbations do not have a 
profound negative impact on HRQOL that is not explained by differences 
in function of lungs, nutrition status or demographic factors. In spite of 
this, lung function, nutrition, 6-min walk, age, gender, and insurance 
status were not significantly associated with HRQOL in this study 
population (59). 
On short term, well-being and quality of life of CF patients is improved by 
rhDNase, through improvement in lung function and a reduction of RTI-
incidence (14, 50).  
In the study of Oster et al. (16), questionnaires were developed to 
evaluate well-being (feeling, energy, activity, sleep, appetite) and 
physical symptoms (sputum production, frequency and severity of cough, 
chest congestion). The results mentioned that compared to the placebo-
group, there was significantly less dyspnoea, significantly improved well-
being and there were significantly fewer CF related symptoms in the 
rhDNase-group. This implies that when CF patients are treated with 
rhDNase they have a better quality of life compared to patients who are 
not treated with rhDNase. 
Another study noted that baseline HRQOL assessments show that adults 
with CF, reported decrements in health status and functioning. In this 
study, a significant association was found between the rhDNase therapy 
and one-year change in HRQOL. One of their suggestions was that a 
further evaluation of the relation between hospital admission and changes 
in HRQOL is required (17). Chapter 6 
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As opposed to life expectancy, morbidity and mortality, quality of life is 
mainly not affected by the CF disease as such (e.g. dietary requirements), 
but much more by the symptoms and respiratory tract inflammations and 
infections. Hospitalization affects quality of life also in a negative sense. 
RhDNase has a positive short-term effect on the quality of life as 
mentioned above. In the reviewed studies, long-term effects and delivery 




We searched for articles on recombinant human DNase (rhDNase) in 
international literature databases (Medline and Embase), which were 
published in English and Dutch in the beginning of the nineties. Additional 
references were identified from the reference lists of these articles.  
The search terms were ‘cystic fibrosis’, ‘recombinant human DNase 
(rhDNase)’, ‘dornase alpha’, ‘pharmaco-economics’, ‘cost-effectiveness’, 
‘cost-utility’, ‘health- economics’, ‘dry powder inhalation’, ‘aerosol 
inhalation’, ‘nebulization’ and ‘delivery (systems)’, or one of the possible 
combinations of these terms. The searches were last updated  February 
18
th, 2003. 
The selection was based on articles with economic analyses in patients 
with cystic fibrosis that receive rhDNase by inhalation. All 
pharmacoeconomic analyses, such as cost-effectiveness, cost-utility and 
cost-benefit analyses, were included. Articles on efficacy, tolerability, 
safety and compliance with respect to rhDNase, were also included in this 
review. Papers on efficacy, tolerability, safety and compliance are 
reviewed in the next section, as these provide the basis of 
pharmacoeconomic assessments. Section 5 reviews the general 
pharmacoeconomics, whereas section 6 considers the drug-delivery 
systems with regard to economics.   
  
CLINICAL PROFILE OF INHALED RHDNASE 
Efficacy  
The Cystic Fibrosis Foundation has suggested a definition of the disease 
severity based on the Forced Expiratory Volume in 1 second (FEV1) and 
the corresponding Forced Vital Capacity (FVC):  
-  Mild: FEV1 ≥70% of predicted value or FVC ≥85% of predicted  Preclinical development of rhDNase 
 
171 
-  Moderate: 40% ≤ FEV1 < 70% of predicted value or 60% ≤ FVC < 
85% of predicted  
-  Severe: FEV1 < 40% of predicted value or FVC ≤ 60% of 
predicted (8). 
Most of the reviewed studies used a daily dose of 2.5 mg rhDNase in 
patients with CF and observed the short term effects of rhDNase. Long-
term effects (benefits) are not yet available. Consequently, it is uncertain 
to what extent the short-term effects can be used to predict any long-
term benefit (60). 
Fuchs et al (54) found a reduction in exacerbations of respiratory 
symptoms and a slight improvement in pulmonary function after 2.5mg 
rhDNase therapy in a randomized, double-blind, placebo-controlled study 
in which 968 patients participated. One or more exacerbations occurred 
in 27% of the patients who received a placebo, 22% in patients who 
received once daily rhDNase and 19% in patients who received twice daily 
rhDNase (2 x 2.5 mg). The FEV1 improved with about 6% in patients who 
received rhDNase (24, 53, 54). The study of Menzin et al (6) showed that 
the reduction of the viscosity of purulent sputum by rhDNase as is studied 
in early clinical trials of aerosol delivery, accomplishes improvement in 
pulmonary function (FeV1) of 10 to 15% in patients with CF. In this study, 
a reduction in RTIs as consequence of rhDNase therapy was also found.  
Cobos et al (61) studied the minor to moderate benefits in short-term 
clinical trials. In this study, 166 patients continued rhDNase therapy 
during the data collection. After one and after two years of treatment 
with rhDNase, the mean changes in FEV1 were 3,3% and 5,1%, 
respectively. At the end of the same periods 34% of patients had 
improved their baseline FeV1 by 10% or more but in about 50% of the 
patients the level fell below the baseline. The medium-term response to 
rhDNase treatment was correlated with an early response during the first 
3 months. There was a large inter-individual difference in change in 
pulmonary function documented and there were no consistent changes in 
exacerbation pattern found during the first year of rhDNase treatment. 
Johnson et al (48) performed an observational study in 283 CF patients 
(>6 years; FEV1 < 40% predicted). The treatment group received 18 
months rhDNase, while the control-group, consisting of 2382 patients, had 
never received rhDNase. The FEV1 for patients treated with rhDNase 
improved with 3,9% of the predicted value while the untreated control 
group had a decline in FEV1 of 1,6% of the predicted value. This study Chapter 6 
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provided some evidence for effectiveness, without statistic significance, 
of rhDNase. 
Milla (35) studied patients with CF retrospectively on spirometric 
parameters for two years. 190 Patients were included, who after two 
years of rhDNase administration showed a positive trend with respect to 
malnutrition and hardly hospital admissions. There was a mild decline in 
FEV1, while FeV1/FVC remained stable.  
In the study of Geller (23) characteristics of two different aerosol delivery 
systems that might affect efficacy in patients with mild CF, were 
reviewed. The reviewed systems were a Hudson T Up-draft II with a 
Pulmo-Aide compressor or the Durable Sidestream nebulizer, powered by 
a CR50 compressor. The delivery system with the smaller droplet size  - 
the Sidestream nebulizer - tended to provide more improvement than the 
system with a larger droplet size. The results of the study indicate a 
statistically not-significant improvement in CF patients who received the 
smaller particle size aerosol (4.3% versus 2.5%, p = 0.06). 
Johnson et al (7) showed in a phase ІІІ trial that rhDNase therapy (once or 
twice daily; 24 weeks) in CF patients resulted in significant reductions in 
the number of respiratory symptoms and exacerbations in lung disease. 
This resulted in a reduction in the use of parenteral antibiotics and 
significant improvement in pulmonary function and also a reduction of 
hospitalizations. 
Suri et al (12) compared the consequences of three therapies in children: 
1) daily rhDNase (2.5 mg), 2) alternate day rhDNase (2.5 mg) and 3) 
hypertonic saline (two times per day) during 12 weeks. The study was an 
open randomised cross-over trial, in which 48 children with CF were 
allocated. This resulted in a significant greater increase in mean FeV1 (2-
14%) with daily rhDNase compared with hypertonic saline, while daily and 
alternate daily rhDNase did not differ significantly. 
In another clinical trial, Grieve et al (51) investigated the effect of 12 
weeks treatment with daily rhDNase, alternate day rhDNase or hypertonic 
saline (HS) in a randomized, crossover study, in which 40 children with CF 
were allocated. They found a 14% (5-23%) improvement in FEV1 for daily 
rhDNase compared with HS, while alternate day rhDNase compared to HS 
resulted in a 12% (2-22%) improvement in FeV1. There was, as also 
described by Suri et al (12), little difference between FEV1 of daily and 
alternate day rhDNase. Preclinical development of rhDNase 
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The publication of Conway (50) provides evidence that rhDNase is 
effective in patients older than 5 years of age. Early studies of rhDNase 
showed an increase in baseline FEV1 of about 9-14% and that the 
improvement in pulmonary function maintained at a plateau about 6% 
higher than placebo for continued rhDNase treatment. A similar effect is 
seen for FVC. Also it was mentioned that a 24 week phase ІІІ study 
resulted in a decrease of RTIs and exacerbations, which reduced 
antibiotic therapy by 28 to 37% and also reduced the number of 
hospitalizations. The longer term effects in 188 patients showed 
persistent benefit for FVC of 9% of predicted and for FEV1 of 5% of 
predicted. In a clinical study of a group of 65 children treated with 
rhDNase for 6 months an increase of 14% in FeV1 was shown and in 45 of 
59 adults with 15 months treatment, an increase of 15% in FeV1 was 
achieved, which was maintained by rhDNase therapy (50). 
The Pulmozyme (rhDNase) Early Intervention Trial (PEIT) of Robinson et al 
(62), showed reduction in the risk of pulmonary exacerbations and 
thereby a reduction of 34% in parenteral antibiotic therapy. This study 
also showed an improved forced expiratory flow at 25 to 75% of FVC and 
improvement in FeV1 o v e r  a  2  y e a r  p e r i o d  i n  C F  p a t i e n t s  w i t h  a l m o s t  
normal lung function. The results of this study, conducted at 49 sites in 
12 countries in a randomized trial (placebo-controlled) design, showed 
benefits from rhDNase in CF patients from early intervention in the course 
of their lung disease. 
In another, this time short term, study of rhDNase of Robinson et al (63), 
an increase of 7.5% in FeV 1 and 5.4% in FVC from baseline was seen in 
patients who received rhDNase compared with placebo. The authors were 
unable to demonstrate improvements in either ciliary or cough clearance 
with regard to the short term use of rhDNase.  
The reports of the efficacy as mentioned above are encouraging, with 
short-term effects of rhDNase relatively positive as indicated in the 
reviewed studies. In the mild and moderate state of CF improvement in 
the pulmonary symptoms (measured in FeV1, FVC and number of 
exacerbations) can be of great influence in the reduction of antibiotic 
therapy and hospitalization of CF patients. This results in a reduction of 
costs of care in CF.  However, the efficacy in severe pulmonary disease is 
more uncertain, some studies show improvement, some show no 
differences and some indicate even slight worsening in the number of 
exacerbations (8). This might be due to large inter-individual differences Chapter 6 
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with respect to the efficacy of rhDNase. The limited amount of 
information about the long term effects is a problem in predicting or 
defining the efficacy of rhDNase. 
 
Tolerability, Safety and Compliance 
Adverse drug events during rhDNase therapy are generally mild and the 
drug is well tolerated. The most common adverse effects are respiratory 
related (24). In infants and young children, exposure to rhDNase appeared 
to be safe over a 2 week period (56).  
RhDNase is currently only administered by nebuliser (aerosol). Therefore, 
it is difficult to find out whether adverse events were related to the drug 
or to the method of administration. The severity of the disease is of 
importance in this possible relation. The variability in adherence to 
rhDNase treatment is a debatable subject in the validation of the safety 
and efficacy of rhDNase. Nebulization as an administration technique 
leads to lower compliance to the therapy of CF patients, whilst the 
compliance is of utmost importance, since the efficacy of the treatment 
heavily depends on the compliance (64).  
Post-marketing clinical experiences have confirmed the relative safety of 
rhDNase that was documented in clinical trials. Voice alteration, 
hoarseness, laryngitis, pharyngitis and rash are the most common adverse 
events in patients using rhDNase (8, 56, 57, 62). These symptoms are self-
limited and do not require medication. Next to these adverse events, 
chest pain and conjunctivitis also have been reported. These events were 
not more frequently reported than with placebo. The percentage of 
withdrawal from therapy in the clinical trials was not significantly 
different for rhDNase compared to placebo (8). 
Information on adverse events of rhDNase after long term therapy is 
scarcely documented. In a two year study in patients with mild to 
moderate CF, no serious adverse drug events in treatment with rhDNase 
were found (34). 
Up to now, rhDNase has shown to be a well-tolerated drug, which can be 
used safely with few adverse drug events that do not require new drug 
therapies to treat those adverse events.    
 
PHARMACO-ECONOMIC ANALYSIS OF AEROSOL RHDNASE 
The few cost(-effectiveness) studies available concerning rhDNase, are 
often published as abstracts or short reports while fully-reported cost-Preclinical development of rhDNase 
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effectiveness analyses are lacking. For that reason only little information 
is available about the methodology and about cost categories. In short, 
some costing has been done with respect to aerosol rhDNase but a full 
cost-effectiveness analysis is (yet) lacking (6, 7, 12, 14, 16, 45, 51, 53, 
55). Below, the empirical evidence on pharmaco-economics of rhDNase is 
taken from the four most comprehensive studies on the topic (12, 14, 16, 
51). These studies are evaluated with respect to several criteria that we 
feel are currently the most important for conducting “good” pharmaco-
economic research: for example, the societal perspective should be taken 
(including all relevant cost categories, even indirect costs of production 
losses if important), taking the adequate time frame (including long-term 
effects) and results should preferably be expressed per life-year gained 
(LYG) or per quality-adjusted life-year (QALY) gained (65).   
According to Oster et al (16), rhDNase reduced the estimated average 
costs of RTI-related care over 24 weeks by €912 – €1,884 compared with 
placebo. Limited to only protocol-defined RTIs, the reduction of the costs 
was estimated at €681 - €1,057. The findings in this study suggest that 
rhDNase therapy may prevent approximately 31-33 RTI-related 
hospitalizations per 100 patients on an annual basis. This would 
correspond with a saving of €2,016 - €4,144 per patient annually. Also, 
this paper mentions that the reduced costs of RTI-related care are 
expected to be about 33% (18.3-37.5%) of the total costs of rhDNase-
therapy. As mentioned, this analysis does not include all relevant cost 
categories that may be specified.  
McIntyre (14) used the results of the study of Oster et al (16) to estimate 
the net costs per LYG as a cost-effectiveness outcome. For that purpose 
annual costs of rhDNase of €5,040 were assumed. The discounted lifetime 
costs for a CF patient was estimated at €163,100, including the 
acquisition costs of rhDNase and the additional costs of treatment for 3 
extra years of life. The net costs per LYG were subsequently estimated at 
€19,110 and the additional cost of rhDNase treatment at €1,736 per year. 
The authors conclude that taking into account the potential long-term 
benefits, rhDNase may be conceived a cost-effective option. 
Suri et al (12) compared mean incremental costs of daily and alternate 
day rhDNase with hypertonic saline (HS) over a 12 week period as 
investigated in a clinical trial(66), in what they labelled themselves a 
cost-consequence analysis. The mean incremental costs of daily rhDNase 
compared with HS were €986 and the incremental cost of using daily over Chapter 6 
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alternate day rhDNase was €359. A formal cost-effectiveness analysis to 
analyse whether the increased effectiveness of daily rhDNase compared 
to HS twice daily delivered by nebulizer was not done. It was merely 
concluded that daily rhDNase was more expensive and significantly 
increases health care costs (12). Administering rhDNase on an alternate 
day rather than on daily basis may be as effective, with a potential cost 
saving.  
In the study of Grieve et al (51) daily rhDNase was found to be more 
effective than HS and almost as effective as alternate day rhDNase. For a 
ceiling ratio of €140 per 1% gain in FeV1, the mean net benefits of daily 
and alternate daily rhDNase compared with HS were €811 and €832, 
respectively. The mean net benefit of alternate compared with daily 
rhDNase was €21. It was concluded that if decision makers were prepared 
to pay €140 per 1% gain in FeV1 over a 12 week period (ceiling ratio), both 
rhDNase therapies may be conceived cost-effective. 
Generally, the long-term perspective is often missing in these studies and 
they often only include the cost savings by reducing exacerbations and 
RTI’s. Ergo, hospital admissions and reduced costs for antibiotic therapy 
were included, but direct costs for, for example, adverse drug reactions 
were not. Additionally, direct non-medical costs such as travelling to the 
health-care service, and indirect costs of productivity losses were not 
estimated. Finally, we note that only one study estimated net costs per 
LYG, and none estimated QALYs gained, despite the fact that important 
health-related quality-of-life effects exist. 
 
ECONOMIC ASPECTS OF RHDNASE DELIVERY SYSTEMS 
The cost-effectiveness analysis done as mentioned above were all based 
on rhDNase administration via a nebulizer. As mentioned previously, the 
Dry Powder Inhalation (DPI) of rhDNase may offer advantages, in 
particular more efficient administration (table 2). Focussing at drug-
delivery systems for patients with CF (for example, DPI vs. aerosol 
inhaler) no cost-effectiveness analysis was found. Potential advantages of 
a DPI of rhDNase are:  
-  An improved compliance to therapy, 
-  Improved (deep) lung deposition, 
-  No need for electricity or compressed air, 
-  A reduced administration time 
-  No need to cool the rhDNase-ampoule (29, 36, 56, 67, 68) Preclinical development of rhDNase 
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On the other hand, a short-coming of DPI’s is that the patient’s own 
inhalation strength is needed for the deposition of rhDNase in the lungs. 
This can be a problem for patients with severe CF-related symptoms and 
exacerbations.  
 
Table 2. Advantages and disadvantages of DPI vs nebulization, partly taken from 
De Boer et al. (69) 
Dry Powder Inhalation  Nebulization 
Advantages Disadvantages  Advantages Disadvantages 
Less expensive  Performance 
depends on the  
patient's inspi-




    
Propellant free  Resistance of the 






























    
Less potential 
problems  
with drug stability 
  Potential  problems 
with drug stability 
    




  Large  number  of 
combinations of 
devices possible Chapter 6 
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To appreciate the economic aspects of delivery systems in general we 
note the study of Massie et al (70) comparing a nebulizer (aerosol 
delivery) with DPI in asthma. In this study it is mentioned that the 
equipment for aerosol delivery is costly (air compressor and nebulizer), 
less than 5% of the nebulized dose is actually delivered to the airway 
(relatively high wastage) and the duration of delivery confronts the 
patient with problems. These problems can negatively affect patients’ 
adherence to the treatment. In short, the nebulization delivery may be an 
inefficient and relatively expensive delivery system, if DPI is available 
(70).  
DPIs are self-actuating, provided that sufficient inspiratory flow is 
generated. DPIs are less expensive than nebulizers and they offer 
advantages in terms of better deposition, better disease control and the 
ease of use. The low cost of DPIs may be further decreased by a reduction 
in the number of costly complications and exacerbations, due to better 
compliance. Furthermore, DPIs enhance patient comfort. A drawback of 
DPI is the requirement for the ability to develop sufficient inspiratory 
flow, which is often impossible for children under the age of 6-8 years 
(70).  
 
EXPERT OPINION  
CF is a costly disease, in which rhDNase is one of the therapeutic options. 
But the wastage of rhDNase and other disadvantages of nebulization make 
the therapy expensive. A better, efficient and easier delivery system for 
rhDNase can possibly improve efficiency and reduce wastage of rhDNase. 
For that reason, it could be more cost-effective than nebulization. From 
an ethical point of view it is better to provide rhDNase by DPI, since the 
adherence of patients to nebulization is quite low as described by 
Burrows (64). Low adherence results in in-effective therapy and could 
lead to increased costs. This can be one of the reasons why DPI could be 
more cost-saving than nebulized rhDNase. Other advantages of DPI like 
the absence of the need for electricity, easier usage and more efficient 
delivery of rhDNase (compared to the nebulization) are also relevant with 
respect to potential cost-savings of rhDNase therapy. 
For drugs which have a significant impact on the total health care budget, 
large efforts should be made to develop an adequate dosage form. In this 
way, innovative research is stimulated which potentially results in lower 
cost as can be proved with rhDNAse. However, the focus when introducing Preclinical development of rhDNase 
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a new drug is primarily directed toward the regulatory agencies and their 
requirements regarding efficacy and safety, which is completely 
understandable for reasons of public protection. On the other hand, the 
horizon should be put beyond the regulatory hurdle and put to the group 
of patients who are to receive the new drug. If beforehand it is already 
known that compliance is a problem with a certain dosage form, action 
should be taken to avoid that problem. At the time of introduction of 
rhDNase to the market, the technology to create a dry powder of labile 
substances was not fully available. However, this technology has 
improved over the past decade and is readily available. Moreover, DPI 
technology has improved meanwhile. Therefore, DPI is now an option 
when such drugs are developed. This gives rise to great opportunities, as 
for example shown by insulin (71-74).  
Our opinion is that DPI will gain a greater share in the field of inhalation 
due to obvious reasons like patient adherence, ease of use, efficiency and 
cost-effectiveness. As mentioned in chapter 2, the deposition efficiency 
of DPI may be 4- to 6-fold that of a nebulizer (28, 35, 36). For illustrative 
purposes we crudely estimated cost-effectiveness outcome of once-daily 
DPI rhDNase administration based on McIntyre (14), in which net costs per 
LYG for once-daily aerosol delivery were estimated at € 19,110 in the 
baseline. Due to higher deposition efficiency of DPI, we conservatively 
assumed that for DPI delivery 30% less rhDNase is necessary to reach at 
least the same benefits and effectiveness as in delivery by nebulizer(14, 
16). Then, for DPI rhDNase therapy net costs per LYG may be estimated at 
€ 12,100. This corresponds with a reduction in the cost-effectiveness ratio 
of almost 40% for DPI delivery of rhDNase compared to delivery by means 
of nebulization. Incremental cost-effectiveness for DPI over nebulization 
may then be estmated at € 5,100.  
 
FIVE-YEAR VIEW 
With respect to the cost-effectiveness analysis in rhDNase (aerosol-
delivery) treatment, gaps were detected in the methods and cost 
components included. For the future it is advisable to carry out a cost-
effectiveness analysis in which al cost components (direct and indirect) 
are included and the outcome should preferably be expressed in costs per 
Quality Adjusted Live Year (QALY) or costs per life-year gained. 
Extrapolating from short-term results in clinical trials to long-term 
pharmaco-economic outcomes, for example, life-years gained, requires Chapter 6 
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modelling within an adequately chosen time frame. Such a model should 
include up to date epidemiological data, for example, from CF-registries 
that exist for several countries, such as the Netherlands. 
It may be estimated that DPI will result in better adherence to the 
expensive therapy. The higher deposition efficiency of DPI compared to 
nebulization will result in a cost-reduction. Furthermore, to nebulize a 
drug there are numerous options to choose from considering only the 
numerous available nebulizing techniques and nebulizers. Moreover, these 
different nebulizers have different performances with respect to the rate 
of nebulization and the characteristics of the aerosol they create. For the 
physician it is difficult to choose an appropriate nebulizer which gives an 
appropriate particle size distribution. In contrast, a DPI is developed 
alongside with the formulation. This means that the inhalator is 
specifically designed to give the best result in terms of de-agglomeration 
of the formulation. The inhalator is so to say “dedicated” to the specific 
formulation. For the physician it has advantages and the patient 
eventually benefits most of DPI. It is expected that DPI-use will increase 
over the next period and that nebulization will still be a therapeutic 
option for a small number of drugs. For high-cost medication, such as 
rhDNase, it will be more likely to be developed as a DPI, as the cost-
reduction may be expected to have the greatest impact compared to 
nebulization for these drugs. 
 
Key Issues 
Patients with Cystic Fibrosis have thick, tenacious sputum. They are 
chronically colonized with bacteria. This leads to frequent exacerbations 
and is a burden for these patients. Of the patients which are hospitalized 
each year (around 33%), 75% is treated for pulmonary infections. 
Recombinant human Deoxyribonuclease I (rhDNase) is a protein which has 
beneficial effects on lung function (FEV1/FVC) and number of 
hospitalizations. 
RhDNase is currently administered by nebulization which is an inefficient 
method of administration. Dry powder inhalation of rhDNase is almost 
available and is likely to be more effective than nebulization. 
In this review we investigated the pharmacoeconomic effect of dry 
powder inhalation versus nebulization of rhDNase. 
We performed an extensive review of the available literature but scarce 
information about pharmacoeconomics of rhDNase is available. It was Preclinical development of rhDNase 
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found that rhDNase does have a moderate effect and that dry powder 
inhalation can possibly be cost-saving with the same efficacy as obtained 
by nebulization. 
We conservatively assumed that for DPI delivery 30% less rhDNase is 
necessary to reach at least the same benefits and effectiveness as in 
delivery by nebulizer. This corresponds with a reduction in the cost-
effectiveness ratio of almost 40% for DPI delivery of rhDNase compared 
nebulization.   
We hypothesize that the patients benefit most from dry powder 
inhalation due to increased mobility and ease of use. It is expected that 
DPI-use will increase over the next period and that nebulization will still 
be a therapeutic option for a small number of drugs. For high-cost 
medication, like rhDNase, it will be more likely to be developed as a DPI, 
since there might be a cost-reduction compared to nebulization. 
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The purpose of this study was to formulate hemin as a powder for 
inhalation and to show proof of concept of heme oxygenase 1 (HO-1) 
expression in the lungs of mice by inhalation of hemin. Hemin was 
spray dried from a neutralized sodium hydroxide solution. The particle 
size distribution of the powder was between 1-5 μm. Dispersion from 
the Twincer dry powder inhaler showed a fine particle fraction (<5 
μm) of 36%. A specially designed aerosol box based on the Twincer
®-
inhaler was used for a proof of concept study of HO-1 induction by 
inhalation of hemin in mice. The aerosol in the exposure chamber of 
the aerosol box remained aerosolized up to 5 minutes. A rhodamin B 
containing aerosol was used to show that the aerosol box gave 
deposition over the entire lung indicating the suitability of the model. 
Additionally, inhalation of hemin showed a dose dependent increase in 
HO-1 protein expression in the lungs. In conclusion, hemin was 
successfully formulated as a powder for inhalation and the inhalation 
model allowed controlled HO-1 expression in the lungs of mice. Future 
studies investigating the utility of inhaled hemin in treating disease 
states are warranted. 




The heme oxygenase (HO) metabolic pathway has recently received an 
explosion of research interest due to its potent physiological and 
cytoprotective properties, e.g. (1-3). The inducible (HO-1) and the 
constitutively expressed (HO-2 and HO-3) forms of HO catalyze the 
oxidation of heme to biliverdin, carbon monoxide and iron (4). 
Subsequently, biliverdin is rapidly converted to bilirubin which is a potent 
endogenous antioxidant (5). All three downstream products 
(biliverdin/bilirubin, CO and Fe/ferritin) participate in the cellular 
defense. HO-1 has an integral role in the response to oxidative stress and 
inflammation and is induced by numerous oxidative and inflammatory 
stimuli (6). 
Recently, it was shown that HO-1 expression in lung tissue and 
macrophages obtained by bronchoalveolar lavage of patients with chronic 
obstructive pulmonary disease (COPD) is decreased compared with 
healthy controls (7, 8). COPD is a respiratory disease characterized by a 
chronic inflammatory response in the lungs, which is primarily caused by 
the toxic effects of smoking. It is tempting to hypothesize that in COPD 
patients an imbalance between systemic reactive oxygen species and 
relative antioxidant systems exists, which is possibly caused by 
insufficient upregulation of HO-1 (9). One of the substances that induces 
HO-1 is hemin (ferriprotoporphyrin IX), the oxidized form of heme (10, 
11). Induction of the heme oxygenase pathway by inhalation of natural 
substrates, such as hemin, could therefore be of great benefit in diseases 
like COPD (12, 13). So far, inhalation of hemin in humans has been 
performed only once as a control to show that the HO-1 pathway is 
involved in asthma (13). In that study, nebulization of 2 ml of 10
–4 M 
hemin resulted in increased levels of exhaled CO, indicating that the HO-
1 pathway can be induced by inhalation of hemin. However, no direct 
evidence of HO-1 induction was given. 
In the clinical setting, nebulization is characterized by a low deposition 
efficiency (typically 2-27%), and needs electricity or pressurized air for 
the aerosol to be created. In contrast, dry powder inhalation is 
characterized by higher deposition efficiency (up to 60%) and the patient 
delivers the driving force for the aerosol to be created (14-17). Moreover, 
nebulization is accompanied by patient immobility, whereas dry powder 
inhalers are easy to carry and use. Furthermore, dry powder inhalation is 
likely to result in increased patient compliance, especially in chronic use. Chapter 7 
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The aim of this study was to formulate hemin as a powder for inhalation 
and to show a proof of concept for induction of heme oxygenase 1 
expression in the lungs of mice by inhalation of hemin. To obtain the 
proof of concept we administered hemin as a powder for inhalation to 
mice by using a specially designed aerosol box, which is based on the 
Twincer
® dry powder inhaler (18).  
 
MATERIALS AND METHODS 
Materials 
Hemin (51280) and rhodamin B (83689) were purchased from Sigma-
Aldrich Chemie B.V. (Zwijndrecht, The Netherlands). Inulin, with a 
degree of polymerization of 23, was a generous gift of Sensus (Breda, The 
Netherlands). Sodium hydroxide (NaOH), hydrochloric acid (HCl) and 
ammonia (NH4) were of analytical grade and purchased from commercial 
suppliers. Demineralized water was used throughout the experiments. 
 
Methods 
Quantitative determination of hemin 
Sample concentrations for determination of solubility and drug load were 
spectrophotometrically analyzed in phosphate buffered saline (PBS) with 




In order to measure the maximum solubility in different alkaline 
solutions, 7 solutions with a pH between 11.0 and 14.0 were prepared in 
steps of 0.5 pH units. To these solutions excess hemin was added under 
constant stirring. After 30 minutes, the solutions were centrifuged at 
10,000 rpm for 10 minutes. The supernatant was pipetted and diluted 
with a phosphate buffered solution and measured spectrophotometrically.  
 
Powder production by spray drying 
Due to an excess of sodium hydroxide in the solution to increase 
dissolution of hemin, the pH of that solution remains high. If such a 
solution is spray dried, the resultant powder causes an alkaline pH shift 
upon reconstitution. To avoid alkaline pH changes upon reconstitution of 
the spray dried powder, the pH needs adjustments during or before spray 
drying. Two methods were used for pH adjustment. In the first method a In vivo induction of heme oxygenase I 
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sodium hydroxide solution (0.7% w/v) with pH 13.5 was immediately 
before spray drying adjusted to pH 7.6 with hydrochloric acid. The second 
method consisted of spray drying an ammonia solution (1.2% w/v) with a 
pH of 13.5. During spray drying, ammonia evaporates and is not present in 
the dried powder any longer.  
Four powders were spray dried. The first powder was prepared by 
dissolving hemin in a sodium hydroxide solution (0.7% w/v) at a pH of 13.5 
to obtain a total concentration of 4.5% w/v. After pH adjustment the 
solution was filtered through a 1.2 µm filter. Hemin was not removed by 
filtration from the solution. After spray drying, this powder thus 
contained sodium chloride and hemin. The hemin drug load was 
determined to be 63% w/w. 
The second powder was produced by dissolving hemin in an ammonia 
solution (1.2% w/v) with a pH of 13.5. After spray drying, this powder 
thus only contained pure hemin. This powder was used as a control in the 
dissolution experiments. 
Finally, spray dried controls containing rhodamin B or inulin were 
prepared by dissolving the respective controls in a sodium hydroxide 
solution followed by pH adjustment before spray drying. Rhodamin B 
served as a control for the in vivo deposition characteristics and thus the 
suitability of the aerosol box; inulin served as a control for the local 
effect of powder inhalation with sodium chloride.  
Spray drying was performed with a Büchi 190 Mini Spray Dryer (Büchi, 
Flawil, Switzerland) equipped with a two-fluid nozzle (0.5 mm). The 
solutions were sprayed at a fluid flow rate of 3.2 ml/min and an 
atomizing air flow rate of 800 l/h. The settings of the aspirator (14) and 
heater (14) resulted in temperatures at the inlet and outlet of 180 °C and 
120 °C, respectively. 




Dissolution experiments were carried out using an USP dissolution 
apparatus I (Rowa Techniek B.V., Leiderdorp, The Netherlands) at 37 ºC 
and 100 rpm in 1000 mL phosphate buffered solution with 10 mg hemin, 
corrected for drug load. Samples from the dissolution vessel were 
spectrophotometrically analyzed at 385 nm. 
 Chapter 7 
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Laser diffraction, scanning electron microscopy and cascade impactor 
analysis 
Particle size distributions of the spray dried samples were measured with 
a Helos Compact model KA laser diffraction apparatus (100 mm lens, 
Fraunhofer theory) equipped with a RODOS dispersing system (Sympatec 
GmbH, Clausthal-Zellerfeld, Germany) operated at a dispersion pressure 
of 5 bar. All measurements were performed in triplicate. The particle size 
distribution in the exposure chamber was measured by placing the 
complete aerosol box in the laser beam. To avoid scattering by the 
Perspex walls, the light was directed through two opposing openings. 
Scanning electron micrographs (SEM) were recorded with a JEOL JSM 
6301-F Microscope (JEOL, Japan). The powder was dispersed on top of 
double-sided sticky carbon tape on metal disks and coated with 150 nm of 
gold/palladium in a Balzers 120B sputtering device (Balzers UNION, 
Liechtenstein). 
The aerodynamic particle size distribution was measured with cascade 
impactor analysis using a multi-stage liquid impinger (Erweka, 
Heusenstamm, Germany) with a Twincer
®-inhaler (18) attached to the 
induction port. A solenoid valve was used in combination with a timer to 
control the flow (corresponding with 4 kPa pressure difference) through 
the inhaler and the cascade impactor for the duration of 3 seconds. The 
stages of the cascade impactor were filled with 20 mL phosphate buffered 
saline (PBS). A total amount of ~100 mg was delivered in 10 separate 
doses. The concentration of the drug on the different stages was 
measured by UV absorbance at 385 nm; deposition was subsequently 
calculated as the percentage of the metered dose. The fine particle 
fraction (< 5 μm at the flow rate corresponding with 4 kPa across the 
Twincer, FPF) was calculated by interpolation of the cumulative mass plot 
versus effective cut-off diameter. The FPF is expressed as a percentage of 
the metered dose. All cascade impactor experiments were carried out in 
triplicate. 
 
Aerosol box for passive pulmonary delivery of powders for inhalation 
As a proof of concept of HO-1 induction by inhalation of hemin a new 
device was developed to allow passive, pulmonary dry powder delivery to 
small laboratory animals. The device, hereafter called aerosol box (figure 
1), is actually an accessory for the Twincer
®, an effective dry powder 
inhaler which delivers high dosed formulations in highly constant particle In vivo induction of heme oxygenase I 
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size distributions (fine particle fraction of 40-50%) independent of the 
pressure drop between 1 and 4 kPa (18). The efficient aerosol generation 
at low pressure drops makes the Twincer
® most suitable for the aerosol 
box where the operator manually generates the air flow that disperses 
the powder. The device consists of the Twincer
®, a cylinder with piston to 
provide a pressure drop across the inhaler and transfer of the aerosol to 
last part of the device, the exposure chamber in which a fan is built. Mice 
are attached to the exposure chamber. In total, up to twelve mice can be 
attached to the exposure chamber. 
About 15 mg of powder, equivalent to 9.45 mg active ingredient (hemin, 
inulin or rhodamin B) and 5.55 mg sodium chloride, was dispersed in the 
aerosol box. In this study, one dose is defined as 5 minutes exposure to an 
aerosol that has been generated from 15 mg of drug formulation. 
 
Animals 
Female A/J mice (aged 8-10 weeks) were obtained from Harlan (Zeist, 
the Netherlands) and were held at the Central Animal Facility of the 
Groningen University. The experiments were approved by the Committee 
on Animal Experimentation of the University Medical Center Groningen 
and were performed under strict governmental law, adhering to the 
Principles of Laboratory Animal Care. 
 
Experimental setup 
The mice used in this study were divided into 6 groups. Group 1 consisted 
of one mouse that was not exposed to any aerosol and served as a 
control. Groups 2, 3, 4 (n=2 for each group) were exposed to 2, 4 and 6 
doses of spray dried hemin, respectively. Group 5 (n=2) was exposed to 6 
doses of spray dried inulin and served as control for sodium chloride that 
was present in the spray dried powders. Inulin, a naturally occurring 
oligosaccharide was chosen because oligosaccharides contribute 
marginally to the osmotic pressure due to their high molecular weight. 
Group 6 (n=2) was exposed to 6 doses of spray dried rhodamin. Group 6 
was used to investigate the deposition of dispersed powder in the lungs of 
mice. Deposition of rhodamin was visualized in 4 µm sections of frozen 
lung tissue by fluorescent microscopy. 
 
 



































Figure 1. (Top) The aerosol box, a utility for the Twincer
® (A). By pulling the 
piston in the cylinder (B) an aerosol is created and can be transferred to the 
exposure chamber (C) to which 12 small laboratory animals can be fitted. A fan 
(D) creates a laminar airflow in the exposure chamber to minimize sedimentation 
effects. (Middle) Detail of the Twincer
® attached to the aerosol box. (Bottom) 




Protein samples were made from whole lung tissue using a sonicator 
(Bandelin sonopuls HD2070, Berlin, Germany). The proteins were 
separated on molecular weight using Sodium Dodecyl Sulphate-
Polyacrylamide Gel Electrophoresis (SDS-PAGE) and blotted on a 
nitrocellulose membrane. The membrane was blocked overnight in 5% low 
fat milk and the proteins were detected with anti-heme oxygenase-1 
(Stressgen, Victoria, Canada) followed by a peroxidase labeled goat-anti-
rabbit antibody (DakoCytomation, Heverlee, Belgium). As a protein 
loading control the membrane was stripped using an 25mM Glycine-HCl 
buffer containing 1% SDS (pH:2) and stained for β-actin (Abcam loading 
control, Cambridge, UK) followed by a peroxidase labeled goat-anti-rabbit 
antibody (Dako). The bands of interest were visualized using enhanced 
chemiluminescence. 
Band-sizes of each group were quantified using Matlab 6.5.1 (The 
MathWorks Inc, Natick, USA) and the Dipimage toolbox (Quantitative 
Imaging Group, Faculty of Applies Sciences, Delft University of 
Technology, the Netherlands) (19, 20). In short, the grey-scale images 
were made binary with the Isodata threshold algorithm which calculates 
the best threshold value out of the grey value histogram of the image 
(21). Data are given as the ratio between the number of pixels of the HO-




HO-1 protein expression was demonstrated in 3 µm sections of paraffin 
embedded lung tissue with antibodies against HO-1 (Stressgen 896, San 
Diego, CA, United States). Presence of leukocytes was demonstrated in 4 




Formulation. A series of experiments was carried out to measure the 
solubility of hemin at different pH levels. Hemin is practically insoluble in 
water (at pH ~7) and organic solvents (22). However, under alkaline 
conditions hemin is soluble. In alkaline solutions, hemin (FePP-Cl) reacts 
with excess hydroxide to form hematin (FePP-OH). Hematin acts as an Chapter 7 
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intermediate in a polymerization reaction which results in a oxy-bridged 
dimer and probably other polymers (22). 
 
FePP-Cl + OH
- → FePP-OH + Cl
- 
2FePP-OH → (FePP)2O + H2O 
 
The solubility of hemin (figure 2; solid line, primary y-axis) reached a 
maximum at pH 13.5. At pH>13.5 a large variation in solubility was 
observed which indicates the occurrence of degradation reactions, such 
















Figure 2. Solubility of hemin (solid line, primary y-axis) as a function of pH and 
calculated content of hemin in spray dried powder (dotted line, secondary y-axis) 
as a function of pH. The calculated con c e n t r a t i o n  o f  N a O H  v e r s u s  p H  i s  
represented by the dashed line (primary y-axis).(n=3) 
 
Since the pH of the sodium hydroxide solution determines the amount of 
hemin that can be dissolved, the sodium hydroxide concentration is the 
main parameter that determines the efficiency of the spray drying 
process. The higher the sodium hydroxide concentration, the higher the 
hemin concentration in the solution. On the other hand, it should be 
realized that an increase in the sodium hydroxide concentration requires 
increased amounts of hydrochloric acid for neutralization. This effect will 
lead to a shift towards higher sodium chloride fractions in the powder, In vivo induction of heme oxygenase I 
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which of course reduces process efficiency in terms of drug load. Finding 
the most efficient process condition is a matter of balancing between the 
solubility of hemin, which is positively affected by the sodium hydroxide 
concentration, and the hemin drug load in the powder, which is 
negatively affected by the sodium hydroxide concentration. These effects 
are shown in figure 2 (dotted line, secondary y-axis). 
 
With increasing pH the drug load of hemin in the spray dried product 
initially rose up to a maximum of 90% at a pH of 11.8. At this pH the total 
concentration of hemin and NaOH was only 2.5 mg/ml. Spray drying of a 
solution with such a low concentration does not result in a high yield. 
Therefore the pH was increased to 13.5, which resulted in a solution with 
a total concentration of 45 mg/ml and a drug load of 63% after spray 
drying as was confirmed by chemical analysis. The spray dried hemin 
powder consisted of highly irregular particles (figure 3), which were in a 
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Table 1. particle size obtained from RODOS dispersion (5 bar) at 10, 50 and 90% 
cumulative undersize of the spray dried powders. All powders were spray dried 
from a sodium chloride solution, except pure spray dried hemin, which was spray 












Spray dried hemin  1.01  2.14  3.67  1.25 
Spray dried hemin from ammonia  0.95  2.06  3.50  1.24 
Spray dried inulin  0.92  2.29  4.66  1.64 
Spray dried rhodamin B  0.87  2.02  3.42  1.26 
* Span = (x90-x10)/x50 
 
Spray dried hemin from a neutralized sodium chloride solution displayed a 
faster dissolution profile compared to spray dried hemin from NH3 as 
shown in figure 4. After 2 minutes 50% of spray dried hemin was 
dissolved, compared to 20 minutes for spray dried hemin from NH3, while 


















Figure 4. Dissolution rate of spray dried hemin in the presence of NaCl (z) and 
pure spray dried hemin from ammonia ({). (n=3) 
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Complete dissolution of the powder spray dried from the NH3 solution 
took 110 minutes. The powder with the fastest dissolution rate was used 
to perform further experiments (aerosol behavior and proof of concept).  
In table 1 the particle size distributions of the spray dried powders are 
shown. The particle size distributions are comparable, only spray dried 
inulin had a somewhat wider size distribution.  
Cascade impactor analysis (figure 5) showed a delivered dose from the 
Twincer at 4 kPa of approximately 77% with a fine particle fraction (<5 



















Figure 5. Cascade impactor analysis of spray dried hemin with NaCl after 
dispersion by the Twincer
® at 4 kPa. Fine particle fraction (FPF) represents 
particles <6.8 µm. Error bars represent highest and lowest value. 
 
Validation of aerosol box.  
After dispersion in the aerosol box (figure 6B), most particles (<90%) were 
between 1 and 5 μm. In the aerosol box the size distribution moved 
towards finer particles in time, indicating sedimentation. Larger 
agglomerates (5-10 μm) sediment fast and such agglomerates are no 
longer present after 1 minute. The change in particle size distribution will 
not substantially affect the inhalable fraction in the inhaled air however, Chapter 7 
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since the volume fraction of such agglomerates in the aerosol is small. 
Sedimentation was confirmed by a decline in the optical concentration 
(i.e. amount of laser light that is blocked by the aerosol). After 5 minutes 
the optical concentration was 0.0%, whereas the starting concentration 
was 1.54% on average. The amount of aerosol in the exposure chamber 
after 5 minutes was therefore negligible due to sedimentation. Therefore, 
we exposed the mice for 5 minutes per dose to the aerosol because a 


























Figure 6. (A) Geometrical particle size distributions of spray dried hemin as 
measured by RODOS dispersion at 5 bar and (B) in the exposure chamber of the 
aerosol box immediately (────), 1 minute (········), 2 minutes (─  ─  ─), 3 
minutes (─ ·· ─), 4 minutes (──  ──) and 5 minutes (─ · ─ ·) after dispersion by 
the Twincer
®. (Fig.4A: n=3; Fig.4B n=4) In vivo induction of heme oxygenase I 
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To obtain an indication of the amount of drug that a mouse actually 
inhales, an in vitro measurement was performed by withdrawing 20 
ml/min of air during 5 minutes from the exposure chamber. It was shown 
that this volume contained about 0.02% of each dose, an amount that 
consequently can be assumed as the administered dose. The assumption 
of 20 ml/min was on the low side, since respiratory minute volumes of 
mice of 45 – 50 ml/min have been described (23, 24). 
In vivo deposition of inhaled powder in the lungs from the aerosol box was 
demonstrated by exposing mice to rhodamin B. Rhodamin B had a similar 
particle size distribution as spray dried hemin (Table 1). By using 
fluorescent microscopy, rhodamin deposition on the epithelial lining of 
the airways was demonstrated (figure 7). Rhodamin deposition was 


















Figure 7. Example of rhodamin fluorescence in lung tissue. The fluorescent signal 
(red) of rhodamine in lung tissue is shown to be present in the epithelial lining of 
the airways. Magnification: 20x 
 
Proof of concept 
Different doses of spray dried hemin were administered to achieve HO-1 
induction in lung tissue. Figure 8 shows a clear relationship between the 
dose of spray dried hemin and the level of HO-1 protein expression in lung Chapter 7 
 
204 
homogenate. Furthermore, inhalation of inert powder (spray dried inulin) 
containing sodium chloride did not result in increased expression of HO-1.  
HO-1 protein expression was found to be particularly increased in alveolar 
macrophages (figure 9). The airway epithelium stains faintly and shows no 
differences after hemin inhalation. The HO-1 expression as shown with 
HO-1-staining in the spray dried inulin exposed mice was comparable to 




















Figure 8. (A) HO-1 protein expression. Protein bands for HO-1 (top) and β-actin 
(loading control, bottom) detected by Western blot analysis are shown; each 
band represents 1 mouse. From left to right: one control mouse that was not 
exposed to aerosol, 2 mice that were exposed to 2, 4 or 6 doses (2x, 4x and 6x) 
of spray dried hemin during 10, 20 or 30 minutes, respectively, and finally 2 mice 
that were exposed to 6 doses spray dried inulin (6x inu) during 30 minutes. (B) 
Ratio of the HO-1 and ￿-actin band size as obtained with Western blot for the 




























Figure 9. A representative picture of the HO-1 expression (dark red) in lung 
tissue of the control and after inhalation of 2, 4 and 6 doses of spray dried hemin 
is shown (25x magnification). Particularly, alveolar macrophages (indicated with 
an arrow) show an increased HO-1 expression after hemin inhalation. 
Magnification: 25x 
 
The inflammatory side effects of spray dried hemin inhalation were 
studied by histological staining of leukocytes in lung tissue. Visual 
observation showed increased numbers of leukocytes surrounding the 
airways after inhalation of 4 and 6 doses of spray dried hemin, while in 
the control mouse and after inhalation of 2 doses of spray dried hemin 





























Figure 10. Leukocytes expressed in lung tissue. A representative picture of the 
leukocyte expression (CD45 positive cells) in lung tissue of the control and after 
inhalation of 2, 4 and 6 doses of spray dried hemin is shown. Arrows in top 
pictures indicate airways; arrows in bottom pictures indicate areas with 
increased numbers of leukocytes surrounding the airways. Magnification: 50x 
 
DISCUSSION 
Hemin, as shown in this study, can be formulated as a powder for 
inhalation by spray drying. Furthermore, spray dried hemin resulted in 
dose-dependent HO-1 induction after nose-only exposure of mice to the 
aerosol, showing that dry powder inhalation of hemin is possible and 
effective in inducing the HO-1 metabolic pathway.  
Spray drying of hemin was performed from two solutions that had initial 
high pH values. An advantage of spray drying an ammonia solution that 
contains hemin is that ammonia evaporates during spray drying, resulting 
in pure hemin powder. In contrast, spray drying of the neutralized sodium 
hydroxide solution results in a powder that contains 37% w/w sodium In vivo induction of heme oxygenase I 
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chloride and 63% w/w hemin. However, the latter solution results in a 
powder that dissolves much more rapidly than the pure spray dried 
powder. This is attributed to the presence of sodium chloride in the spray 
dried powder which improves wetting and increases the surface over 
which dissolution occurs. The technique may be beneficial for other 
poorly soluble compounds too, especially for those compounds that have 
a pH-dependent solubility. 
Spray drying has become one of the standard techniques for the 
preparation of inhalation powders (25, 26). One of the advantages of 
spray drying over conventional techniques such as milling is the improved 
control over the particle size. From both the sodium hydroxide and 
ammonia solution the obtained powders were in the appropriate size 
range for inhalation, as measured with laser diffraction and cascade 
impactor analysis. 
Clearly, the sodium chloride in the formulation did not increase HO-1 
expression as was shown by the similarity in band size of HO-1 expression 
of the inulin control, after 6 doses, and the control that did not receive 
any aerosol.  
The suitability of the Twincer-based aerosol box for pulmonary 
administration in freely breathing mice was demonstrated in this study. 
The  in vitro laser diffraction measurements showed that an aerosol 
consisting of particles suitable for inhalation is present in the aerosol box 
for at least 5 minutes. Moreover, the in vivo study with rhodamin B 
showed that the aerosol reached all parts of the lung. It should however 
be realized that the individual mouse receives only a small fraction, 
about 0.02%, of the total dose in the Twincer. The major limitation in this 
setup is the relative small volume that is inhaled by mice. 
One study exists where inhalation of hemin in human subjects has been 
investigated (13). However, the dose in our study is much higher than the 
dose used in the human study. The nebulized dose in the human study 
was 2 ml of 10
-4 M hemin, which is equivalent to 1.6 μg/kg for a person of 
80 kg. The lowest dose in our study is estimated to be 171 μg/kg, which 
corresponds to at least 100 times the dose used by Horvath et al. (13). 
Since there was no information available on the dose-effect relationship 
of hemin we exposed mice to different doses. The dose escalation in our 
study was thus 171, 342 and 523 μg/kg. The relatively high doses that the 
mice inhaled led to concerns about the toxicity of hemin since it has been 
reported that hemin possesses oxidative properties especially at high Chapter 7 
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doses which is due to excess iron (27). Ambiguous effects have been 
ascribed to hemin (28). In moderate amounts and bound to proteins it is 
an essential element in various biological processes (10, 29). Large 
amounts of hemin can be toxic by mediating oxidative stress and 
inflammation, which is mainly due to release of iron (27). 
The higher doses indeed led to infiltration of leukocytes into the airways. 
This inflammatory cell recruitment could be the result of increased 
production of inflammatory mediators by epithelial cells in response to 
toxic effects of the increasing dose of spray dried hemin. This possibility 
is in agreement with other in vitro and in vivo studies showing increased 
adhesion molecule expression and tissue infiltration of leukocytes after 
hemin administration to vascular cells (30, 31). On the other hand, we 
found that 171 μg/kg hemin did not result in increased numbers of 
inflammatory cells. However, inhalation of this dose of spray dried hemin 
was sufficient for a clear increase in HO-1 expression in lung tissue, 
indicating that this was a safe and effective dose of spray dried hemin. 
To conclude, we presented a novel preparation of a hemin formulation by 
spray drying and showed proof of concept of the hemin formulation and a 
new pulmonary administration technique. The substance, hemin, induced 
the HO-1 expression in a dose dependent manner. Future studies 
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Concluding remarks and future perspectives 
 Chapter 8 
 




Over the past decades there has been a growing interest in the 
development of biopharmaceuticals as inhalation products, not only to 
obtain a local therapeutic effects but also to obtain a systemic 
absorption. As a consequence, pulmonary drug administration is nowadays 
connected to various therapeutic treatment modalities. Drug inhalation is 
no longer solely applied for treatment of local lung diseases, but its scope 
has widened to treat systemic diseases, to evoke a systemic effect 
without systemic absorption (e.g. vaccination) or to obtain systemic and 
local levels to treat for instance tuberculosis or cystic fibrosis.  
Those biopharmaceuticals that are suited for inhalation can be 
formulated as a liquid, that is aerosolized by means of auxiliary energy at 
administration, or, they can be formulated as a powder for inhalation 
which is aerosolized upon inhalation by utilizing the patients’ inspiratory 
force. Dry powder inhalation is the preferred means of administration for 
most patients as electricity or pressurized air are not needed. In addition, 
the short administration time, the better stability of the powder 
compared to a liquid formulation, the higher lung deposition, the more 
robust and reliable inhalation mode and size of the administration device 
are also advantageous.. 
 
In this thesis, we successfully formulated a number of 
biopharmaceuticals, each with different physico-chemical properties, as a 
dry powder for inhalation. Depending on the physical properties of the 
biopharmaceutical (e.g. stability, solubility, pKa, molecular weight) a 
certain formulation strategy can be chosen. Relatively stable (small) 
peptides, such as cetrorelix or cyclosporine A, can be formulated as a 
powder for inhalation by using standard milling techniques and 
formulation as adhesive mixture or spherical pellet. More complex 
manufacturing processes and/or formulations may be needed when the 
biopharmaceutical is sensitive to chemical or physical degradation (e.g. 
rhDNase). So far the preferred manufacturing process seems to be spray 
drying because it is (next to freeze drying) the single process that has 
been successfully employed in commercial scale manufacturing for many 
years. Consequently, this process is well-known and well-described. A 
major disadvantage of the common freeze drying process is the fact that 
the obtained solid material has particulate properties that are unsuitable 
for inhalation and the material shows poor milling properties (e.g. high Chapter 8 
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tendency to stick to the walls of the equipment, moisture sensitivity, high 
tendency for crystallization). All other manufacturing processes (like 
spray freeze drying or supercritical drying) need further development and 
scale up and they are therefore expected to be more expensive. To 
protect chemically and/or physically sensitive biopharmaceuticals, we 
have demonstrated the versatility of sugar glass technology. Of the 
currently available excipients that can be used in sugar glass technology, 
inulin seems one of the best materials to meet stability demands: its high 
glass transition temperature allows storage at room temperature while 
the amorphous state is maintained. Other excipients, such as trehalose or 
sucrose tend to collapse at ambient conditions rendering them useless as 
inhalation products. Moreover, sugar glass technology in combination with 
spray (freeze) drying can be used for particle design. Particle size, shape 
and density can be designed to render material that in combination with 
the chosen inhaler provides the best possible aerosol. In addition, with 
sugar glass technology, the dissolution rate of poorly soluble active 
ingredients can be improved, which may improve their bioavailability.  
 
Efficacy and safety research in animals are a relevant part of the pre-
clinical development program of new drug products. For inhalation 
products it is almost impossible to mimic the pulmonary drug 
administration in humans. First, significant differences exist between man 
and animal regarding lung anatomy and breathing profile. Second, 
spontaneous inhalation through an inhaler is only rarely performed by 
most animals. Two powders for inhalation were tested in mice or rats, for 
which two different administration methods were used. The 
administration method of dry powder in mice was an aerosol chamber. 
The powder was aerosolized into the chamber by creating an inspiratory 
air flow through an inhaler. Mice were put in restrainers and attached to 
the aerosol chamber such that only their nose was exposed to the aerosol. 
The amount the mice inhaled depended on the aerosol concentration in 
the chamber and duration of exposure. With this model, different aerosol 
properties may be investigated when coupled with an appropriate method 
to determine deposition. The method used for aerosol administration to 
rats was intratracheal administration with the PennCentury insufflator. 
With the insufflator, aerosol properties are of less importance, yet 
accurate doses can be administered, which makes this method suitable 
for experiments where accurate dose administration is needed. Both Concluding remarks and future perspectives 
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methods, nose-only exposure and insufflation, are complementary and 
considered essential models for inhalation product development. 
 
FUTURE PERSPECTIVES 
Biopharmaceuticals that will be evaluated as inhalation products should 
possess a true therapeutic advantage. When the only reason to develop 
a n  i n h a l a t i o n  p r o d u c t  i s  t h a t  i t  i s  “ a  m o r e  c o m f o r t a b l e  r o u t e  o f  
administration than the injection” the chances of market success are 
limited as was shown by the Exubera
® case. Only in those cases where 
pulmonary administration offers a true therapeutic advantage, such as an 
increased efficacy or an improved safety, pulmonary biopharmaceuticals 
may become successful. Typical examples of such biopharmaceuticals 
are: 
•  biopharmaceuticals that can be used to treat local lung disease,  
•  biopharmaceuticals that evoke the best systemic therapeutic response 
after inhalation (e.g. vaccination), or  
•  biopharmaceuticals that cause serious side effects when administered 
via another route (e.g. injection)  
•  biopharmaceuticals that require rapid absorption, but for any reason 
cannot be injected (e.g. for hygienic reasons) 
 
For each biopharmaceutical suited for inhalation a taylor-made 
manufacturing process and formulation is to be designed that meets 
general requirements, such as the pharmaceutical aspects as well as 
aspects related to efficacy, safety, patient compliance and health care 
costs. The technology to develop and manufacture biopharmaceuticals as 
powders for inhalation is nowadays available although the application of 
the technology is still rather limited.  
One of the major research topics that may enable a broader use of this 
technology in the future is the understanding of the processes that occur 
during particle formation. With this knowledge, particles that are easily 
dispersible and demonstrate excellent deposition characteristics can be 
prepared. Drug product and administration device should be regarded as a 
single entity since not all formulations will be optimally aerosolized with 
just one inhaler; i.e. the best possible inhaler will not be suitable for all 
different formulations. The optimal result can only be reached when 
formulation and inhaler are optimized regarding the specific 
characteristics and interactions they have. Furthermore, computational Chapter 8 
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fluid dynamics and computational particle tracking will receive more 
attention in the inhalation field, since these technologies can speed up 
product development, both by indicating the optimal starting point for a 
development based on in silico simulations as well as through the 
generation of additional information on deviating performance during 
development. 
 
Further refinement in animal models for pulmonary drug products is also 
anticipated but also urgently required. To appropriately test inhalation 
drug products, improved animal models are needed since the use of 
animal models is a prerequisite to substantiate the marketing 
authorization dossier. These models should be able to discriminate 
between different drug products in terms of aerosol behaviour and 
subsequent pharmacokinetics and –dynamics. In addition, the deposition 
characteristics would need to be analyzed. Improvements in methods to 
determine the deposition characteristics in laboratory animals are 
possible, for example by in vivo bioluminescence or fluorescence. 
 
Safety of biopharmaceuticals is a key aspect as protein structures may 
change as a consequence of purification, production, storage or even use. 
Such changes may lead to unwanted immunological responses, even when 
patients are immune tolerant to the endogeneous protein. As at present 
the exact role of an altered protein structure is unknown, 
biopharmaceuticals are likely to be subjected to rigorous immunological 
profiling in animal studies, but also in humans. 
 
Finally, many research efforts will be fuelled by various societal aspects 
related to the current state of the pharmaceutical industry and policies 
around it. The declining success of pharmaceutical research is emptying 
the industry’s pipelines; this will result in fewer new drug products that 
enter the market. Those products that are promising should be brought to 
the market as fast as possible and in the end in the most optimal way 
possible, in order to cover for losses of unsuccessful development 
projects.  
Tighter requirements from regulatory authorities address society’s 
requirement for more efficient and safer medicines, preferably provided 
at lower costs. However, since safety and efficacy can only be improved 
through extensive research and optimized drug administration, possible Concluding remarks and future perspectives 
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future cost savings can only be generated through significant investments 
in today’s pharmaceutical research and development. 
 
To conclude, this thesis demonstrates that many manufacturing processes 
and formulations are already available to design tomorrow’s 
biopharmaceutical drugs as inhalation products. 

















The rapid developments in molecular biology and biotechnology during 
the past decades have resulted in the successful introduction of a number 
of biopharmaceuticals (among which many therapeutic peptides and 
proteins) on the market. Biopharmaceuticals are a special class of 
medicines in the sense that, in general, they are chemically and 
physically not stable. In addition, biopharmaceuticals rely on a certain 
(three dimensional) folding structure for their efficacy and safety. 
Retaining the folding structure is essential to develop efficacious and safe 
drug products of these substances. 
Of all biopharmaceuticals, a number may well be suited for inhalation. 
The objective of the inhalation can be to exert either a local or systemic 
action, or both. Various device types are available for inhalation. The 
aerosol can be created from liquids or dry powders. Nebulization is not 
patient friendly; it is time consuming, requires electricity or pressurized 
air and the efficacy of aerosolisation and lung deposition are poor which 
is associated with unnecessary wastages. On the other hand, dry powder 
inhalation typically needs less than a minute for completion and the 
efficiency of aerosol production and lung deposition are relatively high. 
As biopharmaceuticals are often manufactured in solutions, a drying step 
is required to make them suitable for powder inhalation. Especially those 
biopharmaceuticals that depend on their tertiary structure for activity, 
require stabilization during drying and storage. Excipients like sugars 
seem suitable for this purpose. They immobilize the molecules and offer 
the possibility to replace the hydrogen bonds between drug and solvent. 
Several drying methods are available and a number of these methods 
have been investigated in this thesis: freeze drying, spray-freeze drying 
and spray drying. Other techniques like supercritical fluid extraction may 
be suitable too. Spray-freeze drying gives a solid powder as end-product. 
By appropriate settings of the process conditions a powder with the 
desired aerodynamic particle size may be obtained. Spray drying also 
provides the possibility to produce a powder within the desired size 
range.  
In this thesis we investigated the formulation of several peptides and 
proteins as powder for inhalation. Furthermore, a “proof-of-concept” 
study was performed with several products. We examined a selection of 
peptides and proteins, with different properties in terms of hydrophilicity 
and molecular size. Finally an innovative concept, based on the inhalation Chapter 9 
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of a small molecule that induced the endogenous production of a protein 
(an enzyme) was investigated. 
 
In  Chapter 2, three manufacturing methods were evaluated for their 
ability to produce a dry powder inhalation of cetrorelix, a hydrophilic 
peptide that consists of 10 amino acids. Cetrorelix was milled, spray dried 
and spray-freeze dried. The fragile structure of the spray-freeze dried 
powder made it unsuitable for processing to an adhesive mixture. The 
three methods resulted in particles with different morphologies, although 
all were in the appropriate size range for inhalation. The aerosolization 
behavior of the mixtures with milled and spray dried cetrorelix was tested 
in two commercially available devices: a capsule-based inhaler and the 
Novolizer. The capsule-based inhaler uses the rotation and vibration of 
the capsule for deagglomeration, while the Novolizer utilizes a cyclone-
based principle that uses impact forces for deagglomeration. When the 
adhesive mixtures of milled and spray dried cetrorelix were dispersed 
with the capsule based inhaler and the Novolizer, both powder mixtures 
had appeared to have a higher fraction of cetrorelix on the third and 
fourth stages of the cascade impactor when dispersed with the Novolizer. 
The morphology of the spray dried powder turned out to be better 
suitable for aerosolisation than that of the milled material in both 
inhalers. This investigation showed that the adequate development of 
inhalation systems requires a dual approach in which the specific 
combination of both the formation and device should be optimized. 
 
In  Chapters 3 and 4 the hydrophobic peptide Cyclosporine A was 
investigated. Cyclosporine A is a cyclic undecapeptide, consisting of 11 
amino acids. The inhalation of this drug could be used to prevent 
rejection of lung transplants. The utility of solid dispersion technology to 
manufacture a Cyclosporine A powder for inhalation was investigated. 
The solid dispersions were produced from a co-solvent system of water 
and Tert-butyl alcohol (TBA) using inulin with a degree of polymerization 
of 23 as carrier. After spray-freeze drying, a homogeneous powder 
Cyclosporine A and inulin with a high dissolution rate is produced. Fourier 
transform infrared spectroscopy (FTIR) was used to evaluate how 
Cyclosporine A was incorporated in the matrix. It was demonstrated that 
a t  i n c r e a s i n g  d r u g  l o a d s ,  m o r e  C y c l o s p o r i n e  A  w a s  p r e s e n t  i n  a  
hydrophobic environment, indicating that more Cyclosporine molecules Summary 
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were in close contact with each other, and possibly formed small clusters 
of even particles within the matrix. The formation of clusters might 
explain why powders with higher drug loads dissolved slower. 
Spray-freeze drying results in low density particles with a very high 
specific surface area of more than 100 m
2/gr. In spite of their large 
geometric size, the particles had still an aerodynamic size within the 
desired range of 1 to 5 μm, which is explained by the high porosity of the 
particles. The aerodynamic particle size was appropriate for inhalation, 
with a mass median aerodynamic diameter of 3.39 µm. The solid 
dispersion with 50% w/w CsA had the appropriate quality attributes for 
inhalation; a high dissolution rate and excellent aerodynamic behaviour. 
 
Chapter 4 describes the in vivo properties of the Cyclosporine A powder 
for inhalation in rats. Chapter 4A focuses on pharmacokinetics and 
efficacy in preventing lung rejection of the Cyclosporine A powder for 
inhalation (iCsA) in a rat model. The pharmacokinetics of 10 mg/kg iCsA 
and Neoral, the oral commercial product containing Cyclosporine A, were 
studied. Although iCsA and Neoral resulted in comparable systemic 
exposure as determined by the area under the curve of the plasma 
concentration versus time curve and the same kidney exposure, iCsA had 
109-fold higher lung tissue levels than Neoral. 
In the proof-of-concept study, the rat model demonstrated acute 
rejection within 8 days as a result of the incompatibility of the donor and 
recipient. iCsA was already effective at a lower dose than Neoral. 
However, in the used iCsA dose (5 mg/kg) local reactions in the lungs of 
healthy, non-transplanted, rats were observed. Therefore, in Chapter 4B 
the effects of lower doses were studied and compared with the effects to 
placebo. At a dose of 0.8 mg/kg, iCsA seemed to cause no different effect 
as a placebo.  
Although in Chapter 4A we demonstrated that doses lower than 5.0 mg/kg 
would not prevent rejection in the animal, the 0.8 mg/kg dose is relevant 
to humans, since it was described before that in man lower inhaled doses 
were already effective. We anticipate to administer a dose of 6.25 mg 
CsA twice daily, which would correspond to approximately 0.1 mg/kg for 
a 60-kg person. Even at such a dose, the local lung tissue levels of iCsA 
would increase substantially, while the contribution to systemic levels 
would be relatively small which reduces the risk of associated Chapter 9 
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nephrotoxicity. Hence, the efficacy of the treatment could possibly be 
improved in patients that otherwise have no therapeutic options left. 
 
Chapter 5 describes a study into the possibilities of formulating a large 
protein, recombinant human deoxyribonuclease I (rhDNase) as a powder 
for inhalation, whereas Chapter 6 provides a pharmacoeconomic analysis 
of such a product.  
To formulate the protein we evaluated different excipients, processes 
and process conditions. In addition, the efficacy of the most suitable 
formulation was demonstrated with an ex vivo model. The excipient 
selection was performed by freeze drying deoxyribonuclease I in the 
presence of sucrose, trehalose and two types of inulin. Sucrose was found 
to be unsuitable as stabilizer, whereas trehalose appeared to be the best 
stabilizer. Furthermore, spray drying and spray-freeze drying were 
compared as potential manufacturing processes under different process 
conditions. Spray drying was the best suited process, as particles with a 
mass median aerodynamic diameter of 2.3 µm could be produced. Of the 
tested compositions only the inulin (DP 23) formulation could be stored at 
ambient conditions. The inhalation characteristics of this formulation 
were also good, with a fine particle fraction (< 5 µm) of approximately 
40%. Therefore, we evaluated the visco-elastic properties of sputum from 
CF patients before and after applying the rhDNase/inulin DP23 
formulation. The rhDNase powder for inhalation significantly decreased 
both elasticity and viscosity. We concluded that even larger proteins can 
be formulated as a powder for inhalation. Careful screening of excipients 
and processes may lead to the best possible combination, resulting in an 
inhalation powder with the best possible properties in terms of activity, 
storage stability and aerodynamic particle size.  
 
Chapter 6 describes the pharmacoeconomic aspects of nebulization 
versus dry powder inhalation of rhDNase, a key product in the 
management of cystic fibrosis. The potential advantages of dry powder 
inhalation are i) improved compliance to therapy, ii) improved deep lung 
deposition,  iii)  no need for electricity of pressurized air, iv) reduced 
administration time and v) no need to cool the rhDNase solution. These 
benefits may among others lead to less exacerbations and less 
hospitalizations. The costs of rhDNase nebulization were estimated at 
€19.110 for a Life Year Gained (LYG), while the cost for a LYG of dry Summary 
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powder inhalation was estimated at €12.100, which is 40% less than 
nebulization. This demonstrates that it may be useful to investigate 
already in an early stage of development what the pharmacoeconomic 
impact of certain formulation decisions may be.  
 
In Chapter 7 a highly innovative biopharmaceutical type of invention was 
explored. The small organic molecule, hemin was pulmonary administered 
in order to induce the endogenous production of a protein heme 
oxygenase I (HO-1). Such a approach would omit the difficult formulation 
of a protein for inhalation. HO-1 is a protein of interest because this 
enzyme is decreased in COPD patients compared to healthy subjects.  
In the formulation process an alkaline solution of the poorly soluble hemin 
was neutralized immediately before spray drying, to yield a product 
containing hemin and sodium chloride. A new administration device for 
administering inhalation powders to small laboratory animals, using the 
natural breathing pattern, was also developed. It was demonstrated that 
HO-1 could be induced in a dose-dependent manner with inhaled hemin. 
This study showed that also with small organic molecules a 
biopharmaceutical intervention may be possible. Furthermore a novel 
method to allow preclinical testing of inhalation powders was introduced. 
This method is unique as it uses the inspiratory air flow of the animals, 
instead of “forcing” the powder into the lungs by insufflation. This opens 
the possibility to study the deposition characteristics of different powders 
in the preclinical setting. 
 
In conclusion, the selected therapeutically active compounds could all be 
formulated as a powder for inhalation. Depending on the properties of 
the molecule, taylor-made formulation strategies could be employed to 
guarantee the structural integrity during drying and subsequent 
reconstitution. In some cases the pulmonary administration of a small 
molecule that induces the endogenous production of the therapeutic 
protein may be a good alternative, since it simplifies the formulation and 
less critical parameters need to be taken care of. As powders for 
inhalation rely on their aerodynamic properties for deposition and 
efficacy, there is a need to test the powders on these properties in a non-
invasive manner in laboratory animals. In this thesis we used the 
insufflation and nose-only exposure approach. Insufflation is more suited 
for accurate dose-effect studies, while nose-only exposure can be used to Chapter 9 
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deliver a proof-of-concept, in which dose precision is less critical. In such 
a system, various formulation attributes (size, density) may be tested to 
find the best inhalable powder. 
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Longtransplantatie is een behandeling welke voor de meeste indicaties 
overlevingswinst betekent. Eén van de complicaties is chronische 
afstoting. Dit is een complicatie welke zeer ernstig is en waarvoor tot op 
heden geen farmacotherapeutische opties voorhanden zijn. Het 
eindstadium van chronische afstoting is ofwel re-transplantatie of 
overlijden. 
Ciclosporine A is een geneesmiddel wat veel gebruikt wordt ter 
voorkoming van afstoting. De belangrijkste bijwerking van ciclosporine is 
echter nefrotoxiciteit waardoor de dosis verlaagd moet worden. Op den 
duur leidden de dosisaanpassingen tot een grotere kans op chronische 
afstoting. Met andere woorden; de overlevingswinst bij longtransplantatie 
wordt geremd door de toxiciteit van de behandeling. 
Lokale toediening van ciclosporine A, middels inhalatie, is dan ook een 
farmacotherapeutische optie voor het behandelen van chronische 
afstoting omdat de systemische circulatie minimaal wordt belast met 
ciclosporine en omdat lokaal hoge spiegels kunnen worden gehaald. 
In dit protocol wordt een studie beschreven waarin 5 tot 7 patienten met 
matige tot milde (bronchiolitis obliterans syndroom stadia 1 en 2) 
chronische afstoting behandeld gaan worden met droog poeder inhalatie 
van ciclosporine gedurende een periode van zes maanden. De formulering 
en de inhaler zijn ontwikkeld door de werkgroep Farmaceutische 
Technologie en Biofarmacie van de Rijksuniversiteit Groningen. De 
primaire vraagstelling in dit onderzoek is of droog poeder inhalatie van 
ciclosporine A effectief is in de behandeling van chronische afstoting, 
welke niet behandelbaar is met de huidige farmacotherapeutische opties, 
in patiënten met een longtransplantaat? Daarbij wordt de nierfunctie ook 
gemeten ten tijde van de studie om te onderzoeken of de eventuele 
werkzaamheid niet gepaard gaat met nefrotoxiciteit. 
Voor deze studie zijn weinig extra procedures nodig, behalve een 
éénmalige inhalatie van radioactief materiaal om de efficientie van de 
inhalatie te bepalen, het innemen van de studiemedicatie en de bepaling 
van ciclosporinebloedspiegels. De patienten in de studie mogen hun 
huidige immuunsuppressieve therapie blijven gebruiken om te waarborgen 
dat er zo weinig mogelijk afstoting plaatsvindt. 
Het voorliggende protocol is het eerste in een reeks van onderzoeken. 
Deze studie is erop gericht om informatie te krijgen over de efficientie 
van de inhalatie, de hoogte van ciclosporine bloedspiegels na inhalatie en iCsA klinisch studie protocol 
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de effectiviteit van droog poeder inhalatie van ciclosporine op de 
behandeling van patienten met chronische afstoting van het 
longtransplantaat. Het is de bedoeling dat dit onderzoeksgeneesmiddel 
uiteindelijk uitgelicenseerd wordt aan een geinteresseerd bedrijf. 
 
INTRODUCTIE EN RATIONALE 
Longtransplantatie in het algemeen 
Longtransplantatie wordt vanaf midden jaren 80 van de vorige eeuw 
succesvol toegepast. De indicatie van longtransplantatie is een 
eindstadium longziekte, zoals cystische fibose, longfibrose en pulmonale 
hypertensie. De prognose van dergelijke patiënten zonder transplantatie 
is zeer beperkt, in het algemeen is de overleving minder dan twee jaar. 
Met transplantatie wordt door de International Society for Heart and Lung 
Transplantation (ISHLT) een mediane overleving van 4,4 jaar gemeld. In 
Groningen is de mediane overleving zelfs 7,5 jaar. Dit betekent dat bij de 
meeste indicaties het uitvoeren van longtransplantatie overlevingswinst 
oplevert. Daarnaast treedt na transplantatie een normalisering van de 
longfunctie op en neemt de kwaliteit van het leven significant toe. [1] 
 
Therapie van longtransplantatie 
Om een longtransplantaat succesvol te laten functioneren is het remmen 
van het immuunsysteem van de ontvanger onvermijdelijk. Dit wordt in de 
praktijk gedaan met onder meer systemische toediening van zogenaamde 
calcineurine-blokkers als ciclosporine (CsA) en tacrolimus (Tac). Het 
succes van longtransplantatie en transplantatie in het algemeen is 
grotendeels te danken aan deze middelen. CsA en Tac worden veelal in 
combinatie gegeven met nucleosideremmers (azathioprine en 
mycofenolaat-mofetil) en corticosteroïden. 
Omdat de calcineurine-blokkers niet universeel effectief zijn in een 
volledige preventie van acute longtransplantaatrejectie (AR) en de 
daaraan gerelateerde chronische dysfunctie van het longtransplantaat 
(Bronchiolitis Obliterans Syndroom; BOS) blijft er risico bestaan op 
a f s t o t i n g .  Z o  w o r d t  d e  k a n s  o p  m i n i m a a l  1  A R  e p i s o d e  n a  
longtransplantatie variabel beschreven  (30 – 80%). Het optreden van BOS, 
al dan niet in combinatie met daaraan gerelateerde pulmonale infecties, 
de belangrijkste risicofactor voor de lange termijn overleving na 
longtransplantatie. Om BOS zoveel mogelijk te voorkomen zijn hoge doses 
calcineurine-blokkers nodig. De systemische toediening resulteert in een Appendix 
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aantal nadelen. Er is een toegenomen risico op infectie en maligniteit en 
de behandeling heeft nefro- en neurotoxiciteit tot gevolg. Het optreden 
van hypertensie door nierinsufficiëntie (ontstaan door behandeling met 
hoge doses calcineurine-blokkers) beperkt de overleving en kwaliteit van 
het leven sterk. De dagelijkse praktijk is dan ook dat de dosering van 
calcineurine-blokkers wordt aangepast op geleide van de mate van 
afstoting en de nierfunctie. Het zoeken naar de balans in werking 
(voorkomen/behandelen BOS) en bijwerking (optreden niertoxiciteit) 
beperkt de therapeutische effectiviteit op de lange termijn. De 
prevalentie in het optreden van BOS bedraagt 20% en 70% na 
respectievelijk 2 en 7 jaar na longtransplantatie (www.ishlt.org). BOS en 
BOS gerelateerde infectie zijn verantwoordelijk voor ongeveer 50% van de 
late mortaliteit. Hierom is preventie en behandeling van BOS één van de 
belangrijkste uitdagingen op het gebied van longtransplantatie. 
 
Pulmonale toediening van calcineurine-blokkers  
Eén van de mogelijkheden om de systemische bijwerkingen van 
calcineurineblokkers te vermijden en tegelijkertijd de lokale dosis in het 
getransplantanteerde orgaan te verhogen is inhalatie. Dankzij deze 
voordelen zou inhalatie bij uitstek geschikt zijn om niet behandelbare 
chronische afstoting alsnog te behandelen door de hogere lokale dosis. Dit 
idee is niet nieuw, de Pittsburgh-groep (hoofdonderzoeker Iacono) is al 
ongeveer 15 jaar bezig met het vernevelen van een CsA-oplossing. In het 
kort zijn dit enkele belangrijke conclusies: 
•  Verneveling van ciclosporine leidt in vergelijking tot systemische 
toediening tot hogere concentraties in longweefsel [2] 
•  Verneveling geeft minder afstoting-gerelateerde inflammatie [3] 
•  Er is een correlatie tussen de remming in afname van FEV1 met de 
pulmonale depositie van ciclosporine; 5 mg perifere depositie lijkt 
het cut-off point te zijn [4] 
•  In een case control studie werd bij 39 patienten met Bronchiolitis 
Obliterans na verneveling van ciclosporine een significante 
overlevingswinst (1 tot 2 jaar) aangetoond ten opzichte van twee 
retrospectieve controle groepen (100 en 59 patienten). [5] 
 
De hierboven beschreven behandeling met verneveling van ciclosporine is 
altijd gesponsord door Novartis. Novartis is voor de hier voorgestelde 
studie meerdere malen geraadpleegd over samenwerking; dit was iCsA klinisch studie protocol 
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juridisch gezien niet mogelijk daar de rechten met betrekking tot het 
product (Pulminiq) zijn verkocht aan Chiron. Chiron wilde vervolgens niet 
samenwerken omdat het product alleen op de Amerikaanse markt zal 
worden gebracht. De status van het product is dat men wacht op 
marktautorisatie van de FDA. Tot op heden heeft verneveling van 
ciclosporine een NDA (investigational New Drug Application – 50-799 - [6], 
antwoord FDA [7], beide bijgevoegd als bijlage bij dit protocol) status. 
Uit deze gegevens blijkt dat verneveling van ciclosporine een effectieve 
en aantrekkelijke optie is voor de behandeling van chronische afstoting 
welke niet meer behandelbaar is met de huidige therapeutische opties. 
De FDA heeft aan de hand van NDA 50-799 enkele vragen gesteld aan een 




Verneveling is echter een methode die niet praktisch is. De duur van 
toedienen is ongeveer 20 tot 30 minuten en dan bereikt slechts 10% van 
de dosis de luchtwegen. Daarnaast is perslucht of stroom nodig om de 
druppeltjes te creëren. Dit beperkt de mobiliteit van de patient. Van 
droog poeder inhalatie is bekend dat de dosis die de luchtwegen bereikt 
tot 4x zo hoog is in vergelijking met verneveling. Daarnaast duurt de 
inhalatiemanoeuvre veel korter. Droog poeder inhalatie zou dus een 
betere optie zijn. In de tijd dat Iacono en cs. begonnen met verneveling 
was er geen geschikte droog poeder formulering van ciclosporine 
beschikbaar vanwege de fysisch chemische eigenschappen van 
ciclosporine. Ciclosporine is namelijk slecht wateroplosbaar (slechts 3 
mg/L) en derhalve zou puur microniseren resulteren in een nauwelijks 
werkzaam poeder. De werkgroep Farmaceutische Technologie en 
Biofarmacie (Farmacie, faculteit der Wiskunde en Natuurwetenschappen, 
Rijksuniversiteit Groningen) hebben ciclosporine echter geformuleerd als 
een amorf suikerglas in combinatie met inuline. De zo onstane 
formulering heet in vakjargon een solid dispersion. Solid dispersions 
worden vaak toegepast om de oplossnelheid te verbeteren van slecht 
wateroplosbare stoffen. Het is gebleken dat ciclosporine geformuleerd als 
solid dispersion sneller oplost dan puur ciclosporine. Voorts is gebleken 
dat deze formulering zeer goede inhalatie-eigenschappen heeft.[8] 
(tevens bijgevoegd als bijlage) Deze formulering zou dan ook geschikt zijn 
voor de behandeling van patiënten welke een longtransplantatie hebben Appendix 
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ondergaan en niet behandelbare (met de huidige farmacotherapeutische 
opties) chronische afstoting vertonen. Het vernieuwende binnen deze 
mETC aanvraag is dat er droog poeder inhalatie wordt gebruikt in plaats 
van verneveling. Dit zal de therapietrouw moeten verbeteren alsmede de 
effectiviteit. De hulpstof is tevens minder schadelijk (inuline versus 
propyleenglycol) en is de dosis vele malen lager (dagelijks 12,5 mg vs 150 
mg) dankzij verhoogde efficientie. Dit zijn twee belangrijke argumenten 
waarom het onderzoeksgeneesmiddel in het voorliggende protocol een 
beter product is dan de verneveling. Daarnaast is er voor dit 
geneesmiddel een inhaler ontworpen, genaamd de twincer. Het principe 
waarmee de deeltjes in de juiste deeltjesgrootte vrijkomen uit de inhaler 
is eerder gebruikt[9-12] en deze inhaler is een doorontwikkeling 
daarvan.[13] De inhaler bestaat uit vier gedeelten: een bodemplaat met 
daarin ruimte voor de blister en het desintegratieprincipe, een 
middenplaat met daarin het tweede gedeelte van het 
desintegratieprincipe en de topplaat met het mondstuk. Daarnaast 












De Twincer, links de gemonteerde versie, rechts de vier onderdelen los 
(rechts de onderplaats, links de bovenplaat) 
 
Omdat met inhalatie de systemische bijwerkingen in principe kunnen 
worden geminimaliseerd met gelijkblijvende effectiviteit is het de 
bedoeling om uiteindelijk te onderzoeken in hoeverre droog poeder 
inhalatie van ciclosporine ingezet kan worden als standaard behandeling 
van patiënten met longtransplantatie. Voordat er genoeg data 
beschikbaar is om aan te tonen dat dit mogelijk is, zullen verschillende 
onderzoeken plaats moeten vinden. Het voorliggende protocol vormt de iCsA klinisch studie protocol 
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eerste stap binnen dit geheel. Blijkt dat chronische afstoting succesvol 
behandelt kan worden met droog poeder inhalatie van ciclosporine 
bovenop de standaardtherapie zonder extra systemische bijwerkingen dan 
kan de volgende stap gezet worden. Is de behandeling wel effectief dan 
zou een volgende studie antwoord moeten geven op de vraag in hoeverre 
inhalatie van ciclosporine effectief is in het behoud van longfunctie 
terwijl de orale immuunsuppressieve therapie wordt afgebouwd. Indien 
blijkt dat deze studie niet effectief is in het behandelen van chronische 
afstoting dan nog is vervolg onderzoek mogelijk op het voorkomen van 
nierschade door systemische immuunsuppressie of op de lengte van een 
chronische afstoting vrij interval. 
Het is de bedoeling dat dit product uiteindelijk zal worden 
uitgelicenseerd aan een geïnteresseerd bedrijf welke dit dan op de markt 
zou kunnen gaan brengen. 
 
Samenvattend over de wetenschappelijke vraagstelling voor deze studie: 
is droog poeder inhalatie van ciclosporine A effectief in de behandeling 
van chronische afstoting, welke niet behandelbaar is met de huidige 
farmacotherapeutische opties, in patiënten met een longtransplantaat? 
 
DOELSTELLINGEN 
De primaire en de secundaire doelstelling zijn - inherent aan het 
onderzoeksgeneesmiddel en route van toediening - onlosmakelijk met 
elkaar verbonden. Met het onderzoeksgeneesmiddel in dit voorliggende 
protocol wordt getracht een betere behandeling met in ieder geval 
vergelijkbare systemische bijwerkingen (hopelijk, en naar verwachting, 
minder op o.a. de nier) en betere lokale verdraagzaamheid dan eerdere 
formuleringen van geïnhaleerd ciclosporine.  
 
Primaire doelstelling 
De primaire doelstelling van dit onderzoek is het effectief onderdrukken 
van chronische afstoting van de getransplanteerde long. Dit wordt 
bewerkstelligd door inhalatie van ciclosporine als droog poeder als extra 
therapeutische interventie, bovenop de standaardtherapie. De hypothese 
is dat door de lokale toediening van ciclosporine hogere lokale spiegels 
worden bereikt in vergelijking met systemische toediening waardoor het 
immuunsysteeem krachtiger wordt onderdrukt en dat daardoor de 




De secundaire doelstelling is dat de primaire doelstelling wordt gehaald 
zonder extra nefrotoxiciteit. Omdat geneesmiddelen welke op het 
calcineurinesysteem werken vaak nefro- en neurotoxisch zijn, kan 
theoretisch gezien de therapeutische interventie met geïnhaleerd 
ciclosporine in deze proefopzet aanleiding geven tot extra nefrotoxiciteit. 
Dit zou kunnen ontstaan doordat ciclosporine voor een deel door de long 
wordt geabsorbeerd en in de systemische circulatie terechtkomt. De 
verwachting is dat de hoeveelheid geabsorbeerd ciclosporine dermate 
laag is dat dit geen nefrotoxiciteit met zich meebrengt.[14] 
 
Andere doelstellingen 
Om het effect van geïnhaleerd ciclosporine te kunnen correleren aan de 
mate van afstoting is het van belang om naast de therapeutische 
interventie een studie uit te voeren waarin wordt onderzocht hoeveel van 
het poeder op een bepaalde plaats in de longen terechtkomt. Dit zal 
worden bepaald met een depositiestudie in samenwerking met nucleaire 
geneeskunde van het UMCG hetgeen onderdeel is van dit protocol (zie ook 
§8 Radiofarmacon voor depositie). 
 
STUDIE-OPZET 
De studie is als een descriptieve interventiestudie opgezet. Voor dit 
format is gekozen omdat er binnen de kliniek van het UMCG de laatste 
jaren een afname is opgetreden in het aantal patiënten die chronische 
afstoting ervaren en voldoen aan de inclusie- en exclusiecriteria. Naar 
verwachting zijn dit transversaal 5 tot 7 patiënten. Omdat chronische 
afstoting een ernstige complicatie met sterk beperkte levensverwachting 
is en omdat er geen farmacotherapeutische opties meer voorhanden zijn 
voor deze aandoening is gekozen voor een descriptieve, interventie 
studie. Dit betekent dat 5 tot 7 bekende patienten die voldoen aan in- en 





De interventie met droog poeder inhalatie van ciclosporine is in algemene 
zin bedoeld voor patiënten die een longtransplantaat hebben ontvangen 
en heeft als therapeutische indicatie het voorkomen en onderdrukken van iCsA klinisch studie protocol 
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chronische afstoting van de getransplanteerde long. De patiëntenselectie 
voor deze studie is echter strikter, binnen deze studie gaat het om 
patiënten met een getransplanteerde long die reeds een bepaalde mate 
van chronische afstoting hebben ontwikkeld. Voor deze groep patiënten 
zijn er geen (farmaco-)therapeutische opties meer voorhanden en daarom 
neemt dit onderzoeksgeneesmiddel een potentieel belangrijke plaats in 
bij de behandeling van chronische afstoting. 
 
Inclusiecriteria 
•  Leeftijd: ouder dan 18 jaar 
•  Toestemming middels Informed Consent 
•  Primaire longtransplantatie met tacrolimus als 
onderhoudsimmunosuppressivum 
•  Bronchiolitis Obliterans Syndroom (BOS) stadium 1 tot en met 3: 
FEV1 <80% ten opzichte van basisniveau 
•  Minimaal 3 maanden na de laatste gebruikelijke interventie 
wegens BOS 
•  Verslechteren klinisch beeld (FEV1) na laatste gebruikelijke 
interventie wegens BOS 
•   
Exclusiecriteria 
•  Leeftijd: jonger dan 18 jaar 
•  Niet wilsbekwaam 
•  Huidige behandeling bevat ciclosporine 
•  Bronchiolitis Obliterans Syndroom stadium 0: FEV1>80% 
•  Glomerulaire filtratiesnelheid lager dan 30 ml/min 
•  Klinisch stabiele patiënten 
•  Chronische luchtweginfecties in het kader van BOS 
•  Zwangerschap 
 
Aantal patiënten 
Het maximaal aantal haalbare patiënten binnen de kliniek zal worden 
geincludeerd in deze pilot studie. Voorlopige analyses wijzen uit dat dit 
een populatie betreft van 5 tot 7 patiënten welke voldoen aan de in- en 
exclusiecriteria. De ervaring is dat deze patienten zeer gemotiveerd zijn 
om te participeren in onderzoek derhalve is de verwachting dat 5 tot 7 






De interventie bestaat uit inhalatie van CsA als droog poeder, 
geformuleerd als een solid dispersion (definitie solid dispersion: een 
groep geneesmiddelvormen waarin één of meer actieve stoffen 
gedispergeerd zijn over een matrix van een biologisch inerte stof). Deze 
solid dispersion wordt verkregen met sproeivriesdrogen. De formulering 
van CsA in inuline wordt in blisters uitgevuld. De blisters worden 
vervolgens in speciaal daarvoor ontwikkelde single-use inhalatoren 
geplaatst. De blisters zitten daarna vast in de inhalator en kunnen niet 
meer worden verwijderd. De inhalator is dan onderdeel van het 
geneesmiddel en heeft als zodanig dan ook geen type goedkeuring nodig. 
De patient dient twee inhalaties van 12,5 mg per inhalatie tot zich te 
nemen. Een meer gedetailleerde omschrijving is te vinden in §7, 
“onderzoeksgeneesmiddel”.  
In dit onderzoek wordt geen placebo meegenomen omdat de patient in de 
gekozen studie opzet zijn eigen controle is. 
 
Gebruik van co-medicatie 
Het gebruik van het onderzoeksgeneesmiddel als rescue therapie is 
bovenop de bestaande therapie bij chronische afstoting. Dit wordt gedaan 
om een maximaal effect te bewerkstelligen in de behandeling van 
chronische afstoting. Het gebruik van co-medicatie in deze studie is dan 
ook zonder limitaties toegestaan, daar co-medicatie een belangrijke 
component is voor de effectieve behandeling van longtransplantatie 
patiënten. Het gebruik van geneesmiddelen wordt overigens oplettend 
gevolgd door de longtransplantatie-afdeling. Voor de 
bloedspiegelbepaling is echter noodzakelijk dat de patienten niet op 
andere wijze ciclosporine krijgen toegediend dan via inhalatie. 
 
Escape medicatie 
Voor deze groep patiënten zijn er geen farmacotherapeutische opties 
meer mogelijk, derhalve is escape medicatie niet van toepassing. 
Mochten er toch andere alternatieven mogelijk zijn, dan zullen die niet 
door de studie worden beperkt. 




Naam en beschrijving 
Ciclosporine A voor inhalatie. Ciclosporine A is een wit, volumineus 
poeder. Het poeder zit voorverpakt in een gesealde blister welke in een 
gesloten inhaler zit. Na openen van de blister via een treklipje is de 

























Figuur 1. werkingsmechanisme ciclosporine A 
 
Samenvatting van bevindingen uit niet-klinische studies 
Farmacologie 
Ciclosporine bindt aan ciclophylline en dit complex is een potente 
remmer van calcineurine, welke de expressie van een aantal cytokines 
reguleert waaronder interleukine-2 (Figuur 1). In aanwezigheid van 
ciclosporine worden transcriptie factoren van de NFAT (nuclear factor Appendix 
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activated T-cells) familie niet geactiveerd hetgeen resulteert in een 
falende activatie van interleukine-2, een belangrijke T-cel groei factor. 
De cellulaire respons is geinhibeerd op het moment van lymfocyt 
proliferatie. Daarom zou met lokale immuunsuppressieve therapie met 




Er zijn geen specifieke studies verricht waarin geneesmiddelinteracties 
met geinhaleerd ciclosporine zijn onderzocht. Echter, het is te 
verwachten dat er lage systemische opname zal zijn van ciclosporine na 
inhalatie. Na verneveling van ciclosporine is dit ongeveer 5 tot 11% van de 
toegediende dosis. Na droog poeder inhalatie is dit naar verwachting 
ongeveer eenzelfde percentage. Geneesmiddelinteracties met 
ciclosporine na intraveneuze en orale toediening zijn wel goed 
omschreven en dat maakt het mogelijk om uitspraken te doen over 
mogelijke – systemische - interacties. Stoffen welke het CYP3A4 
enzymsysteem beïnvloeden hebben een mogelijk effect op het 
metabolisme van ciclosporine. Daarnaast kunnen stoffen welke het 
CYP450 systeem induceren het metabolisme verhogen en de concentratie 
verlagen van ciclosporine.  
Gebaseerd op de IB tekst van Neoral
® is het volgende een samenvatting 
van geneesmiddelen welke een interactie met ciclosporine hebben. 
Geneesmiddelen welke de ciclosporine-spiegel kunnen verhogen zijn 
calciumblokkers (o.a. diltiazem, verapamil), antimycotica (o.a. 
fluconazol, itraconazol, ketoconazol), antibiotica (o.a. clarithromycine, 
erythromycine), glucocoricosteroiden (methylprednisolon), allopurinol, 
bromocryptine, danazol, metoclopramide, colchicine en amiodaron. 
Geneesmiddelen welke de ciclosporine-spiegel kunnen verlagen zijn 
antibiotica (nafcilline, rifampine), anticonvulsiva (carbamazepine, 
fenobarbital, fenytoine), octreotide en Sint Janskruid. Orlistat verlaagt 
de absorptie van ciclosporine in gezonde vrijwilligers met ongeveer 33%. 
Geneesmiddelen welke een interactie met ciclosporine hebben en tevens 
de renale disfunctie kunnen verergeren zijn NSAID’s, aminoglycosiden, 
melfalan, amfotericine B, tacrolimus, cimetidine en ranitidine. Patiënten 
met psoriasis welke immuunsuppressieve stoffen of lichttherapie krijgen 
zouden niet tegelijkertijd ciclosporine mogen ontvangen omdat er een 
mogelijkheid is op een te sterk onderdrukt immuunsysteem. iCsA klinisch studie protocol 
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Ciclosporine kan ook een effect hebben op de spiegels van andere 
geneesmiddelen. De methotrexaat-spiegel stijgt 30% en de spiegel van de 
7-hydroxymetaboliet stijgt zelfs 80% bij gelijktijdig gebruik van 
ciclosporine. Er treedt een verlaagde klaring op van prednisolon, digoxine 
en lovastatine bij gebruik van ciclosporine. Ciclosporine mag niet worden 
gebruikt in combinatie met kaliumsparende diuretica omdat 
hyperkaliemie op kan treden. Vaccinatie kan verminderd effectief zijn bij 
gelijktijdig gebruik van ciclosporine en het gebruik van “levende” vaccins 
zou moeten worden vermeden. 
 
Niet klinische farmacokinetiek en metabolisme 
Met betrekking tot het onderzoeksgeneesmiddel van het hier voorliggende 
protocol zijn er geen dierstudies uitgevoerd. Wel zijn er dierstudies 
uitgevoerd met verneveld ciclosporine en deze gegevens worden hier 
gebruikt om informatie te verschaffen over ciclosporine na inhalatie. 
Deze dierstudies zijn uitgevoerd om te bepalen wat de werkzaamheid is 
van verneveld ciclosporine in long transplantatie modellen. Het bleek dat 
gezonde ratten na een eenmalige dosering van 3 mg/kg verneveld 
ciclosporine een 100-200x hogere longweefselconcentratie van 
ciclosporine hadden in vergelijking met lever, nier, hart en bloed. Na 24 
uur was residueel ciclosporine alleen aanwezig in het long parenchym. 
Het oppervlak onder de curve (AUC0-∞) was ongeveer 46.000 ng·uur/gr in 
de long en 2.500 ng·uur/gr in bloed. Dit betekent dat de totale 
hoeveelheid in de long ongeveer een factor 20 hoger is dan in het bloed. 
In een model waarin de linkerlong was getransplanteerd in de rat gaf een 
dagelijkse dosis van 18 mg/kg een depositie van 3,6 mg/kg/dag.[15] Na 7 
doses waren de ratten beschermd tegen allograft rejectie (gemiddelde 
graad 1,2±0,4; p<0,05) wat beter was dan intramusculair toegediend 
ciclosporine (gemiddelde graad 1,8±0,38). De schaal liep van 0, geen 
allograft rejectie, tot 4, vasculaire trombose and intra-alveolaire 
bloedingen. Als laatste is een studie in ratten uitgevoerd waarin 
onderzocht is in hoeverre verneveling of intramusculaire injectie van 
ciclosporine effectief was in het tegengaan van rejectie. [16] De 
resultaten toonden aan dat een systemische dosis van 15 mg/kg 
(intramusculair toegediend) ciclosporine een gelijkwaardige rejectie-







Systemische toediening: De systemische toxiciteit van ciclosporine is goed 
onderzocht in mens en dier. De farmacologische werkzaamheid en 
toxiciteit na systemische blootstelling in dieren zijn vergelijkbaar met de 
effecten in de mens.[17-20] De belangrijkste ongewenste effecten in de 
mens zijn, na toediening van klinisch relevante doseringen, renale 
disfunctie, hypertensie, dislipidemie, hirsutisme en tremor. Daarnaast 
bestaan een aantal minder vaak voorkomende bijwerkingen als 
hyperkaliemie en thrombocytopenie. 
Pulmonale toediening:  Er is een beperkte hoeveelheid gepubliceerde 
literatuur beschikbaar over de lokale toxiciteit (respiratoir systeem) van 
geïnhaleerd ciclosporine in dieren.[6] De primaire data over toxiciteit na 
pulmonale toediening is afkomstig uit twee belangrijke 28-daagse 
inhalatie-toxiciteit studies in ratten en honden. In deze studies werden de 
dieren maximaal tolereerbare (rat) of maximaal haalbare (hond) doses 
toegediend. Dit levert belangrijke informatie over de veiligheid van 
ciclosporine na inhalatie bij een maximale dosis en levert een schatting 
over de “worst case” toxiciteit. 
 
In de 28-daagse inhalatie studie in ratten kregen de dieren doses van 7,4, 
24,3 en 53,8 mg/kg ciclosporine per inhalatie (verneveling) toegediend. 
Er waren behandeling-gerelateerde hematologische, serum en nier 
bevindingen welke overeenkomstig zijn met systemische blootstelling 
maar geen pulmonaire abnormaliteiten na histologische controle.  
 
In de 28-daagse inhalatie studie in honden werden de dieren gedoseerd 
met 4,4, 7,6 en 9,6 mg/kg ciclosporine middels verneveling. Bij de hoge 
dosis was de respiratoire flowrate lager dan bij de andere groepen, 
hierdoor had de hoge dosis groep een geschatte vergelijkbare depositie 
als de groep met de middelste dosering. Dit toonde aan dat een langere 
doseertijd niet resulteerde in substantieel verhoogde toediening. Er 
waren geen ciclosporine-gerelateerde bijwerkingen. In honden werden 
geen klinisch relevante bijwerkingen in het respiratoire systeem 
gevonden. 
Microscopisch onderzoek toonde in de groep met de middelste en hoogste 
dosering minimale en lokale ulceraties van het laryngeale slijmvlies aan, 
welke gepaard gingen met ontsteking. Deze ontstekingen waren iCsA klinisch studie protocol 
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gemiddeld genomen ter grootte van een speldenpunt in een overig 
normaal uitziende larynx. Andere honden hadden geen laryngeale 
ontstekingen, hetgeen er op duidt dat de ontsteking niet duidelijk te 
relateren was aan de behandeling. 
 
Inuline 
Inuline is een natuurlijke grondstof die voorkomt in onder andere chigorij 
(witlof). Chemisch gezien bestaat inuline uit een glucose-eenheid die 
gepolymeriseerd is met fructose-eenheden (GFn) (Figuur 2). Binnen de 
farmaceutische wereld is inuline nog nooit in inhalatie toegepast, daarom 
is er ook weinig informatie over de veiligheid van inuline. Inuline wordt 
daarentegen veel gebruikt in de voedselindustrie en wordt ook gebruikt 

















Figuur 2. structuurformule inuline 
 
Er is één artikel [26] welke de toxicologie van carboxymethylinulines 
(chemisch gemodificeerde inulines) beschrijft. In de betreffende studie is 
de sub-acute (4 weken) orale toxiciteit bepaalt in ratten tot een dosering 
van 1000 mg/kg/dag. Er werden geen behandelingsgerelateerde effecten 
gezien op lichaamsgewicht, voedselconsumptie, mortaliteit, hematologie, 
klinisch bloed beeld, gewicht van organen en pathologie. Verder 
veroorzaakte carboxymethylinuline geen dermale sensitisatie (als getest Appendix 
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met cavia’s) en mutagene activiteit (getest met Salmonella stammen en 
Escherichia coli). De resultaten met carboxymethylinuline zijn 
vergelijkbaar met andere natuurlijk voorkomende carbohydraten 
(sorbitol, sucrose, glucose) en oligofructoses. Derhalve is aannemelijk dat 
inuline geen toxiciteit in de gegeven dosering zal veroorzaken. De 
blootstelling aan inuline is in deze studie 12,5 mg/dag, wat overeenkomt 
met circa 0,18 mg/kg/dag voor een persoon van 70 kg. In §7.3.3.2 zal 
verder ingegaan worden op de veiligheid van inuline. 
 
Samenvatting van bevindingen uit klinische studies 
Samenvatting van uitkomsten uit klinische studies 
In dit protocol is de studiemedicatie een poeder voor inhalatie. Met dit 
poeder zijn nog geen klinische studies uitgevoerd, maar wel met vloeistof 
voor verneveling welke ontwikkeld is door Chiron ontwikkeld als vloeistof 
voor verneveling. De laatste klinische studie heeft uiteindelijk 
geresulteerd in een New Drug Application (NDA 50-799) bij de FDA. De 
belangrijkste studie waarop NDA 50-799 is gebaseerd is een mono-center, 
gerandomiseerde en dubbel blinde klinische studie (ACS 001). Deze was 
ontworpen om de effectiviteit van geïnhaleerd ciclosporine op het 
verlagen van transplantaat-rejectie en verbeteren van de resultaten van 
long transplantatie. De klinische studie bevatte twee fasen: een initiele 
open label pilot fase en vervolgens een geblindeerde en gerandomiseerde 
fase. In de pilot fase ontvingen 10 patienten open label verneveld 
ciclosporine en werden vervolgens prospectief gevolgd om de veiligheid 
en tolereerbaarheid te onderzoeken. In de gerandomiseerde fase werden 
56 patienten geincludeerd binnen 7 tot 42 dagen na enkele of dubbele 
long transplantatie en behandeld met ofwel verneveld ciclosporine of 
placebo. Van de 56 patienten ontvingen 26 patienten ciclosporine in 
propyleenglycol en 30 alleen propyleenglycol. 
 
Alle patiënten ondergingen een initiele dosis-titratie periode om de 
maximaal verdraagbare dosis te vinden tot een maximum (protocollair 
vastgelegd) van 300 mg. Na deze 10-daagse periode dienden de patiënten 
de therapie drie keer per week te gebruiken voor een periode van twee 
jaar. Gedurende 24 tot 46 maanden vond follow-up plaats. 
 
Van de placebogroep stierf 47 procent van de patiënten tegen 12% van de 
met ciclosporine-verneveling behandelde patiënten (Figuur 3). Dit iCsA klinisch studie protocol 
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resultaat is een zowel klinisch als statistisch significante (log-rank 
P=0,007) verbetering. De niet-aangepaste schatting van het risico op dood 
onder de ciclosporine patiënten ten opzichte van placebo was 0,213 (95% 
betrouwbaarheidsinterval= 0,061; 0,743), hetgeen een reducite betekent 
van 79% op het overlijdensrisico als patiënten met verneveld ciclosporine 
worden behandeld. Het gevonden resultaat bleef men ook zien na 
stratificatie op transplantaattype, primaire diagnose, cytomegalovirus 
(CMV) positieve/negatieve donor match of mismatch of het optreden van 
















Figuur 3. Geschatte duur van overleving van long transplantaat; alle 
gerandomiseerde en behandelde patiënten 
 
De werkzaamheid van verneveld ciclosporine wordt toegekend aan een 
verlaagde incidentie van chronische afstoting, in lijn met de lokale 
toediening van ciclosporine naar het luchtweg-epitheel. Patiënten welke 
behandeld waren met verneveld ciclosporine hadden een sterk verbeterde 
chronische afstoting vrije overleving in vergelijking met patiënten welke 
behandeld waren met placebo. Chronische afstoting werd 
gediagnosticeerd met ofwel een biopsie en onderzoek op obliterans 
bronchiolitis (histologisch onderzoek) ofwel klinisch op de aanwezigheid 
van het bronchiolitis obliterans syndroom (een onverklaarbare daling in 
FEV1 van 20% of meer). Binnen de placebogroep overleefde slechts 8% van 
de patiënten zonder chronische afstoting tegen 69% van de groep die Appendix 
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verneveld ciclosporine kreeg. Het risico op chronische rejectie of dood 
was 28% onder de ciclosporinegroep ten opzichte van de placebogroep 
(95% betrouwbaarheidsinterval=0,124; 0,630). 
 
Klinische farmacokinetiek en metabolisme 
Met het vernevelde en droog poeder product zijn geen distributiestudies 
uitgevoerd. Vanwege de toedieningsroute (inhalatie) kan echter wel 
worden verwacht dat in de longen de hoogste concentratie zal worden 
bereikt. Deze concentratie zal hoger zijn dan die verkregen met andere 
toedieningsroutes. Ciclosporine wordt wel geabsorbeerd via de long en 
gedistribueerd door het lichaam. Ciclosporine passeert de placenta en 
bevindt zich ook in moedermelk. Preferentiële opname van ciclosporine 
vindt plaats in de lever, pancreas en vetweefsel. Vanwege de lipofiliteit 
van ciclosporine wordt de bloed-hersen barriere nauwelijks gepasseerd. In 
plasma is de concentratie van ciclosporine omgekeerd evenredig met de 
hematocriet concentratie in het bloed. Ongeveer 33% tot 47% van het 
systemische ciclosporine wordt gevonden in plasma, 4% tot 9% in 
lymfocyten, 5% tot 12% in granulocyten en 41% tot 58% in erythrocyten. In 
plasma is ongeveer 90% gebonden aan lipoproteinen. Geneesmiddelen 
welke de binding van ciclosporine aan lipoproteinen beïnvloeden kunnen 
ook de klinische werkzaamheid beïnvloeden. 
Uit Burckart et al [27] kan worden gevonden dat de tijd tot maximale 
concentratie na verneveling (Tmax) 0,68 (±0,30) uur is. De halfwaardetijd 
is 40,7 (±17,7) uur. De uitgebreide biotransformatie van ciclosporine leidt 
tot ongeveer 15 metabolieten. Biotransformatie vindt hoofdzakelijk 
plaats door middel van het cytochroom P450 afhankelijke mono-
oxygenase systeem in de lever. De belangrijkste biotransformatie bestaat 
uit de mono- en dihydroxylering en N-demethylering van ciclosporine. 
Geneesmiddelen welke het CYP450 remmen of induceren kunnen de 
spiegels van ciclosporine verhogen of verlagen. De tot nu geidentificeerde 
metabolieten bevatten de intacte eiwitstructuur van de oorspronkelijke 
stof; sommige bezitten een zwakke immuunsuppressieve werking (tot een 
tiende van de onveranderde stof). De eliminatie kinetiek van ciclosporine 
is doorgaans variabel en gerelateerd aan het ziekteproces, de toestand 
van het getransplanteerde orgaan en de co-medicatie. Daarom is 
regelmatige controle van de bloedspiegels belangrijk. iCsA klinisch studie protocol 
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De uitscheiding van ciclosporine vind hoofdzakelijk via de gal plaats, 
terwijl slechts 6% van een systemische dosis wordt uitgescheiden via de 
urine. 
 
Veiligheid en effectiviteit in mensen 
Veiligheid en effectiviteit ciclosporine 
Uit de ACS001 studie van NDA 50-799 is gebleken dat ciclosporine een 
goed veiligheidsprofiel heeft. Lange termijn toedieningen leidde niet tot 
exacerbaties van bekende toxiciteit na orale of intraveneuze toediening. 
Specifiek gezien was er geen bewijs voor een verhoogd risico op 
nefrotoxiciteit, neurotoxiciteit, een verhoogde kans op infecties, of een 
verhoogd risico op maligniteiten. De vernevelvloeistof werd wel 
geassocieerd met irritatie van de longen en bronchospasmen, maar de 
bijwerkingen waren over het algemeen mild tot matig van aard en 
begonnen vroeg na de start van de therapie. De bijwerkingen leidden niet 
tot ernstige respiratoire complicaties. 
Omdat het onderzoeksgeneesmiddel in dit protocol geen propyleenglycol 
bevat zoals het product beschreven in NDA 50-799 zullen er vooral 
uitspraken worden gedaan over de veiligheid van ciclosporine per 
inhalatie. Overigens is van propyleenglycol gerapporteerd dat het irritatie 
en bloedingen kan veroorzaken in honden en ratten (zie 2
e alinea, pagina 
7 van [7], bijgevoegd als bijlage). Omdat inuline nog niet is toegepast in 
inhalatie zal hier nog nader op in worden gegaan. 
De data over veiligheid van ciclosporine per inhalatie is afkomstig uit 
twee studies: ACS001 en ACS002 (NDA 50-799). In studie ACS001 waren 66 
patienten geincludeerd en in ACS002 (een safety studie) waren 70 
patienten geincludeerd in 1 van de 7 protocol-armen.  
Vanuit ACS001 rapporteerden alle patiënten één of meer AE’s en AE’s 
werden ingedeeld in 24 van de 26 MedDRA System Organ Classes (SOCs). 
De meeste SOCs bevatten meer dan 35% van de patiënten (zie tabel 1). 
 
Het grootste aantal gemelde bijwerkingen was afkomstig uit de 
Respiratoir/Thorax/mediastinum classificatie. Van de placebogroep gaf 
97% van de patiënten aan hier bijwerkingen te ervaren (dit moet 
afkomstig zijn van propyleenglycol) tegen 100% van de ciclosporinegroep. 
Het bleek dat er een syndroom van bronchiale irritatie en 
luchtwegobstructie optrad in de ciclosporinegroep. De groep welke 
ciclosporine per verneveling kreeg had een hogere incidentie van Appendix 
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bronchospasmen, hoest, geexacerbeerde dyspnoe, excessieve bronchiale 
secretie, luchtweginfecties en als irritant ervaren piepen. Dit was 
waarschijnlijk een direct effect van ciclosporine in de luchtweg en was 
niet verwacht gezien de route van toediening. De overgrote meerderheid 
van de patiënten merkte op dat dit type bijwerkingen vooral optrad bij 
aanvang van de medicatie, tijdens de dosis-escalatie fase. De meeste 
patiënten hadden aanvakelijk premedicatie als bronchodilatoren en lokale 
anesthesie nodig, maar het gebruik hiervan werd verminderd na 10 dagen 
therapie. Bronchiale reactiviteit lijkt de belangrijkste bijwerking te zijn 
van geïnhaleerd ciclosporine. 
 
Tabel 1. Bijwerkingen na verneveling van ciclosporine 
MedDRA  
System Organ Class 
Adverse Event  Placebo  Ciclosporine-
verneveling 
      (n=30)  (n=26) 
Oog  Wazig zien  8 (27%)  15 (42%) 
Gastrointestinaal Overgeven  0  4  (11%) 
Plaats van toediening  Borstpijn  6 (20%)  15 (42%) 
Onderzoek hartruis  0  6  (17%) 
Metabolisme/voeding Hyperlipidemie  0  5  (14%) 
Musculatuur/bind-        
   weefsel/bot  Rugpijn  3 (10%)  12 (33%) 
Centraal zenuwstelsel  Slaperigheid  0  6 (17%) 
Psychiatrie Verwardheid  0  4  (11%) 
Renaal/urinaal  Alle  19 (63%)  29 (81%) 
   Frequentie van urineren  5 (17%)  14 (39%) 
   Polyurie  1 (3%)  6 (17%) 
Voortplantingssysteem  Alle  4 (13%)  10 (28%) 
Respiratoir/thorax/ 
   mediastinum  Acuut respiratoir falen  0  4 (11%) 
   Hoest  8 (27%)  18 (50%) 
   Geexcacerbeerde dyspnoe  4 (13%)  11 (31%) 
   Pharyngitis  5 (17%)  14 (39%) 
   Respiratoire stoornis  0  7 (19%) 
   Ademhalingskanaal stoornis  1 (3%)  6 (17%) 
 iCsA klinisch studie protocol 
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Uit ACS002 is gebleken dat de SAE’s niet het gevolg zijn van inhalatie van 
ciclosporine. De gerapporteerde bijwerkingen in deze studie waren 
vergelijkbaar met die in ACS001. 
De reden waarom patiënten de studie niet af konden maken was het 




Veruit de meeste informatie over inuline is bekend uit de 
voedselindustrie. Meestal betreft het dan gegevens over orale toediening. 
Inuline wordt niet opgenomen in het maagdarmkanaal (niet verteerbaar) 
en wordt veel gebruikt als vet en suiker vervanger voor diverse 
producten. Als zodanig wordt de dagelijkse inname van inuline geschat (in 
Europa en de Verenigde Staten) op 3 tot 11 gram. Dit feit is de hoeksteen 
van de veiligheidsoverwegingen van inuline. Voorzover bij ons bekend zijn 
er in de literatuur geen specifieke aanwijzingen om de veiligheid van 
inuline te betwijfelen. Hoewel dit geen bewijs is van veiligheid is het wel 
een comfortabel feit.[21-23, 28, 29] 
Uiteraard wordt inuline in de voedselindustrie alleen oraal ingenomen. 
Het feit dat het een niet verteerbaar molecuul is maakt dat het 
systemisch gezien niet wordt opgenomen. Na orale inname wordt het via 
de faeces weer uitgescheiden. Dit is uiteraard anders na bijvoorbeeld 
inhalatie of injectie. Het verloop van inuline is dan anders. Inuline wordt 
al sinds 1931 gegeven als intraveneuze injectie om de glomerulaire 
filtratiesnelheid (GFR) te bepalen. Dit is een standaard procedure 
geworden zonder enige toxiciteitseffecten.[24, 25] Tot op heden is deze 
methode de referentiemethode wanneer andere procedures getest 
worden om de GFR te meten.[24] Inuline is een ideale stof om de GFR te 
bepalen omdat inuline vrijelijk wordt gefilterd door de nieren van de 
bloedbaan, niet wordt gemetaboliseerd en geen tubulaire secretie of 
absorptie ondergaat. Met andere woorden, wanneer inuline in de 
bloedbaan aanwezig is wordt het gefilterd door de nieren en onveranderd 
uitgescheiden in de urine. Na inhalatie zal een deel worden opgenomen in 
de bloedbaan (net als ciclosporine) en een deel zal worden geklaard via 
het maagdarmkanaal. In het eerste geval zal inuline volledig oplossen en 
geklaard worden via de longmembraan. Daarna vindt filtering in de nier 
plaats en wordt inuline via de unrine onveranderd uitgescheiden. In het 
tweede geval zal een deel direct van de formulering direct worden Appendix 
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ingeslikt (dat gedeelte wat niet in de long terechtkomt) en een deel zou 
via de mucociliaire lift naar het maagdarmkanaal worden gebracht. In dit 
geval zal inuline onveranderd via de faeces worden uitgescheiden. Er zal 
in ieder geval geen accumulatie plaatsvinden van inuline in het lichaam 
dankzij de goede wateroplosbaarheid. 
In 1992 heeft een commissie van experts middels een review van tot dan 
gepubliceerde studies dan ook geconcludeerd dat “er geen reden is om te 
geloven dat oligofructoses of hun metabolieten potentieel toxisch zijn 
door vergroot gebruik in voedsel; in tegendeel, recente bevindingen 
beschrijven de gezondheidsbevorderende voedingseigenschappen van 
deze stoffen”. In 2002 heeft de FDA een Generally Regarded as Safe 
(GRAS) statement gegeven over inuline.[30] 
Bij de vakgroep farmaceutische technologie en biofarmacie is wel 
eenmalig inuline via inhalatie toegediend aan muizen om te onderzoeken 
in hoeverre dit effect had op de pathologie van longweefsel; dit bleek 
niet verschillend te zijn van muizen die niets kregen.[Data on file] 
Gezien de gegevens die tot op heden bekend zijn over inuline wordt het 
gelegitimeerd geacht om inuline te gebruiken als farmaceutische 
hulpstof. Uiteraard is bekend dat het gebruik van een nooit eerder 
gebruikte hulpstof een bepaald risico met zich meedraagt, maar dat risico 
is volgens de onderzoekers verwaarloosbaar. 
 
Samenvatting bekende en mogelijke risico’s en voordelen 
Hoewel alle data tot nu toe is gegenereerd uit verneveling van 
ciclosporine in één centrum, is gebleken dat inhalatie van ciclosporine 
effectief is in het verlagen van mortaliteit door het verminderen van de 
incidentie van chronische rejectie. Dit is ook gebleken uit andere 
studies.[4, 5]  
De risico’s van inhalatie van ciclosporine zijn klein. Zo is de systemische 
concentratie na verneveling van ciclosporine minder dan 15% van de 
systemische concentratie na orale toediening. Een vergelijkbare ratio is 
te verwachten na droog poeder inhalatie. Deze lage systemische 
concentratie geeft geen aanleiding tot extra systemische toxiciteit als 
nefrotoxiciteit, neurotoxiciteit en maligniteiten. 
De bijwerkingen van ciclosporine na verneveling (vergelijkbaar met droog 
poeder inhalatie) waren hoofdzakelijk pulmonaal gerelateerd. Het meest 
genoemd werden hoest, piepen, en dyspnoe en waren 
hoogstwaarschijnlijk gerelateerd aan bronchospasmen.  iCsA klinisch studie protocol 
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Ciclosporine is een standaardbehandeling voor meer dan 20 jaar. Het 
veiligheidsprofiel van ciclosporine is goed bekend en het is daarom 
onwaarschijnlijk dat er nog nieuwe systemische toxiciteiten gevonden 
zullen worden. 
 
Beschrijving en rechtvaardiging toedieningsroute en dosering 
Als route voor toediening is gekozen voor inhalatie. Vanwege de ernstige 
toxiciteit in de klinisch gehanteerde orale doses na longtransplantatie is 
het verlagen van de systemische dosis prioriteit één. Dit leidt vaak tot 
dosisaanpassingen op geleide van het klinische beeld (graad van afstoting 
en nierfunctie). Met een slechte nierfunctie is de dosis dermate laag dat 
het risico op chronische afstoting drastisch toeneemt. Door ciclosporine 
per inhalatie aan te bieden kan de systemische dosis laag worden 
gehouden en wordt een situatie bereikt waarin optimale bescherming 
tegen chronische afstoting met weinig systemische toxiciteit hand in hand 
gaan. Dit verlaagt de mortaliteit en morbiditeit. 
Uit literatuur is gebleken dat meer dan 5 mg ciclosporine in de longen 
effectief is in het verminderen van chronische afstoting. Het wordt 
geschat dat de depositie na inhalatie van het poeder ongeveer 40% is, dat 
wil zeggen dat 40% van de aangeboden dosis op de plaats van werking 
komt. Daarnaast is het gehalte aan ciclosporine in de formulering 50%. 
Met deze gegevens kan worden teruggerekend wat de dosering dient te 
zijn: 
De dosis is (100%/40%)*(100%/50%)*5 mg= 25 mg van een 50% 
ciclosporine/50% inuline formulering. Dit wordt gegeven in twee of drie 
doses van ieder 12,5 mg poeder. 
 
De getallen en schattingen zijn als volgt verkregen. Uit de literatuur 
(verneveling) blijkt dat minimaal 5 mg CsA nodig is in de longen om 
effectiviteit te halen. Uit eerder onderzoek over droog poeder inhalatie 
van colistine[31, 32] is gebleken dat droog poeder inhalatie met behulp 
van een op een air classifier gebasseerde inhaler zeer effectief is. In deze 
studie wordt eenzelfde soort inhaler gebruikt. Het is gebleken dat 25 mg 
droog poeder inhalatie effectiever was dan verneveling van 160 mg 
colistine wanneer gebruik werd gemaakt van een inhaler met een air 
classifier. Er werd bij droog poeder inhalatie een hogere serum 
concentratie gemeten en Tmax was eerder bereikt bij droog poeder 






































) Verneveld CsA (300 mg, depositie 10%)
DPI CsA (25 mg, gehalte 50%, depositie
40%)
depositie van ciclosporine A als droog poeder geschat op 40%. Daarnaast is 
de farmacokinetiek van ciclosporine na verneveling en droog poeder 
uitgerekend op basis van in de literatuur gevonden waarden en 
schattingen. Voor verneveling zijn alle benodigde gegevens bekend: dosis 
(300 mg), dosisopbouw (1
e dosis is 100 mg, 2
de dosis is 200 mg, 3
de en 
volgende doses zijn 300 mg), doseerfrequentie (eens in de twee dagen), 
depositie (10%) en halfwaardetijd (40,7 uur). Voor droog poeder inhalatie 














Figuur 4. Berekende en geschatte farmacokinetiek van ciclosporine als 
verneveling en droog poeder inhalatie 
 
Dosis: 12,5 mg per inhalatie 
Frequentie: 2x per dag 
Gehalte CsA in formulering: 50% 
Depositie: 40% 
Uit Figuur 4 blijkt dat de hoeveelheid ciclosporine opbouwt in de loop van 
de tijd, na circa 100 uur is een stabiele spiegel bereikt van ca. 10 mg. Dit 
ligt boven de beschreven spiegel van 5 mg en wordt dus als voldoende 
geacht. Indien de depositie van droog poeder inhalatie lager blijkt te zijn, 
dan dient na heroverweging de dosis op geleidde van de depositiestudie 
aangepast te worden. 
 
Doseringen, dosisaanpassingen en methode van toediening  
Ciclosporine-poeder voor inhalatie wordt dagelijks in twee of drie doses 
gegeven van 12,5 mg elk. Iedere dosis bevat 6,25 mg ciclosporine en       iCsA klinisch studie protocol 
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6,25 mg inuline. Ciclosporine wordt via inhalatie, als droog poeder, te 
worden toegediend.  
Routinematig zal de ciclosporine-spiegel in patiënten worden gemeten. 
Daarnaast wordt er bij de start van de studie een depositiestudie 
uitgevoerd. Van alle geincludeerde patienten wordt de depositie bepaald. 
Op basis van het gemiddelde wordt het aantal doses bepaald. Alle 
patienten worden met dezelfde dosis behandeld (dwz 2 of 3 doses per 
dag). Is de depositie gemiddeld lager dan 40% dan worden drie doses 
gegeven en is de depositie hoger dan 40% dan wordt voor twee doses 
gekozen. 
Dosisaanpassingen worden gegeven per inhaler (12,5 mg poeder). Een te 
lage dosis is het minst wenselijk, een hoge dosis is minder gevaarlijk 
gezien de berekende farmacokinetiek (Fig 4). Ten aanzien van de 
hoeveelheid doses kan worden gemeld dat twee doses met een depositie 
van 40% dezelfde berekende piekspiegels geeft als drie doses met een 
depositie van 30%. 
 
Productie en etikettering van onderzoeksgeneesmiddel 
Het geneesmiddel wordt onder verantwoordelijkheid van de 
ziekenhuisapotheek geproduceerd onder de geldende kwaliteitsnormen 
(GMPz). De betreffende productieruimtes zijn vrij gegeven voor productie 
en er wordt gewerkt met productieprotocollen. Voordat tot productie is 
overgegaan, wordt het product onderworpen aan ontwerpkwaliteit waarin 
zaken als grondstoffen, farmacologie, werkzaamheid en dergelijke aan 
bod komen. Hiertoe is een dossier aangelegd. 
 
Drug accountability 
Voor de logistiek van het onderzoeksgeneesmiddel draagt de 
ziekenhuisapotheek van het UMCG zorg. Per patient wordt na het eerste 
bezoek voor twee weken aan geneesmiddel meegegeven. Na het tweede 
bezoek is dat steeds voor 4 weken. Bij ieder bezoek dient de patient de 
gebruikte inhalatoren te retourneren aan de behandelend arts die ze 
vervolgens aan de ziekenhuisapotheek doet toekomen. Door telling van 
uitgegeven en geretourneerde inhalatoren kan per patient het 




RADIOFARMACON VOOR DEPOSITIE 
Voor het vaststellen van de dosis is het van belang om te weten welk 
percentage van het geneesmiddel in de longen komt (zie ook §9.1.3.1; 
depositie en §3.3 Andere doelstellingen). Er is uitgegaan van een 
theoretisch percentage van 40%; met dat percentage is een dosis geschat 
van twee maal daags 12,5 mg (zie ook §7.5). Het doel van de 
depositiestudie is drieledig: 
1)   De patienten krijgen een inhalatie-instructie en feedback over hun 
inhalatie-manoeuvre. 
2)    De onderzoekers krijgen inzicht over de depositie van het 
onderzoeksgeneesmiddel en efficientie van de inhaler wat kan 
leidden tot eventuele verbeteringen. 
3)    De depositiestudie kan aanleiding geven tot dosisaanpassingen 
zodat onder- en overdosering kan worden voorkomen. 
 
Het onderzoeksgeneesmiddel wat gebruikt wordt voor het meten van de 
depositie is de bestaande formulering waarin ciclosporine A vervangen is 
door Amerscan Hepatate II Agent ([
99mTc]-technetium-tincolloid), een 
geregistreerd middel. 
99mTechnetium/tincolloid wordt geproduceerd door 
radiofarmacie, afdeling Nucleaire Geneeskunde in het UMCG onder 
verantwoordelijkheid van de ziekenhuisapotheek. Bereiding van het 
poeder voor inhalatie is identiek aan bereiding poeder met ciclosporine 
alleen dan met radioactiviteit. In verband met het gebruik van 
radioactiviteit zal deze bereiding plaatsvinden in het B/lab van de 
radiofarmacie op de afdeling Nucleaire Geneeskunde. De dosis die de 
patienten binnen zullen krijgen is ongeveer 50 MBq. Het middel dient te 
voldoen aan de vigerende eisen als gesteld in de Europese Pharmacopee 
en wordt dan ook als zodanig getest. De stralingsbelasting van de patient 
is geschat op 1,7 mSv na een dosering van 50 MBq. De schatting voor de 
stralingsbelasting is als volgt tot stand gekomen. Bij inhalatie van het 
99mTc-gelabelde micro-sferen zal 90% in de long worden opgenomen, 10% 
blijft in de inhalator. Bovendien zal er geen overdracht naar het bloed 
plaatsvinden. Voor de stralingsbelasting van een dergelijk ligand kan het 
Effective Dose Equivalent (EDE, ICRP 53 p. 10) op grond van het 
farmacologisch gedrag worden uitgerekend. Aangenomen wordt dat 50% 
van de gamma energie in het longweefsel wordt gedeponeerd. Dit 
betekent dat er per toegediende MBq No= 2.805E+10 kernen zullen 
vervallen in het longweefsel. De stralingsbelasting wordt dan 2.8-04 iCsA klinisch studie protocol 
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J/MBq in de long. Bij een gewicht van 1 kg (MIRD) wordt de 
stralingsbelasting van de long 0.28 mSv/MBq. Voor de bijdrage tot het 
EDE moet gerekend worden met een gewichtsfactor van 0.12 (ICRP 53). 
Daar er geen verdere verspreiding door het lichaam plaatsvindt is de EDE 
voor 
99mTc-microsferen 0.034 mSv/MBq. Bij een dosering van 50 MBq 
wordt de stralingsbelasting 1.7 mSv (EDE). 
 
Het meten van de depositie gebeurt na inhalatie van het radioactieve 
onderzoeksgeneesmiddel (zonder ciclosporine) via de inhaler die ook 
gebruikt wordt in de rest van de studie. Enkele minuten na inhalatie 
wordt door de afdeling Nucleaire Geneeskunde anterior en posterior een 
statische scan opgenomen. Ook de inhalaer wordt gemeten. De scan 
wordt vervolgens uitgewerkt door de afdeling Nucleaire Geneeskunde 
(mond/keel holte, long perifeer en centraal en inhaler) om een 
massabalans te kunnen bepalen van het radioactief gelabelde poeder. 
 
Het bepalen van depositie van droog poeder inhalatie met technetium is 
iets wat al geruime tijd gebeurt.[33-35] Het is een geruststellend feit dat 
vaker studies zijn uitgevoerd met technetium in het kader van depositie 
van droog poeder inhalatie. In het hier gebruikte proces wordt 
technetium ingesloten in het deeltje voor inhalatie en is daarom 
uitermate geschikt voor het uitvoeren van de depositie bepaling omdat 
technetium terecht zal komen daar waar ook het geneesmiddel terecht 
komt. Gezien de verwachting met het onderzoeksgeneesmiddel zal er ook 
in het geval van het radiofarmacon niets achterblijven in de long en 




Primaire studie parameter/eindpunt 
De primaire studieparameter is de “Forced Expiratory Volume in the first 
second” (FEV1). Deze waarde vormt de basis voor de stadiëring van het 
bronchiolitis obliterans syndroom, zie tabel 2.[36] 
In deze studie worden patiënten met ongestoorde transplantaatfunctie 
(BOS 0 stadium) niet blootgesteld aan het onderzoeksgeneesmiddel. De 
reden hiervoor is dat ciclosporine als rescue therapie wordt ingezet, dat 
wil zeggen bij die patienten waar geen farmacotherapeutische opties 
meer voorhanden zijn. Uit de literatuur is bekend dat na vernevelen van Appendix 
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ciclosporine (300 mg CsA in propyleen glycol) de afname van de FEV1 in de 
loop van de tijd (chronische afstoting is een progressief verslechterende 
aandoening) kan worden geremd.[38, 39] In deze studie willen we 
hetzelfde voor de droog poeder inhalatie proberen te bewerkstelligen. 
Indien de afname in FEV1 kan worden geremd ten opzichte van het FEV1 
beloop voorafgaand aan de interventie is droog poeder inhalatie van 
ciclosporine effectief. Deze internationaal erkende benadering [36] is 
aangegeven in de onderstaande figuur 5. 
 
Tabel 2. Stadium BOS en correlatie met longfunctie 
BOS stadia  Longfunctie 
BOS 0  FEV1>90% t.o.v. basislijn en FEF25-75>75% t.o.v. basislijn 
BOS 0-p  FEV1 81%-90% t.o.v. basislijn en/of FEF25-75≤75% t.o.v. basislijn 
BOS 1  FEV1 66%-80% t.o.v. basislijn 
BOS 2  FEV1 51%-65% t.o.v. basislijn 
BOS 3  FEV1 <50% t.o.v. basislijn 
 
Secundaire studie parameter/eindpunt 
Inhalatie van ciclosporine bovenop de bestaande therapie mag geen extra 
nefrotoxiciteit mag veroorzaken. Nierfunctie wordt standaard bij elke 
poliklinische controle gemeten (serumkreatinine) en bovendien met 
behulp van de glomerulaire filtratie snelheid (GFR) voorafgaand aan en 
bij het einde van de interventie. Hiertoe worden de patiënten actief 
gevolgd. Deze parameter wordt meegenomen omdat het uiteindelijke 
doel voor droog poeder inhalatie van ciclosporine het 
voorkomen/behandelen van chronische afstoting na longtransplantie én 
het voorkomen van ernstige systemische bijwerkingen (neuro-
/nefrotoxiciteit) is. 
 
Andere studie parameters 
Depositie 
Van belang is om te weten hoeveel ciclosporine daadwerkelijk in de 
longen komt. Hiertoe zal van iedere patient worden gevraagd om radio-
actief gelabeld inuline (dwz. zonder de werkzame stof, ciclosporine) te 
inhaleren. Hiermee zal inzicht worden verkregen in de echte 
depositiegegevens en zal het mogelijk zijn effecten te correleren aan de 
dosis. Zie §8 voor een uitgebreide uitleg over het radiofarmacon voor 












































Van de ciclosporine dosis die lokaal in de longen terechtkomt zal een deel 
worden geabsorbeerd in de systemische circulatie. Uit de literatuur is 
gebleken dat dit circa 10% van de oorspronkelijke dosis is. Bij ieder 
bezoek wordt de bloedspiegel gecontroleerd om de veiligheid van 




Binnen deze studie zal er geen randomisatie plaatsvinden vanwege de 
gekozen studie opzet. De studie opzet is gekozen vanwege het feit dat er 
geen farmacotherapeutische opties meer voorhanden zijn voor deze 




In tabel 3 staan de bepalingen weergegeven welke worden voor deze 
studie nodig zijn.  
 











Depositie Inhalatie  radio- 
actief materiaal 
  √ J Ander 
Medicatie Standaardmedicatie  √   N   
 Studiemedicatie    √ J   
Bepalingen Longfunctie  √   N  Primair 




√  √ J Ander 
Medische 
controle 
Routine controle  √   N   
* Bij de bloedspiegel wordt naast de standaard bloedwaarde bepalingen extra op 
ciclosporine gecontroleerd.  
 iCsA klinisch studie protocol 
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Tabel 4. visites 
Bezoek Tijd  (weken)  Procedures 
Routine 
controle 
 Voorstel  studieparticipatie/inclusie-gesprek 
0    Informed consent/Uitleg studie 
1  0  Uitleg inhalatie procedure 
Uitvoeren depositiestudie 
Routine controle (waarin o.a. longfunctie, nierfunctie) 
GFR 
Afleveren studiemedicatie (3 wkn) 
2 2  Routine  controle 
Bepalen ciclosporine-bloedspiegel (dalspiegel en extra 
alleen dit bezoek twee uur na inhalatie) 
Afleveren studiemedicatie (3 wkn) 
Innemen gebruikte inhalatoren 
3 4  Routine  controle 
Bepalen ciclosporine-bloedspiegel 
Afleveren studiemedicatie (4 wkn) 
Innemen gebruikte inhalatoren 
4 8  Routine  controle 
Bepalen ciclosporine-bloedspiegel 
Afleveren studiemedicatie (4 wkn) 
Innemen gebruikte inhalatoren 
5 12  Routine  controle 
Bepalen ciclosporine-bloedspiegel 
Afleveren studiemedicatie (4 wkn) 
Innemen gebruikte inhalatoren 
6 16  Routine  controle 
Bepalen ciclosporine-bloedspiegel 
Afleveren studiemedicatie (4 wkn) 
Innemen gebruikte inhalatoren 
7 20  Routine  controle 
Bepalen ciclosporine-bloedspiegel 
Afleveren studiemedicatie (4 wkn) 
Innemen gebruikte inhalatoren 
8 24  Routine  controle 
Bepalen ciclosporine-bloedspiegel 
GFR 
Afleveren studiemedicatie (4 wkn) 
Innemen gebruikte inhalatoren Appendix 
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Voor de studie zijn weinig extra procedures nodig. Alleen het geven van 
speciale medicatie (voor de depositiestudie en studiemedicatie) is een 
extra belasting voor het ziekenhuis en patient. Daarnaast dient het 
laboratorium een aantal extra bepalingen uit te voeren op de spiegel van 
ciclosporine. 
De totale studieduur bedraagt 6 maanden, hierin dienen de patiënten een 
aantal keer in het ziekenhuis langs te komen. Zie tabel 4 voor het aantal 
visites en de te volgen procedures. 
 
Terugtrekken 
Patiënten mogen zich op ieder tijdstip terugtrekken uit de studie zonder 
persoonlijke gevolgen. Indien nodig kan de behandelend arts ervoor 
kiezen om een patient uit de studie te zetten. Dit kan gebeuren op 
geleide van het klinische beeld (zie §9.7 tabel 5), maar ook bij het niet 
kunnen volgen van het studieprotocol. 
 
Specifieke criteria voor terugtrekken 
Er zijn geen specifieke criteria vastgesteld. 
 
Follow-up van teruggetrokken patient 
Indien een patient zich terugtrekt of uit de studie wordt gezet zal deze 
patient vervallen in het originele follow-up systeem van de 
longtransplantatie eenheid. Indien er sprake is van een niet-verwachte 
verslechtering van het klinische beeld door de studiemedicatie zullen er 
adequate maatregelen worden getroffen op aanraden van de behandelend 
arts. 
 
Voortijdige beëindiging van studie 
De studie zal voortijdig worden beëindigd indien onverhoopt blijkt dat het 
onderzoeksgeneesmiddel dusdanig onveilig is en de patiënten een groot 
risico lopen dat het niet ethisch wordt geacht om de studie voort te 
zetten. 
In deze studie zijn de criteria voor voortijdige beëindiging van de studie 
gedefinieerd op geleide van de veiligheidsgegevens van verneveld 
ciclosporine en op geleide van de relatieve ernst van de bijwerkingen.  
Voor iedere patient wordt individueel door de behandelend arts bepaald 
of het verantwoord is om de studiemedicatie voort te zetten indien deze 
één van de aan de studiemedicatie gelieerde bijwerkingen heeft uit     iCsA klinisch studie protocol 
 
261 
tabel 5. De genoemde bijwerkingen hebben direct invloed op de 
longfunctie en wegen daarom zwaar. Dit betekent overigens niet dat 
andere bijwerkingen uitgesloten worden in de beschouwing. 
Indien meer dan 40% van de patiënten met dezelfde bijwerking als 
genoemd in tabel 5 met de studie stopt of uit de studie wordt gehaald zal 
de Data Safety Monitoring Board bijeen komen en bespreken of de 
betreffende bijwerking een groepseffect betreft of dat deze individueel 
wordt bepaald. De uitkomst van dit gesprek zal bepalen of de studie 
voortijdig wordt gestopt of niet. 
 
Tabel 5. bijwerkingen welke aanleiding geven tot discussie op doorgaan studie en 
medicatie 
Hoest  Acuut respiratoir falen 
Geëxacerbeerde dyspnoe  Pharyngitis 
Respiratoire stoornis  Ademhalingsstoornis 
Chronische luchtweginfectie   
 
VEILIGHEIDSRAPPORTEN 
Sectie 10 WMO 
Volgens artikel 10, eerste lid van de Wet medisch-wetenschappelijk 
onderzoek met mensen zal de uitvoerder van het onderzoek het aan de 
toetsende commissie melden als het onderzoek '…een verloop neemt dat 
in noemenswaardige mate ongunstiger is voor de proefpersoon dan in het 
protocol is voorzien…’. De uitvoering van het onderzoek wordt opgeschort 
totdat een nader oordeel is gegeven (tenzij de gezondheid van de 
proefpersoon opschorting niet toelaat). 
 
Ongewenste voorvallen en ernstige ongewenste voorvallen 
Het GCP richtsnoer definieert een ernstig ongewenst voorval (SAE) of 
ernstige bijwerking (Serious ADR) als: elk ongewenst medisch voorval dat 
bij ongeacht welke dosis: 
•  de dood tot gevolg heeft, 
•  levensbedreigend is, 
•  ziekenhuisopname of verlenging van opname noodzakelijk maakt, 
•  tot blijvende of ernstige invaliditeit/arbeidsongeschiktheid leidt, 
of 




Al deze SAE’s zullen aan de METc worden gemeld volgens de procedures 
van de METc. 
Indien er een SAE optreedt waarbij er een verwachte (waarschijnlijk of 
zeker) relatie is tot de onderzoeksmedicatie zal dit worden gemeld aan 
de registratie-autoriteiten. In het geval van de onderzoeksmedicatie in 
deze studie is gesteld dat deze niet in Nederland is geregistreerd. 
Derhalve is het relevante orgaan de Hoofdinspectie voor de Farmacie en 
de Medische Technologie, Inspectie voor de Gezondheidszorg. 
 
Verdachte en onverwachte ongewenste voorvallen 
Verdachte en onverwachte ongewenste voorvallen zijn ongewenste 
voorvallen welke van nature of in ernst niet consistent zijn met de 
huidige product informatie (Investigator’s Brochure). 
De onderzoekers zullen alle verdachte en onverwachte ongewenste 
voorvallen melden aan het College ter Beoordeling van Geneesmiddelen 
en geaccrediteerde METc. Het rapporteren zal niet langer dan 15 dagen 
duren nadat de onderzoeker van het voorval heeft kennis genomen. Voor 
fatale of levensbedreigende voorvallen wordt binnen maximaal 7 dagen 
een voorlopig rapport opgesteld en wordt maximaal 8 dagen genomen om 
tot een definitief rapport te komen. 
 
Jaarlijks veiligheidsrapport 
De studie heeft een duur van 6 maanden. Daarom zal er niet een jaarlijks 
veiligheidsrapport worden opgesteld. 
 
Follow-up van ongewenste voorvallen 
Alle ongewenste voorvallen worden gevolgd tot ze zijn afgenomen of tot 
er een klinisch stabiele situatie is ontstaan. Afhankelijk van het voorval 
zijn mogelijk additionele testen of medische procedures nodig en/of 
verwijzing naar een huisarts of medisch specialist. 
 
Data Safety Monitoring Board (DSMB) 
Voor deze relatief kleine studie bestaat de Data Safety Monitoring Board 
uit de projectleider (Prof. Dr. H.W. Frijlink), de hoofdonderzoekers (Dr. 
W. van der Bij en Drs. G.S. Zijlstra) en de onafhankelijk arts (Prof. Dr. 
H.A.M. Kerstjens) vanwege het feit dat deze personen de studie van 
dichtbij volgen en daarom snel inzage hebben in eventuele 
veiligheidsproblemen. Daarnaast is de samenstelling van de monitoring iCsA klinisch studie protocol 
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board divers met expertise van apothekers, een arts gespecialiseerd in 




De gemeten waarden zullen als discrete waarden worden genomen. De 
waarden van de pre-interventie controles (afname FEV1, GFR) worden 
gemiddeld evenals de waarden van de interventie (afname FEV1, GFR). 
Ook andere gegevens als leeftijd, type transplantatie en primaire 
diagnoese worden meegenomen. Per patient worden de verkregen 
gegevens in een grafiek uitgezet voor wat betreft de longfunctie voor en 
tijde van de studie. Dit wordt ook gedaan met de ciclosporine 
bloedspiegels, serumcreatininewaarden en GFR voor en na de studie.  
 
Univariate analyse 
De waarden voor afname in FEV1 pre-interventie en post-interventie 
zullen middels een gepaarde t-toets met elkaar vergeleken worden op 
significantie. Ook wordt de GFR pre- en post-interventie met een 
gepaarde t-toets vergeleken. Uiteraard is de steekproef te klein om een 
uitspraak te doen over een eventueel groepseffect. De resultaten worden 
als richting-gevend/hypothese-genererend beschouwd. 
 
Multivariate analyse 
De hoeveelheid patienten in deze studie is te klein om een multivariate 
analyse op uit te voeren. 
 
Interim analyse 
Een interim analyse wordt niet uitgevoerd, omdat de studie 6 maanden 
duurt. Wel zal de data geregeld worden bijgewerkt. 
 
ETHISCHE OVERWEGINGEN 
Verklaring van Helsinki 
De studie zal worden uitgevoerd volgens de principes van de “verklaring 
van Helsinki” (januari 2004) en in overeenstemming met de Wet op 
Medisch-wetenschappelijk onderzoek met Mensen (WMO). Tevens zal 




Recrutering en informed consent 
De recrutering zal plaatsvinden door de behandelend arts (onderzoeker) 
tijdens een routine-onderzoek (follow-up na longtransplantatie). De 
patiënten krijgen standaard twee weken de tijd om na te denken over 
participatie, op verzoek kan dit worden verlengd. Gedurende deze tijd 
staat het ze vrij contact te zoeken met de behandelend arts, 
onderzoeker, onafhankelijk arts (Prof.Dr. H.A.M. Kerstjens) en alle 
anderen. Daarna zal de behandelend arts (onderzoeker) een nieuw 
gesprek met de vrijwilligers aangaan om uit te vinden of het onderzoek 
duidelijk is uitgelegd en zo nodig nogmaals duidelijk te maken. Tijdens 
dit gesprek kan het Informed Consent worden getekend. Het Informed 
Consent wordt vervolgens in een separaat studie-dossier bewaard.  
Omdat de behandelend arts het recruteringsgesprek voert is er sprake van 
een afhankelijkheidssituatie. In het recruteringsgesprek en in de 
patiënteninformatie zal daaom duidelijk worden gemaakt dat ieder 
antwoord geenszins de verstandhouding tussen arts en patient zal 
verstoren en dat het geen effect heeft op de behandeling, dit om de 
belangen van de patient te waarborgen.  
 
Groepsafhankelijke voordelen en risico-analyse 
Dit onderzoek is het eerste in een reeks van onderzoeken. Het risico voor 
de patiënten is ingeschat op vrij laag gezien de ervaring die is opgedaan 
met ciclosporine in het algemeen en verneveling van ciclosporine bij 
longtransplantatie in nauwere zin. Daar waar de hiaten liggen in de 
optimalisering van de therapie voor longtransplantatie patiënten is in de 
voorkoming van systemische toxiciteit (als neuro- en nefrotoxiciteit) met 
behoud van effectieve immuunsuppressie in de getransplanteerde long. 
Volgens de nieuwste inzichten met verneveling van ciclosporine is het 
mogelijk om patiënten effectief te behandelen en de chronische afstoting 
te verminderen ten opzichte van de huidige – orale – therapie. Er is echter 
geen onderzoek gedaan naar de effectiviteit van inhalatie van 
ciclosporine als belangrijkste pilaar voor onderdrukking van het 
immuunsysteem met gelijktijdige voorkoming van nefrotoxiciteit. 
Met dit onderzoek zal worden getracht om aan te tonen dat droog poeder 
inhalatie van ciclosporine ook effectief is in het verminderen van 
chronische afstoting (primair doel). Daarnaast wordt getracht om naast 
het verminderen van de chronische afstoting de nierfunctie in stand te 
houden (secundair doel). Ook wordt informatie gezocht over iCsA klinisch studie protocol 
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inhaleerbaarheid van het poeder (depositie) en absorptie in de 
systemische circulatie vanuit de long (bloedspiegels). De voorstelling van 
de gang van zaken in de onderzoeken hierna is dat de nierfunctie een 
belangrijke rol zal gaan spelen: in hoeverre kan de dosis van de 
systemische therapie omlaag onder opbouwen van droog poeder inhalatie 
met gelijkblijvende mate van chronische afstoting en nierfunctie? Daarna 
zou een onderzoek kunnen volgen waarin de effectiviteit van droog 
poeder inhalatie als monotherapie na longtransplantatie. Dit zou ertoe 
moeten leiden dat ten opzichte van de huidige therapie de kwaliteit van 
het leven sterk toe zou moeten nemen. Er zou onder 
longtransplantatiepatienten minder sterfte komen door afname van de 
mate van chronische afstoting en de nierfunctie zou behouden kunnen 
blijven. Het is de bedoeling dat de gehele longtransplantie populatie van 
deze ontwikkeling zou moeten kunnen profiteren daar getracht wordt 




Ingevolge art. 7 van de Wet medisch wetenschappelijk onderzoek met 
mensen (Stbl. 1998, 161) is voor de deelnemende proefpersonen een 
verzekering afgesloten die de door het onderzoek veroorzaakte schade 
door dood of letsel van de deelnemende proefpersonen dekt. Deze 
verzekering voldoet aan de bepalingen van het Besluit verplichte 
verzekering bij medisch-wetenschappelijk onderzoek met mensen (Stbl. 
2003, 266).  De aan het onderzoek deelnemende proefpersonen zullen 
schriftelijk worden ingelicht over deze verzekering. 
 
Tegemoetkomingen 
Alle deelnemers in de studie zullen worden gecompenseerd voor de 
gemaakte reiskosten op basis van openbaar vervoer 2
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De snelle ontwikkelingen in de moleculaire biologie en biotechnologie van 
de afgelopen decennia hebben geleid tot de succesvolle introductie van 
een aantal biofarmaceutica, in het bijzonder therapeutische peptiden en 
eiwitten, op de geneesmiddelenmarkt. Biofarmaceutica zijn een speciale 
groep geneesmiddelen, omdat ze in het algemeen zowel chemisch als 
fysisch minder stabiel zijn dan de meeste kleine organisch 
gesynthetiseerde geneesmiddelmoleculen. Daarnaast zijn de meeste 
biofarmaceutica afhankelijk van een ruimtelijke structuur voor hun 
effectiviteit en veiligheid. Het behouden van die ruimtelijke structuur is 
daarom essentieel voor het ontwikkelen van effectieve en veilige 
producten. Zoals uitgelegd in de algemene introductie zijn een aantal 
biofarmaceutica (waaronder therapeutische eiwitten) uitstekend geschikt 
voor pulmonale toediening (inhalatie). 
Het doel van de toediening per inhalatie kan het veroorzaken van een 
lokaal, lokaal en systemisch of alleen systemisch effect zijn. Er zijn 
verschillende typen inhalatoren beschikbaar om een aerosol te creëren. 
De aerosol kan worden gecreëerd vanuit een oplossing of een poeder. 
Wordt een aerosol gecreëerd vanuit een oplossing dan spreken we van 
verneveling. Verneveling is patiëntonvriendelijk, het kost veel tijd en 
vereist de beschikbaarheid van elektriciteit of perslucht. Daarnaast zijn 
de efficiëntie waarmee de aerosol wordt gecreëerd en de longdepositie 
slecht, waardoor relatief veel onnodig verlies optreedt. Een alternatief is 
de inhalatie van het geneesmiddel in poedervorm. Deze technologie kost 
minder dan een minuut voor volledige toediening. Daarnaast zijn de 
efficiëntie waarmee het aerosol wordt gecreëerd en de longdepositie in 
het algemeen hoger dan voor verneveling. 
Omdat eiwitten vaak worden geproduceerd in waterige oplossingen 
vereist de toepassing in een droog poeder inhalator een droogstap. Die 
biofarmaceutica die afhankelijk zijn van hun tertiaire – lees: ruimtelijke – 
structuur voor hun activiteit, zoals eiwitten, moeten tijdens het 
droogproces worden gestabiliseerd. Hulpstoffen die aan de ene kant het 
eiwit fysiek fixeren en aan de andere kant de waterstofbruggen van het 
oplosmiddel kunnen vervangen zijn geschikt om biofarmaceutica te 
stabiliseren tijdens drogen en mogelijk ook tijdens opslag. Suikers zoals 





Verschillende droogmethoden zijn beschikbaar en enkele daarvan zijn in 
dit proefschrift beschreven: vriesdrogen, sproeidrogen en 
sproeivriesdrogen. Andere methoden, zoals bijvoorbeeld superkritische 
vloeistof extractie zouden ook in staat kunnen zijn om een poeder voor 
inhalatie in de juiste aerodynamische deeltjesgrootte te produceren. 
Sproeivriesdrogen heeft als voordeel dat het eindproduct uit vaste 
deeltjes bestaat. Door gebruik te maken van de juiste procescondities 
kunnen deeltjes geproduceerd worden met de gewenste aerodynamische 
diameter tussen 1 en 5 µm. Sproeidrogen geeft ook de mogelijkheid een 
product met de gewenste aerodynamische grootte te produceren. 
In dit proefschrift onderzochten wij in hoeverre biofarmaceutica verwerkt 
konden worden tot een droog poeder formulering. Daarnaast hebben we 
met een aantal producten een proof-of-concept studie uitgevoerd. Een 
aantal verschillende therapeutische peptiden en eiwitten hebben als 
modelstoffen gediend, die allen verschilden in mate van 
wateroplosbaarheid en molecuulgrootte. Daarnaast is een studie 
uitgevoerd met een stof die na inhalatie de lichaamseigen productie van 
een eiwit induceerde zodat de complexe formulering van een enzym kon 
worden vermeden. 
 
In Hoofdstuk 2 zijn drie verschillende productiemethoden vergeleken om 
een droog poeder formulering voor inhalatie te maken van cetrorelix. 
Cetrorelix is een hydrofiel peptide dat bestaat uit 10 aminozuren. Poeder 
met de gewenste deeltjesgrootte werd gemaakt via malen, sproeidrogen 
en sproeivriesdrogen. Alle methoden resulteerden in inhaleerbare 
deeltjes, maar de morfologie van de deeltjes verschilde per methode. Na 
verwerking van de poeders in adhesieve mengsels met lactose bleek dat 
het gesproeivriesdroogd poeder te fragiel was om de kinetische energie 
van de veel zwaardere lactosedeeltjes te weerstaan. De mengsels met 
gemalen en gesproeidroogd cetrorelix werden in twee verschillende 
inhalatoren getest: een capsule-inhalator en de Novolizer. 
Deagglomeratie in de capsule-inhalator vind plaats door de bewegende 
capsule, terwijl in de Novolizer een cycloon voor deagglomeratie zorgt 
middels botsingskrachten. In vitro testen toonden aan dat voor zowel de 
formulering met gemalen cetrorelix en de formulering met 
gesproeidroogd cetrorelix de Novolizer leidde tot efficiëntere 
deagglomeratie. Ook bleek dat naast het type inhalator, de morfologie 
van de deeltjes en daarmee de productiemethode van belang was: Samenvatting 
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gesproeidroogd cetrorelix leidde in beide inhalatoren tot een hoger 
percentage deeltjes die geschikt zijn voor inhalatie. Dit onderzoek leerde 
ons dat het adequaat ontwikkelen van inhalatiesystemen vraagt om een 
duale aanpak, waarin de specifieke combinatie van de inhaler met de 
poederformulering geoptimaliseerd worden.  
 
De  hoofdstukken 3 en 4 beschrijven een studie met een hydrofoob 
peptide, ciclosporine A (CsA). CsA is een slecht wateroplosbaar cyclisch 
peptide van 11 aminozuren. Per inhalatie toegediend CsA zou toegepast 
kunnen worden bij chronische afstoting van getransplanteerde longen, 
een aandoening waarvoor tot op heden geen goede therapeutische 
behandelmogelijkheden zijn. In Hoofdstuk 3 verkenden wij het gebruik 
van de solid dispersion technologie om een inhalatie poeder van CsA te 
ontwikkelen.  Solid dispersions werden bereid door CsA op te lossen in 
tertiair butyl alcohol (TBA) en te mengen met een oplossing van water en 
een wateroplosbare hulpstof, inuline. Door middel van sproeivriesdrogen 
konden we een homogeen poeder van CsA en inuline produceren. Van dit 
poeder werd de oplossnelheid, de dispersie van CsA door de inuline 
matrix en het aerosolisatie gedrag onderzocht. 
De solid dispersions losten sneller op dan het fysieke mengsel van CsA 
met inuline. Met Fourier Transformatie Infrarood Spectroscopie (FTIR) 
werd onderzocht hoe CsA ingebed zat in de hydrofiele matrix door gebruik 
te maken van het feit dat de conformatie van CsA in de hydrofiele matrix 
anders is dan in een hydrofobe matrix. Aangetoond werd dat de 
gemiddelde conformatie van alle CsA moleculen afhankelijk was van het 
gehalte, waarbij lage gehaltes een hoofdzakelijk hydrofiele conformatie 
kenden en hogere gehaltes een meer en meer hydrofobe conformatie 
bezaten. Blijkbaar worden bij hogere gehaltes meer en meer CsA 
moleculen geclusterd, mogelijk tot kleine deeltjes. Dit zou kunnen 
verklaren waarom de oplossnelheid afhankelijk was van het CsA gehalte in 
de solid dispersion. 
Sproeivriesdrogen leidde tot deeltjes met een erg lage dichtheid en een 
erg hoog specifiek oppervlak van meer dan 100 m
2/gr. De deeltjes hadden 
een grote geometrische diameter, maar gecombineerd met de hoge 
porositeit resulteerde dit in een mediane aerodynamische diameter op 
gewichtsbasis (MMAD) van 3.39 µm. Vanwege de goede oplossnelheid en 
de uitstekende aerosoliseringseigenschappen concludeerden wij dat de Appendix 
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CsA solid dispersion met een gehalte van 50% de juiste parameters bezat 
voor gebruik bij longtransplantatiepatiënten. 
 
Hoofdstuk 4 beschrijft de in vivo eigenschappen in de rat van het in 
hoofdstuk 3 beschreven CsA poeder voor inhalatie (iCsA). Hoofdstuk 4A 
richt zich op de farmacokinetiek en effectiviteit in het voorkomen van 
afstoting in een experimenteel longtransplantatiemodel in ratten. De 
farmacokinetiek van 10 mg/kg iCsA in ratten, gegeven middels insufflatie 
werd vergeleken met 10 mg/kg Neoral, oraal toegediend. Neoral is het 
huidige, commercieel beschikbare product. Hoewel iCsA en Neoral tot 
een vergelijkbare systemische beschikbaarheid leidden, resulteerde iCsA 
in een 109 keer hogere spiegel in de long vergeleken met Neoral. 
Om de effectiviteit van iCsA te bestuderen werd in een 
transplantatiemodel de mate van afstoting vergeleken met Neoral. Het 
gebruikte longtransplantatiemodel resulteerde in volledige afstoting 
binnen 8 dagen na transplantatie als gevolg van de incompatabiliteit van 
de donor en ontvanger. iCsA bleek bij lagere dosis dan Neoral al effectief. 
Echter, in de bestudeerde dosering (5  mg/kg) werden microscopische 
reacties in de long waargenomen. Daarom werd in Hoofdstuk 4B 
onderzocht of lagere doses, de hulpstof inuline of insufflatie zelf ook tot 
vergelijkbare reacties zouden leidden. Bij een dosering van 0,8  mg/kg 
iCsA, week het aantal abnormaliteiten niet af ten opzichte van placebo.  
Hoewel in hoofdstuk 4A werd aangetoond dat in het proefdier iCsA doses 
lager dan 5 mg/kg niet effectief waren in het remmen van de afstoting, is 
de veiligheidsstudie met een dosering van 0,8  mg/kg wel degelijk 
relevant, omdat deze dosering boven de dosering ligt waarvan in mensen 
al is aangetoond dat zij na inhalatie effectief kan zijn. 
Voor een persoon van 60 kg zou een dosis van ongeveer 0,1 mg/kg al een 
effect geven. Zelfs in een zo lage dosering zou de CsA spiegel in de long 
vele malen hoger worden dan wanneer alleen Neoral oraal zou worden 
toegediend. Tegelijkertijd zou de plasmaspiegel van CsA, welke is 
gerelateerd aan het optreden van bijwerkingen zoals nierschade, niet 
noemenswaardig hoeven te stijgen. Daarom zijn wij van mening dat de 
behandeling van longtransplantatiepatiënten met chronische afstoting 





Hoofdstuk 5 beschrijft de mogelijkheden om recombinant humaan 
deoxyribonuclease I (rhDNase), een eiwit van 37 kDa, te formuleren als 
een poeder voor inhalatie. In Hoofdstuk 6 worden de farmaco-
economische aspecten van een dergelijk product beschreven en wordt 
een vergelijking gemaakt met de thans commercieel beschikbare 
verneveling (Pulmozyme, 1 mg/ml rhDNase, 2,5 ml). 
Verschillende processtappen om een poeder voor inhalatie van rhDNase te 
ontwikkelen werden bestudeerd. Naast de keuze van de stabiliserende 
hulpstof werden ook de effecten van procescondities op de 
inhaleerbaarheid onderzocht. Daarnaast hebben we met de meest 
geschikte formulering een ex vivo test uitgevoerd om de geschiktheid van 
het concept aan te tonen. 
Van de onderzochte hulpstoffen sucrose, trehalose en inuline bleek 
sucrose niet geschikt als hulpstof. Chemisch gezien bleek trehalose de 
beste stabilisator, omdat het aantal dimere aggregaten niet toenam 
tijdens de stabiliteitstudie. Vervolgens hebben we inuline en trehalose 
formuleringen gesproeidroogd en gesproeivriesdroogd bij verschillende 
procescondities. Sproeidrogen bleek het beste proces te zijn omdat 
deeltjes met een MMAD van 2,3 µm geproduceerd konden worden. Ook 
bleek dat de formulering met inuline als hulpstof bij kamertemperatuur 
bewaard kon worden, in tegenstelling tot trehalose. Dit was 
waarschijnlijk gerelateerd aan de hoge glastransitietemperatuur van 
157˚C van inuline. De inhalatie eigenschappen van de inuline formulering 
waren ook goed met een fijne deeltjesfractie (<5 µm) van ongeveer 40%. 
Daarom hebben we de effectiviteit van de inuline formulering getest met 
behulp van sputum van patiënten met cystische fibrose. Het bleek dat het 
poeder voor inhalatie significant zowel de viscositeit als de elasticiteit 
verlaagde. De conclusie was dat het goed mogelijk is om ook van grotere 
eiwitten als rhDNase een poeder voor inhalatie te ontwikkelen.  
 
De in Hoofdstuk 6 beschreven voordelen van droog poeder inhalatie ten 
opzichte van verneveling zijn i)  een verbeterde therapietrouw, ii) een 
verbeterde longdepositie, iii) elektriciteit of perslucht zijn niet nodig, iv) 
een veel kortere toedieningstijd en v) de formulering hoeft niet gekoeld 
te worden. Deze voordelen zouden mogelijkerwijs kunnen leiden tot 
minder exacerbaties en ziekenhuisopnames. Daarmee zouden wellicht de 
kosten voor behandeling van cystische fibrose af kunnen nemen. De 
farmaco-economische analyse liet zien dat de kosten per gewonnen Appendix 
 
276 
levensjaar €19.110 zijn voor de verneveling, terwijl deze door de 
genoemde voordelen geschat worden op €12.100 voor de poederinhalatie. 
Dit betekent dat met droog poeder inhalatie ongeveer 40% lagere kosten 
gemaakt worden om eenzelfde effectiviteit te bereiken. Voor dure 
therapieën die een centrale rol spelen bij een therapie, zoals rhDNase bij 
cystische fibrose, kan het daarom nuttig zijn om in een vroegtijdig 
stadium te onderzoeken wat de farmaco-economische implicaties zijn van 
een bepaalde formuleringsstrategie.  
 
In  Hoofdstuk 7 werd een alternatieve wijze onderzocht om een 
biofarmaceutische interventie tot stand te brengen: in plaats van een 
eiwit (enzym) te formuleren tot poeder voor inhalatie hebben we een 
natuurlijk substraat, een organisch molecuul, geformuleerd tot poeder 
voor inhalatie. Door het substraat toe te dienen in de longen wordt de 
lichaamseigen productie van het enzym geïnduceerd. Als modelsysteem 
hebben we heme oxygenase I (HO-1) als eiwit en als substraat hemine 
gebruikt, mede omdat in patiënten met chronisch obstructieve 
pulmonaire aandoening (COPD) was aangetoond dat dit enzymsysteem 
verlaagd is ten opzichte van gezonde vrijwilligers. 
Vanwege de slechte oplosbaarheid van hemine bij pH 7 werd hemine 
opgelost in een alkalische oplossing die juist voor het sproeidrogen 
geneutraliseerd werd. Naast het formuleringsonderzoek werd ook een 
toedieningsmethode voor aerosolen aan kleine proefdieren onderzocht, 
waarbij de dieren door de natuurlijke ademhaling het aerosol inhaleren. 
Met het ontwikkelde hemine poeder hebben werd aangetoond dat het 
enzymsysteem op een dosisafhankelijke wijze kon worden geïnduceerd. 
In dit hoofdstuk is aangetoond dat het ook mogelijk is om relatief simpele 
organische moleculen aan te bieden om een effect te bewerkstelligen wat 
gebaseerd is op een biofarmaceutische interventie. Het voordeel hiervan 
is dat er geen ingewikkelde formuleringen nodig zijn voor het betreffende 
eiwit. Daarnaast is een nieuwe toedieningsmethode van aerosolen 
geïntroduceerd. Deze methode is uniek omdat enerzijds iedere 
droogpoeder inhalator aangesloten zou kunnen worden, en anderzijds 
omdat de methode het mogelijk maakt vergelijkend onderzoek te doen 
met een aantal formuleringen in een vroegtijdig stadium van de 
ontwikkeling. Daarnaast maakt de methode gebruik van de natuurlijke 




Tot slot, alle in dit proefschrift onderzochte geneesmiddelen konden 
worden geformuleerd als een poeder voor inhalatie. Afhankelijk van de 
eigenschappen van het specifieke molecuul konden we specifieke 
formuleringstechnologieën aanwenden om de ruimtelijke structuur te 
bewaren tijdens het droogproces, opslag en reconstitutie. In bepaalde 
gevallen zou men kunnen volstaan met aanbieden van een organisch 
molecuul zonder dat het biofarmaceutisch molecuul zelf geformuleerd 
hoeft te worden. Omdat de effectiviteit van de toediening per inhalatie 
afhankelijk is van de aerodynamische eigenschappen van de aerosol (en 
daarmee van het poeder), is er een noodzaak om deze eigenschappen in 
proefdieren te testen via de pulmonaire route. In dit proefschrift zijn 
insufflatie en blootstelling via de neus getest. Insufflatie is vooral 
geschikt voor studies waarin een kwantitatieve relatie met de dosering 
onderzocht wordt, zoals farmacokinetische studies, terwijl blootstelling 
via de neus gebruikt kan worden voor het vaststellen van een proof-of-
concept en het vergelijken van aerodynamische eigenschappen van 
verschillende formuleringen. Appendix 
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Promotie onderzoek is iets waarvan je op sommige momenten denkt dat 
je er alleen voor staat, maar niets is minder waar. Velen hebben mij dan 
ook, direct of indirect, geholpen in de totstandkoming van dit 
proefschrift. Het liefst zou ik iedereen die een steentje heeft bijgedragen 
persoonlijk willen bedanken, maar dan wordt de lijst nog langer. Voor 
degenen die niet met name worden genoemd: weet dat ik jullie steun 
zeer heb gewaardeerd! 
 
Als eerste wil ik mijn promotor, Prof. dr. Erik Frijlink, en co-promotoren 
dr. Anne de Boer en dr. Wouter Hinrichs bedanken voor het vertrouwen 
en creëren van een solide basis om promotie-onderzoek uit te kunnen 
voeren. Erik, je onvoorwaardelijke steun, optimisme en aanstekelijk 
enthousiasme zullen mij altijd bijblijven; ik vond het een eer om bij je te 
promoveren. Anne, je nuchtere Friese gedachtegang, gecombineerd met 
een encyclopedisch geheugen en inventiviteit maakten het samenwerken 
tot iets bijzonders in positieve zin. Ik weet zeker dat jouw concepten 
belangrijk zullen zijn voor de patiënten. Wouter “Funkadelic” Hinrichs, je 
bent een markante persoonlijkheid die naast de wetenschappelijke 
discussies graag tijd vrijmaakt voor etentjes, vroeg of laat gecombineerd 
met muziek. De aardbeienwijn van Groningse bodem was niet te 
versmaden! 
 
De leescommissie, Prof. dr. Chris Vervaet, Prof. dr. Wim Jiskoot en Prof. 
dr. Huib Kerstjens ben ik zeer erkentelijk voor het beoordelen van het 
manuscript. Jullie commentaren hebben het proefschrift nog completer 
gemaakt. 
 
From Sofotec I would like to thank dr. Joachim Goede, dr. Beatrix Fyrnys 
and dr. Meike Irngartinger for their support of my PhD study, especially 
on their work for cetrorelix. Vielen dank! 
 
De afdeling Biofarmacie & Farmaceutische technologie wil ik ook 
bedanken, niet alleen voor het ondersteunen bij de werkzaamheden, 
maar ook voor het plezier dat we buiten het werk hadden. In het 
bijzonder wil ik Paul, Anko, Jan en Joke bedanken. Paul “Are you 
Raymond van Barneveld?” voor de analytische expertise op inhalatie 
gebied en humor, Anko voor de nuchtere analytische en IT ondersteuning, 
Jan voor zijn kunst om alles geregeld te krijgen (de weddenschap staat Appendix 
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nog steeds!) en Joke voor de secretariële ondersteuning. Jullie steun was 
essentieel. 
 
Collega-promovendi Anneke, Dirk Jan, Jonas, Bastiaan, Yu-San, Jean-
Pierre, Fesia, Hans, Vinay. Jullie waren (en zijn) brothers-in-arms. Wat 
jullie delen is de liefde voor wetenschappelijke discussies en uitwassen 
daarvan; wetenschap als levensstijl. Ik hoop jullie in de toekomst ook nog 
vaak tegen te komen. 
 
De vele handen van (bijvak) studenten hebben het werk ook lichter 
gemaakt. Tanja, Maaike, Bart, Sylvia, Michiel, Martijn, Nanja en Joske: 
jullie hebben niet alleen bijgedragen aan de verschillende hoofdstukken, 
maar ook aan mijn persoonlijke ontwikkeling als begeleider. Heel erg 
bedankt dat jullie voor mijn onderzoek kozen. Ik hoop dat het voor jullie 
net zo enerverend was als voor mij. 
 
Binnen dit onderzoek zijn er ook diverse samenwerkingsverbanden binnen 
en buiten de universiteit opgezet. Hoewel sommigen hun plaats als mede-
auteur hebben verdiend, wil ik enkelen in het bijzonder noemen. Dr. Marc 
Sutter van de Universiteit Utrecht: heel erg bedankt voor de goede FTIR 
discussies en gastvrijheid! Ook dr. Marco van der Weert van de 
Kopenhagen Universiteit wil ik in dat kader bedanken. Prof. dr. Jo 
Demeester en Prof. dr. Niek Sanders van de Universiteit van Gent wil ik 
bedanken voor hun pro-actieve inzet bij de visco-elasticiteit metingen. 
Men zegt wel eens dat je “als God leeft in Frankrijk”, maar ik heb 
ervaren dat hetzelfde geldt voor Gent! 
 
Binnen het instituut ben ik erg blij om met Prof. dr. Huib Kerstjens en dr. 
Wim van der Bij samengewerkt te mogen hebben om de klinische studie 
met ciclosporine als poeder voor inhalatie van de grond te krijgen. Ik heb 
veel geleerd van jullie inzicht en motivatie om wetenschap voor de 
patiënt in te zetten. Jullie toegankelijkheid, enthousiasme en een 
kritische blik, gecombineerd met de nodige humor maakten de 




Dr. Jochum Prop en Arjen Petersen: ontzettend bedankt voor jullie hulp 
bij de longtransplantaties. Wat heb ik genoten van het meeturen door de 
microscoop tijdens de longtransplantatie bij ratten. De medewerkers van 
de ziekenhuisapotheek, met name Reinout Schellekens en Erwin 
Jongedijk, ben ik dankbaar voor hun hulp bij het ciclosporine onderzoek. 
Zonder jullie hulp was het nooit zover gekomen.  
 
Corry-Anke, collega eerste auteur op het hemine artikel, we hebben de 
a e r o s o l b o x  g o e d  g e b r u i k t !  J o u w  h u l p ,  j e  e x p e r t i s e ,  m a a r  o o k  d e  
gezelligheid hebben mij veel plezier gebracht binnen (en buiten) het CDL.  
 
Daarnaast wil ik familie en vrienden die belangstelling en interesse 
hebben getoond in mijn onderzoek bedanken. Frans en Elaine: omdat 
jullie deur altijd openstaat voor een retraite in de Bilt of Ouddorp, Top 
2000, dobbelen, de Librije en Oud Sluis. De mannen van de Walvisch: ik 
heb me uitstekend met jullie vermaakt tijdens de vele trainingen, 
wedstrijden en borrels. Ik vind het mooi dat we nog jaarlijks als de 
Gouden Garde bijeenkomen.  
 
Mijn paranimfen Martin en Rolf: Martin, ik wil je niet alleen bedanken 
voor de vele leuke tijden (discussies, films, tennis, pizza’s) in de 
afgelopen jaren tijdens het onderzoek, maar ook in de periode tijdens de 
studie met als (voorlopig) hoogtepunt onze Amerika reis. Ik heb jou 
mogen ondersteunen tijdens jouw promotie, nu mag jij mij in de watten 
leggen! Rolf, je muzikale tips zijn fenomenaal en hebben mij tijdens mijn 
promotie veel plezier bezorgd en doen dat hopelijk ook in de toekomst. Ik 
geniet altijd van je veelzeggende en pakkende one-liners om de voor mij 
onbekende bands te beschrijven. 
 
Lieve Hans en Mathea. Jullie interesse in mijn onderzoek heeft me altijd 
goed gedaan. Nog steeds komen jullie met allerlei suggesties, 
vakinhoudelijk, maar ook voor stellingen. De suggesties voor stellingen 
leidden, onder het genot van een goed glas wijn, steevast tot levendige 
discussies. Ik hoop dat nog in lengte van dagen met jullie te mogen doen. 
 
Lieve Zijlstra-familie: pa, ma en Johan, jullie wijze van opvoeden 
gecombineerd met de mogelijkheden die jullie mij hebben geboden, 
hebben mij gevormd tot wie ik nu ben. Ik wil graag dat jullie weten dat Appendix 
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mede hierdoor dit proefschrift tot stand is gekomen. Nu het proefschrift 
er is komt er vast en zeker meer tijd om samen dingen te ondernemen. 
 
Lieve Roderick en Lennart, jullie laten onvoorwaardelijk zien dat er meer 
is dan werken en daar geniet ik ieder moment van. Het is een cliché, 
maar clichés zijn dan ook waar: jullie zijn het mooiste wat me ooit is 
overkomen. 
 
Mijn liefste Pauline: jij maakt me blij. Je gezelligheid maakte het me 
lastig om de vrije weekenden op te offeren aan schrijven, maar jouw 
onvoorwaardelijke liefde en de ruimte die je mij bood om mij mijn gang 
te laten gaan, zelfs toen het allemaal langer duurde dan verwacht, zijn 
mij de afgelopen jaren tot grote steun geweest. We gaan de “verloren” 
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Spektroskopie in Dortmund, Duitsland onder begeleiding van dr. Bert 
Schoonen en dr. Michael Heise. Het afstudeeronderzoek betrof het 
ontwikkelen van een non-invasieve glucose sensor op basis van infrarood 
spectroscopie. Na zijn afstuderen in 2000 is Gerrit een 
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Prof. dr. Erik Frijlink op droog poeder inhalatie van eiwitten en peptiden. 
Tijdens het promotie-onderzoek heeft Gerrit de apothekersopleiding in 
2002 succesvol afgerond. In 2007 is Gerrit gaan werken bij Disphar 
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